US11911398B2 - Treating Vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 - Google Patents
Treating Vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 Download PDFInfo
- Publication number
- US11911398B2 US11911398B2 US17/237,889 US202117237889A US11911398B2 US 11911398 B2 US11911398 B2 US 11911398B2 US 202117237889 A US202117237889 A US 202117237889A US 11911398 B2 US11911398 B2 US 11911398B2
- Authority
- US
- United States
- Prior art keywords
- hydroxyvitamin
- vitamin
- dosage form
- soft gelatin
- matrix material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active, expires
Links
- JWUBBDSIWDLEOM-NQZHSCJISA-N 25-hydroxy-3 epi cholecalciferol Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@H](O)CCC1=C JWUBBDSIWDLEOM-NQZHSCJISA-N 0.000 title abstract description 105
- KJKIIUAXZGLUND-ICCVIKJNSA-N 25-hydroxyvitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](\C=C\[C@H](C)C(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C KJKIIUAXZGLUND-ICCVIKJNSA-N 0.000 title abstract description 101
- 230000007812 deficiency Effects 0.000 title abstract description 8
- JWUBBDSIWDLEOM-UHFFFAOYSA-N 25-Hydroxycholecalciferol Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CCC1=C JWUBBDSIWDLEOM-UHFFFAOYSA-N 0.000 title abstract 5
- JWUBBDSIWDLEOM-DCHLRESJSA-N 25-Hydroxyvitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C/C=C1\C[C@@H](O)CCC1=C JWUBBDSIWDLEOM-DCHLRESJSA-N 0.000 title abstract 5
- 206010047626 Vitamin D Deficiency Diseases 0.000 title description 16
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 81
- 229930003316 Vitamin D Natural products 0.000 claims description 77
- 235000019166 vitamin D Nutrition 0.000 claims description 77
- 239000011710 vitamin D Substances 0.000 claims description 77
- 229940046008 vitamin d Drugs 0.000 claims description 77
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 74
- 239000011159 matrix material Substances 0.000 claims description 35
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- 239000002552 dosage form Substances 0.000 claims description 21
- 239000007903 gelatin capsule Substances 0.000 claims description 19
- 108010010803 Gelatin Proteins 0.000 claims description 15
- 229920000159 gelatin Polymers 0.000 claims description 15
- 239000008273 gelatin Substances 0.000 claims description 15
- 235000019322 gelatine Nutrition 0.000 claims description 15
- 235000011852 gelatine desserts Nutrition 0.000 claims description 15
- 239000004480 active ingredient Substances 0.000 claims description 13
- -1 fatty acid ester Chemical class 0.000 claims description 12
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 11
- 239000000194 fatty acid Substances 0.000 claims description 11
- 229930195729 fatty acid Natural products 0.000 claims description 11
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 10
- 229920000642 polymer Polymers 0.000 claims description 9
- 239000011647 vitamin D3 Substances 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 7
- 125000005456 glyceride group Chemical group 0.000 claims description 7
- 150000004665 fatty acids Chemical class 0.000 claims description 5
- 125000005397 methacrylic acid ester group Chemical group 0.000 claims description 5
- 229920002125 Sokalan® Chemical class 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 239000004584 polyacrylic acid Chemical class 0.000 claims description 4
- 229920001290 polyvinyl ester Polymers 0.000 claims description 4
- 229920002554 vinyl polymer Polymers 0.000 claims description 4
- 235000019864 coconut oil Nutrition 0.000 claims description 2
- 239000003240 coconut oil Substances 0.000 claims description 2
- 239000003431 cross linking reagent Substances 0.000 claims 5
- 150000002191 fatty alcohols Chemical class 0.000 claims 4
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims 3
- JWUBBDSIWDLEOM-DTOXIADCSA-N calcidiol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C JWUBBDSIWDLEOM-DTOXIADCSA-N 0.000 claims 2
- 239000000203 mixture Substances 0.000 abstract description 106
- JWUBBDSIWDLEOM-XHQRYOPUSA-N (3e)-3-[(2e)-2-[1-(6-hydroxy-6-methylheptan-2-yl)-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol Chemical compound C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2\C1=C\C=C1/CC(O)CCC1=C JWUBBDSIWDLEOM-XHQRYOPUSA-N 0.000 abstract description 86
- 235000021318 Calcifediol Nutrition 0.000 abstract description 86
- 238000009472 formulation Methods 0.000 abstract description 80
- 238000000034 method Methods 0.000 abstract description 18
- 238000013268 sustained release Methods 0.000 abstract description 17
- 239000012730 sustained-release form Substances 0.000 abstract description 17
- 238000001990 intravenous administration Methods 0.000 abstract description 10
- 230000003111 delayed effect Effects 0.000 abstract description 7
- 239000004615 ingredient Substances 0.000 abstract description 3
- 210000004369 blood Anatomy 0.000 description 42
- 239000008280 blood Substances 0.000 description 42
- 210000002966 serum Anatomy 0.000 description 30
- 230000036765 blood level Effects 0.000 description 23
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 21
- 239000011575 calcium Substances 0.000 description 20
- 229910052791 calcium Inorganic materials 0.000 description 20
- 239000005556 hormone Substances 0.000 description 20
- 229940088597 hormone Drugs 0.000 description 20
- 239000002775 capsule Substances 0.000 description 19
- 239000001993 wax Substances 0.000 description 19
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 17
- 238000011282 treatment Methods 0.000 description 15
- 238000013270 controlled release Methods 0.000 description 14
- 230000015556 catabolic process Effects 0.000 description 12
- 239000013589 supplement Substances 0.000 description 12
- 241000282472 Canis lupus familiaris Species 0.000 description 11
- 239000011248 coating agent Substances 0.000 description 11
- 238000000576 coating method Methods 0.000 description 11
- 210000003405 ileum Anatomy 0.000 description 11
- 230000003834 intracellular effect Effects 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 210000000813 small intestine Anatomy 0.000 description 11
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 10
- 230000000968 intestinal effect Effects 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 235000019198 oils Nutrition 0.000 description 10
- 239000011574 phosphorus Substances 0.000 description 10
- 229910052698 phosphorus Inorganic materials 0.000 description 10
- 102000009310 vitamin D receptors Human genes 0.000 description 10
- 108050000156 vitamin D receptors Proteins 0.000 description 10
- 210000001198 duodenum Anatomy 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000012530 fluid Substances 0.000 description 9
- 108010004103 Chylomicrons Proteins 0.000 description 8
- 210000001630 jejunum Anatomy 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 8
- 208000037147 Hypercalcaemia Diseases 0.000 description 7
- 230000009102 absorption Effects 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 7
- 239000002702 enteric coating Substances 0.000 description 7
- 238000009505 enteric coating Methods 0.000 description 7
- 230000000148 hypercalcaemia Effects 0.000 description 7
- 208000030915 hypercalcemia disease Diseases 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000009469 supplementation Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 239000011653 vitamin D2 Substances 0.000 description 7
- 206010020590 Hypercalciuria Diseases 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 230000004075 alteration Effects 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 238000010579 first pass effect Methods 0.000 description 6
- 238000005805 hydroxylation reaction Methods 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 201000005991 hyperphosphatemia Diseases 0.000 description 5
- 239000004922 lacquer Substances 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 230000002459 sustained effect Effects 0.000 description 5
- 230000032258 transport Effects 0.000 description 5
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 4
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 235000021152 breakfast Nutrition 0.000 description 4
- 230000000378 dietary effect Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229960002061 ergocalciferol Drugs 0.000 description 4
- 210000004051 gastric juice Anatomy 0.000 description 4
- 238000001631 haemodialysis Methods 0.000 description 4
- 230000000322 hemodialysis Effects 0.000 description 4
- 230000013632 homeostatic process Effects 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 238000002203 pretreatment Methods 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 235000001892 vitamin D2 Nutrition 0.000 description 4
- 235000005282 vitamin D3 Nutrition 0.000 description 4
- 229940021056 vitamin d3 Drugs 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 239000011612 calcitriol Substances 0.000 description 3
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000001842 enterocyte Anatomy 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 230000031891 intestinal absorption Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 208000005368 osteomalacia Diseases 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 229940068977 polysorbate 20 Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 208000007442 rickets Diseases 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- 229920003166 Eudragit® RL/RS polymer Polymers 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940034982 antineoplastic agent Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229940069978 calcium supplement Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 239000007931 coated granule Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 201000000523 end stage renal failure Diseases 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- 230000002641 glycemic effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 125000001453 quaternary ammonium group Chemical group 0.000 description 2
- 235000010378 sodium ascorbate Nutrition 0.000 description 2
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 2
- 229960005055 sodium ascorbate Drugs 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 102100027518 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial Human genes 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 229920003136 Eudragit® L polymer Polymers 0.000 description 1
- 229920003151 Eudragit® RL polymer Polymers 0.000 description 1
- 229920003152 Eudragit® RS polymer Polymers 0.000 description 1
- 229920003137 Eudragit® S polymer Polymers 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000861278 Homo sapiens 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial Proteins 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical class CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010034156 Pathological fracture Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 102000050760 Vitamin D-binding protein Human genes 0.000 description 1
- 101710179590 Vitamin D-binding protein Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- TYVWBCMQECJNSK-UHFFFAOYSA-N [2-methyl-3-(2-methylprop-2-enoyloxy)butan-2-yl]azanium;chloride Chemical compound [Cl-].CC([NH3+])(C)C(C)OC(=O)C(C)=C TYVWBCMQECJNSK-UHFFFAOYSA-N 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 230000002092 calcimimetic effect Effects 0.000 description 1
- 235000020964 calcitriol Nutrition 0.000 description 1
- 229960005084 calcitriol Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- FSXVSUSRJXIJHB-UHFFFAOYSA-M ethyl prop-2-enoate;methyl 2-methylprop-2-enoate;trimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]azanium;chloride Chemical compound [Cl-].CCOC(=O)C=C.COC(=O)C(C)=C.CC(=C)C(=O)OCC[N+](C)(C)C FSXVSUSRJXIJHB-UHFFFAOYSA-M 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 238000011545 laboratory measurement Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- DNKKLDKIFMDAPT-UHFFFAOYSA-N n,n-dimethylmethanamine;2-methylprop-2-enoic acid Chemical compound CN(C)C.CC(=C)C(O)=O.CC(=C)C(O)=O DNKKLDKIFMDAPT-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002694 phosphate binding agent Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 230000002037 soft tissue calcification Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- RRHXZLALVWBDKH-UHFFFAOYSA-M trimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]azanium;chloride Chemical class [Cl-].CC(=C)C(=O)OCC[N+](C)(C)C RRHXZLALVWBDKH-UHFFFAOYSA-M 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 229940045860 white wax Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Definitions
- the Vitamin D metabolites known as 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 are fat-soluble steroid prohormones to Vitamin D hormones that contribute to the maintenance of normal levels of calcium and phosphorus in the bloodstream.
- the prohormone 25-hydroxyvitamin D 2 is produced from Vitamin D 2 (ergocalciferol)
- 25-hydroxyvitamin D 3 is produced from Vitamin D 3 (cholecalciferol) primarily by one or more enzymes located in the liver.
- the two prohormones also can be produced outside of the liver from Vitamin D 2 and Vitamin D 3 (collectively referred to as “Vitamin D”) in certain cells, such as enterocytes, which contain enzymes identical or similar to those found in the liver.
- the prohormones are further metabolized in the kidneys into potent hormones.
- the prohormone 25-hydroxyvitamin D 2 is metabolized into a hormone known as 1 ⁇ ,25-dihydroxyvitamin D 3 ; likewise, 25-hydroxyvitamin D 3 is metabolized into 1 ⁇ ,25-dihydroxyvitamin D 3 (calcitriol). Production of these hormones from the prohormones also can occur outside of the kidney in cells which contain the required enzyme(s).
- Vitamin D hormones have essential roles in human health which are mediated by intracellular Vitamin D receptors (VDR).
- VDR Vitamin D receptors
- the Vitamin D hormones regulate blood calcium levels by controlling the absorption of dietary calcium by the small intestine and the reabsorption of calcium by the kidneys. Excessive hormone levels, whether transient or prolonged, can lead to abnormally elevated urine calcium (hypercalciuria), blood calcium (hypercalcemia) and blood phosphorus (hyperphosphatemia).
- the Vitamin D hormones also participate in the regulation of cellular differentiation and growth, PTH secretion by the parathyroid glands, and normal bone formation and metabolism. Further, Vitamin D hormones are required for the normal functioning of the musculoskeletal, immune and renin-angiotensin systems. Numerous other roles for Vitamin D hormones are being postulated and elucidated, based on the documented presence of intracellular VDR in nearly every human tissue.
- Vitamin D hormones on specific tissues depend on the degree to which they bind to (or occupy) the intracellular VDR in those tissues.
- the prohormones 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 have essentially identical affinities for the VDR which are estimated to be at least 100-fold lower than those of the Vitamin D hormones.
- physiological concentrations of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 have little, if any, biological actions without prior metabolism to Vitamin D hormones.
- supraphysiologic levels of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 in the range of 10 to 1,000 fold higher than normal, can sufficiently occupy the VDR to exert actions like the Vitamin D hormones.
- Vitamin D supply can cause serious bone disorders, including rickets and osteomalacia, and may contribute to the development of many other disorders including osteoporosis, non-traumatic fractures of the spine and hip, obesity, diabetes, muscle weakness, immune deficiencies, hypertension, psoriasis, and various cancers.
- the TOM also established a Tolerable Upper Intake Level (UL) for Vitamin D of 2,000 IU per day, based on evidence that higher doses are associated with an increased risk of hypercalciuria, hypercalcemia and related sequelae, including cardiac arrhythmias, seizures, and generalized vascular and other soft-tissue calcification.
- UL Tolerable Upper Intake Level
- Vitamin D supplements are far from ideal for achieving and maintaining optimal blood 25-hydroxyvitamin D levels. These preparations typically contain 400 IU to 5,000 IU of Vitamin D 3 or 50,000 IU of Vitamin D 2 and are formulated for quick or immediate release in the gastrointestinal tract. When administered at chronically high doses, as is often required for Vitamin D repletion, these products have significant and, often, severe limitations which are summarized below.
- High doses of immediate release Vitamin D supplements produce marked surges in blood Vitamin D levels, thereby promoting: (a) storage of Vitamin D in adipose tissue, which is undesirable because stored Vitamin D is less available for later conversion to 25-hydroxyvitamin D; (b) catabolism of Vitamin D to metabolites which are less or no longer useful for boosting blood 25-hydroxyvitamin D levels, via 24- and/or 26-hydroxylation; and, (c) excessive intracellular 24- or 25-hydroxylation of Vitamin D, which leads to increased risk of hypercalciuria, hypercalcemia and hyperphosphatemia via mass-action binding to the VDR.
- High doses of immediate release Vitamin D supplements also produce surges or spikes in blood and intracellular 25-hydroxyvitamin D levels, thereby promoting: (a) transiently excessive renal and extrarenal production of Vitamin D hormones, and leading to local aberrations in calcium and phosphorus homeostasis and increased risk of hypercalciuria, hypercalcemia and hyperphosphatemia; (b) catabolism of both Vitamin D and 25-hydroxyvitamin D by 24-and/or 26-hydroxylation in the kidney and other tissues; (c) down-regulation of hepatic production of Vitamin D prohormones, unnecessarily impeding the efficient repletion of Vitamin D insufficiency or deficiency; and, (d) local aberrations in calcium and phosphorus homeostasis mediated by direct binding to VDR.
- Vitamin D supplements produce supraphysiologic, even pharmacological, concentrations of Vitamin D, e.g., in the lumen of the duodenum, promoting: (a) 25-hydroxylation in the enterocytes and local stimulation of intestinal absorption of calcium and phosphorus, leading to increased risk of hypercalciuria, hypercalcemia and hyperphosphatemia; and (b) catabolism of Vitamin D by 24- and 26-hydroxylation in the local enterocytes, causing decreased systemic bioavailability.
- Vitamin D supplementation above the UL is frequently needed in certain individuals; however, currently available oral Vitamin D supplements are not well suited for maintaining blood 25-hydroxyvitamin D levels at optimal levels given the problems of administering high doses of immediate release Vitamin D compounds.
- 25-hydroxyvitamin D levels promoted catabolism of both Vitamin D and 25-hydroxyvitamin D by 24- and/or 26-hydroxylation in the kidney and other tissues, down-regulation of hepatic production of Vitamin D prohormones, unnecessarily impeding the efficient repletion of Vitamin D insufficiency or deficiency, and, additional local aberrations in calcium and phosphorus homeostasis mediated by direct binding to VDR.
- immediate release 25-hydroxyvitamin D 3 promoted its intestinal absorption via a mechanism substantially involving transport to the liver in chylomicrons, rather than bound to the serum DBP. Delivery of 25-hydroxyvitamin D to the liver via chylomicrons significantly increased the likelihood of its catabolism.
- Vitamin D supplementation is needed given the problems encountered with both currently available oral Vitamin D supplements, and with previously used oral 25-hydroxyvitamin D 3 .
- the present invention provides methods for effectively and safely restoring blood 25-hydroxyvitamin D levels to optimal levels (defined for patients as >30 ng/mL 25-hydroxyvitamin D) and maintaining blood 25-hydroxyvitamin D levels at such optimal levels.
- the method includes dosing a subject, an animal or a human patient, orally or intravenously with sufficient 25-hydroxyvitamin D 2 or 25-hydroxyvitamin D 3 or any combination of these two prohormones in a formulation that provides benefits to the recipient that were heretofore unimagined with currently available Vitamin D supplements. That is, the present invention provides effective Vitamin D supplementation that reduces the risk of transient surges (i.e., supraphysiologic levels) of blood 25-hydroxyvitamin D and related side effects.
- an amount of 25-hydroxyvitamin D 2 and/or 25-hydroxyvitamin D 3 is included in a controlled release formulation and is orally administered daily to a human or animal in need of treatment.
- an amount of 25-hydroxyvitamin D 2 and/or 25-hydroxyvitamin D 3 is included in an isotonic sterile formulation suitable for intravenous administration, and is gradually injected thrice weekly into a human or animal in need of treatment.
- This administration of 25-hydroxyvitamin D 2 and/or 25-hydroxyvitamin D 3 significantly: increases the bioavailability of the contained 25-hydroxyvitamin D 2 /25-hydroxyvitamin D 3 ; decreases the undesirable first pass effects of the contained 25-hydroxyvitamin D 2 /25-hydroxyvitamin D 3 on the duodenum; avoids producing supraphysiologic surges in blood levels of 25-hydroxyvitamin D 2 and/or 25-hydroxyvitamin D 3 ; increases the effectiveness of orally administered 25-hydroxyvitamin D 2 /25-hydroxyvitamin D 3 in restoring blood concentrations of 25-hydroxyvitamin D to optimal levels (defined for patients as >30 ng/mL 25-hydroxyvitamin D); increases the effectiveness of orally administered 25-hydroxyvitamin D 2 /25-hydroxyvitamin D 3 in maintaining blood concentrations of 25-hydroxyvitamin D at such optimal levels; decreases disruptions in Vitamin D metabolism and related aberrations in PTH, calcium and phosphorus homeostasis; and, decreases the risk of serious side effects associated with Vitamin D supplement
- the present invention provides a stable controlled release composition
- a stable controlled release composition comprising 25-hydroxyvitamin D 2 and/or 25-hydroxyvitamin D 3 , which is formulated to allow the 25-hydroxyvitamin D to pass through the stomach, and the duodenum and jejunum of the small intestine, to the ileum.
- the composition effectively resists disintegration in gastric juice, and avoids substantial release of the contained 25-hydroxyvitamin D until it reaches the ileum of the small intestine, thereby minimizing absorption substantially mediated by transport to the liver in chylomicrons.
- the disclosed composition is gradually presented to the intralumenal and intracellularluar aspects of the ileum, reducing CYP24-mediated catabolism and provoking a sustained increase in the blood levels of 25-hydroxyvitamin D to optimal levels which can be maintained.
- the invention provides an isotonic sterile formulation suitable for gradual intravenous administration containing 25-hydroxyvitamin D 2 and/or 25-hydroxyvitamin D 3 , which allows the 25-hydroxyvitamin D to completely bypass the gastrointestinal tract, thereby eliminating first pass effects on the duodenum and jejunum, as well as absorption mediated by transport to the liver in chylomicrons.
- the present invention relates to a method for dosing a subject, an animal or a human patient, in need of Vitamin D supplementation with sufficient 25-hydroxyvitamin D 2 , 25-hydroxyvitamin D 3 or any combination of these two prohormones to effectively and safely restore blood 25-hydroxyvitamin D levels to optimal levels (defined for human subjects and patients as >30 ng/mL 25-hydroxyvitamin D) and to maintain blood 25-hydroxyvitamin D levels at such optimal levels.
- the term “substantially constant” with respect to the serum or blood level of 25-hydroxyvitamin D means that the release profile of any formulation administered as detailed hereinbelow should not include transient increases in total serum or blood levels of 25-hydroxyvitamin D 3 or 25-hydroxyvitamin D 2 of greater than approximately 3 ng/mL after administration of a unit dose.
- controlled release and “sustained release” are used interchangeably, and refer to the release of the administered 25-hydroxyvitamin D at such a rate that total serum or blood levels of 25-hydroxyvitamin D are maintained or elevated above predosing levels for an extended period of time, e.g., 4 to 24 hours or even longer.
- Vitamin D toxicity is meant to refer to the side effects suffered from excessive administration of 25-hydroxyvitamin D and excessively elevated 25-hydroxyvitamin D blood levels, including nausea, vomiting, polyuria, hypercalciuria, hypercalcemia and hyperphosphatemia.
- “Supraphysiologic” in reference to intralumenal, intracellularuar and blood concentrations of 25-hydroxyvitamin D refers to a combined concentration of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 during a 24-hour post-dose period which is more than 5 ng/mL greater than the generally stable levels observed over the course of the preceding 24-hour period by laboratory measurement.
- “Vitamin D insufficiency and deficiency” is generally defined as having serum 25-hydroxyvitamin D levels below 30 ng/mL (National Kidney Foundation guidelines, NKF, Am. J. Kidney Dis. 42:S1-S202 (2003), incorporated herein by reference).
- 25-hydroxyvitamin D 2 /25-hydroxyvitamin D 3 as used herein is intended to encompass 25-hydroxyvitamin D 2 , 25-hydroxyvitamin D 3 , or a combination thereof.
- 25-hydroxyvitamin D is intended to refer to 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 collectively.
- an assayed blood level of 25-hydroxyvitamin D will include both 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 , if present.
- any numerical value recited herein includes all values from the lower value to the upper value, i.e., all possible combinations of numerical values between the lowest value and the highest value enumerated are to be considered to be expressly stated in this application.
- a concentration range or a beneficial effect range is stated as 1% to 50%, it is intended that values such as 2% to 40%, 10% to 30%, or 1% to 3%, etc., are expressly enumerated in this specification. These are only examples of what is specifically intended.
- the invention includes compositions comprising oral and intravenous formulations of 25-hydroxyvitamin D 2 and/or 25-hydroxyvitamin D 3 and methods of administering such formulations to treat 25-hydroxyvitamin D insufficiency and deficiency without the potential first pass effects of these prohormones on the duodenum and jejunum; without supraphysiological surges in intralumenal, intracellular and blood levels of 25-hydroxyvitamin D and their consequences; without causing substantially increased catabolism of the administered 25-hydroxyvitamin D; and, without causing serious side effects associated with Vitamin D supplementation, namely Vitamin D toxicity.
- the controlled release compositions intended for oral administration in accordance with the present invention are designed to contain concentrations of the 25-hydroxyvitamin D 2 /25-hydroxyvitamin D 3 of 1 to 50 mcg per unit dose, and are prepared in such a manner as to effect controlled or substantially constant release of the 25-hydroxyvitamin D 2 /25-hydroxyvitamin D 3 into the ileum of the gastrointestinal tract of humans or animals over an extended period of time.
- the compositions ensure a (a) substantially increased absorption of 25-hydroxyvitamin D via transport on DBP and decreased absorption via transport in chylomicrons, and (b) maintenance of substantially constant blood levels of 25-hydroxyvitamin D during the 24-hour post-dosing period.
- compositions intended for intravenous administration in accordance with the present invention are designed to contain concentrations of the 25-hydroxyvitamin D 2 /25-hydroxyvitamin D 3 of 1 to 25 mcg per unit dose, and are prepared in such a manner as to allow gradual injection, over a period of 1 to 5 minutes, to effect controlled or substantially constant release of the 25-hydroxyvitamin D 2 /25-hydroxyvitamin D 3 directly to DBP in the blood.
- the compositions ensure complete bioavailability of the administered 25-hydroxyvitamin D, complete elimination of first pass effects on the duodenum and jejunum, decreased catabolism of 25-hydroxyvitamin D, and maintenance of substantially constant blood levels of 25-hydroxyvitamin D during the 24-hour post-dosing period.
- compositions of the present invention comprise highly stable pharmaceutical formulations into which 25-hydroxyvitamin D 2 and/or 25-hydroxyvitamin D 3 is incorporated for convenient daily oral administration.
- the disclosed compositions produce gradual increases in and then sustained blood levels of 25-hydroxyvitamin D with dual unexpected benefits with continued regular administration over a prolonged period of time of unsurpassed effectiveness in restoring blood 25-hydroxyvitamin D to optimal levels, and unsurpassed safety relative to heretofore known formulations of Vitamin D or 25-hydroxyvitamin D.
- the preparation of a controlled, substantially constant release form of 25-hydroxyvitamin D 2 /25-hydroxyvitamin D 3 suitable for oral administration can be carried out according to many different techniques.
- the 25-hydroxyvitamin D 2 /25-hydroxyvitamin D 3 can be dispersed within a matrix, i.e. a unique mixture of rate controlling constituents and excipients in carefully selected ratios within the matrix, and encased with a coating material.
- Various coating techniques can be utilized to control the rate and/or the site of the release of the 25-hydroxyvitamin D 2 /25-hydroxyvitamin D 3 from the pharmaceutical formulation.
- the dissolution of the coating may be triggered by the pH of the surrounding media, and the resulting gradual dissolution of the coating over time exposes the matrix to the fluid of the intestinal environment.
- 25-hydroxyvitamin D 2 /25-hydroxyvitamin D 3 diffuses from the outer surface of the matrix.
- this surface becomes exhausted or depleted of 25-hydroxyvitamin D 2 /25-hydroxyvitamin D 3
- the underlying stores begin to be depleted by diffusion through the disintegrating matrix to the external solution.
- a formulation in accordance with the present invention provides 25-hydroxyvitamin D 2 and/or 25-hydroxyvitamin D 3 within a matrix that releasably binds the ingredients in a controlled substantially constant release when exposed to the contents of the ileum.
- the 25-hydroxyvitamin D 2 and/or 25-hydroxyvitamin D 3 containing matrix is suitably covered with a coating that is resistant to disintegration in gastric juices.
- the coated controlled release formulation of 25-hydroxyvitamin D 2 /25-hydroxyvitamin D 3 is then administered orally to subjects, e.g., animals or human subjects and patients. As the formulation travels through the proximal portion of the small intestine, the enteric coating becomes progressively more permeable but, in a suitable embodiment, it provides a persisting structural framework around the 25-hydroxyvitamin D 2 and/or 25-hydroxyvitamin D 3 containing matrix.
- the 25-hydroxyvitamin D 2 and/or 25-hydroxyvitamin D 3 containing matrix becomes significantly exposed to intestinal fluids in the ileum through the permeable overcoating, and the 25-hydroxyvitamin D 2 /25-hydroxyvitamin D 3 is then gradually released by simple diffusion and/or slow disintegration of the matrix.
- the 25-hydroxyvitamin D 2 /25-hydroxyvitamin D 3 is absorbed into the lymphatic system or into the portal bloodstream where it is bound to and transported by the DBP.
- the major portion of 25-hydroxyvitamin D 2 /25-hydroxyvitamin D 3 is absorbed at a point beyond the duodenum and jejunum.
- These proximal portions of the small intestine can respond to high intralumenal levels of 25-hydroxyvitamin D 2 /25-hydroxyvitamin D 3 and, in the process, can catabolize significant quantities of the 25-hydroxyvitamin D 2 /25-hydroxyvitamin D 3 .
- the pharmaceutical composition described herein virtually eliminates these potential first pass effects on the proximal intestine, and reduces unwanted catabolism.
- Substantially delayed release of 25-hydroxyvitamin D markedly decreases the amount of 25-hydroxyvitamin D that is incorporated and absorbed from the small intestine via chylomicrons (since chylomicron formation and absorption occurs primarily in the jejunum) and correspondingly increases the amount of 25-hydroxyvitamin D that is absorbed directly through the intestinal wall and onto DBP circulating in lymph or portal blood.
- the controlled release oral formulation of D 2 and/or 25-hydroxyvitamin D 3 is prepared generally according to the following procedure.
- a sufficient quantity of 25-hydroxyvitamin D 2 and/or 25-hydroxyvitamin D 3 is completely dissolved in a minimal volume of USP-grade absolute ethanol (or other suitable solvent) and mixed with appropriate amounts and types of pharmaceutical-grade excipients to form a matrix which is solid or semi-solid at both room temperature and at the normal temperature of the human body.
- the matrix is completely or almost entirely resistant to digestion in the stomach and upper small intestine, and it gradually disintegrates in the lower small intestine.
- the matrix binds the 25-hydroxyvitamin D 2 and/or D 3 and permits a slow, relatively steady, i.e., substantially constant, release of the 25-hydroxyvitamin D 2 /25-hydroxyvitamin D 3 over a period of four to eight hours or more, by simple diffusion and/or gradual disintegration, into the contents of the lumen of the lower small intestine.
- the formulation further has an enteric coating that partially dissolves in aqueous solutions having a pH of about 7.0 to 8.0, or simply dissolves slowly enough that significant release of 25-hydroxyvitamin D 2 /25-hydroxyvitamin D 3 is delayed until after the formulation passes through the duodenum and jejunum.
- the means for providing the controlled release of 25-hydroxyvitamin D 2 and/or 25-hydroxyvitamin D 3 may be selected from any of the known controlled release delivery systems of an active ingredient over a course of about four or more hours including the wax matrix system, and the Eudragit RS/RL system (of Rohm Pharma, GmbH, Rothstadt, Germany).
- the wax matrix system provides a lipophilic matrix.
- the wax matrix system may utilize, beeswax, white wax, cachalot wax or similar compositions.
- the active ingredient(s) are dispersed in the wax binder which slowly disintegrates in intestinal fluids to gradually release the active ingredient(s).
- the wax binder that is impregnated with the 25-hydroxyvitamin D 2 and/or 25-hydroxyvitamin D 3 is loaded into partially crosslinked soft gelatin capsules.
- the wax matrix system disperses the active ingredient(s) in a wax binder which softens at body temperature and slowly disintegrates in intestinal fluids to gradually release the active ingredient(s).
- the system suitably includes a mixture of waxes, with the optional addition of oils, to achieve a melting point which is higher than body temperature but lower than the melting temperature of gelatin formulations typically used to create the shells of either soft and hard gelatin capsules or other formulations used to create enteric coatings.
- the waxes selected for the matrix are melted and thoroughly mixed.
- the desired quantity of oils are added at this time, followed by sufficient mixing.
- the waxy mixture is then gradually cooled to a temperature just above its melting point.
- the desired amount of 25-hydroxyvitamin D 2 and/or 25-hydroxyvitamin D 3 , dissolved in ethanol, is uniformly distributed into the molten matrix, and the matrix is loaded into soft gelatin capsules.
- the filled capsules are treated for appropriate periods of time with a solution containing an aldehyde, such as acetaldehyde, to partially crosslink the gelatin in the capsule shell.
- the gelatin shell becomes increasingly crosslinked, over a period of several weeks and, thereby, more resistant to dissolution in the contents of stomach and upper intestine.
- this gelatin shell will gradually dissolve after oral administration and become sufficiently porous (without fully disintegrating) by the time it reaches the ileum to allow the 25-hydroxyvitamin D 2 and/or 25-hydroxyvitamin D 3 to diffuse slowly from the wax matrix into the contents of the lower small intestine.
- lipid matrices examples include glycerides, fatty acids and alcohols, and fatty acid esters.
- Another suitable controlled-release oral drug delivery system is the Eudragit RL/RS system in which the active ingredient, 25-hydroxyvitamin D 2 and/or 25-hydroxyvitamin D 3 , is formed into granules having a dimension of 25/30 mesh.
- the granules are then uniformly coated with a thin polymeric lacquer which is water insoluble but slowly water permeable.
- the coated granules can be mixed with optional additives such as antioxidants, stabilizers, binders, lubricants, processing aids and the like.
- the mixture may be compacted into a tablet which, prior to use, is hard and dry and can be further coated, or it may be poured into a capsule.
- the thin lacquer begins to swell and slowly allows permeation by intestinal fluids.
- the contained 25-hydroxyvitamin D 2 and/or 25-hydroxyvitamin D 3 is slowly released.
- the 25-hydroxyvitamin D 2 /25-hydroxyvitamin D 3 will have been slowly but completely released. Accordingly, the ingested tablet will release a stream of 25-hydroxyvitamin D 2 and/or 25-hydroxyvitamin D 3 as well as any other active ingredient.
- the Eudragit system is comprised of high permeability lacquers (RL) and low permeability lacquers (RS).
- RS is a water insoluble film former based on neutral swellable methacrylic acids esters with a small proportion of trimethylammonioethyl methacrylate chlorides, the molar ratio of the quaternary ammonium groups to the neutral ester group is about 1:40.
- RL is also a water insoluble swellable film former based on neutral methacrylic acid esters with a small portion of trimethylammonioethyl methacrylate chloride, the molar ratio of quaternary ammonium groups to neutral ester groups is about 1:20.
- insoluble polymers include polyvinyl esters, polyvinyl acetals, polyacrylic acid esters, butadiene styrene copolymers and the like,
- the tablet or capsule is coated with an enteric-coating material which dissolves at a pH of 7.0 to 8.0.
- enteric-coating material is Eudragit L/S which dissolves in intestinal fluid but not in the gastric juices.
- enteric-coating materials may be used such as cellulose acetate phthalate (CAP) which is resistant to dissolution by gastric juices but readily disintegrates due to the hydrolytic effect of the intestinal esterases.
- CAP cellulose acetate phthalate
- controlled release composition in accordance with the present invention when administered once a day, suitably provides substantially constant intralumenal, intracellular and blood 25-hydroxyvitamin D levels compared to an equal dose of an immediate release composition of 25-hydroxyvitamin D 2 /25-hydroxyvitamin D 3 administered once a day
- sterile, isotonic formulations of 25-hydroxyvitamin D 2 , 25-hydroxyvitamin D 3 or combinations thereof may be prepared which are suitable for gradual intravenous administration.
- Such formulations are prepared by dissolving 25-hydroxyvitamin D 2 and/or 25-hydroxyvitamin D 3 in absolute ethanol, propylene glycol or other suitable solvents, and combining the resulting solutions with surfactants, salts and preservatives in appropriate volumes of water for injection.
- Such formulations can be administered slowly from syringes via heparin locks or by addition to larger volumes of sterile solutions (e.g., saline solution) being steadily infused over time.
- the dosage forms may also contain adjuvants, such as preserving or stabilizing adjuvants. They may also contain other therapeutically valuable substances or may contain more than one of the compounds specified herein and in the claims in admixture.
- 25-hydroxyvitamin D 2 , 25-hydroxyvitamin D 3 or combinations thereof together with other therapeutic agents can be orally or intravenously administered in accordance with the above described embodiments in dosage amounts of from 1 to 100 mcg per day, with the preferred dosage amounts of from 5 to 50 mcg per day. If the compounds of the present invention are administered in combination with other therapeutic agents, the proportions of each of the compounds in the combination being administered will be dependent on the particular disease state being addressed.
- calcium salts intended as a calcium supplement or dietary phosphate binder
- bisphosphonates intended as a calcium supplement or dietary phosphate binder
- calcimimetics intended as a calcium supplement or dietary phosphate binder
- calcimimetics intended as a calcium supplement or dietary phosphate binder
- calcimimetics intended as a calcium supplement or dietary phosphate binder
- calcimimetics intended as a calcium supplement or dietary phosphate binder
- calcimimetics intended as a calcium supplement
- higher doses of the compounds of the present invention are used where therapeutic treatment of a disease state is the desired end, while the lower doses are generally used for prophylactic purposes, it being understood that the specific dosage administered in any given case will be adjusted in accordance with the specific compounds being administered, the disease to be treated, the condition of the subject and the other relevant medical facts that may modify the activity of the drug or the response of the subject, as is well known by those skilled in the art.
- Purified yellow beeswax and fractionated coconut oil are combined in a ratio of 1:1 and heated with continuous mixing to 75 degrees Celsius until a uniform mixture is obtained.
- the wax mixture is continuously homogenized while cooled to approximately 45 degrees Celsius.
- 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 are dissolved in absolute ethanol and the ethanolic solution is added, with continuous homogenization, to the molten wax mixture.
- the amount of ethanol added is in the range of 1 to 2 v/v %. Mixing is continued until the mixture is uniform.
- the uniform mixture is loaded into soft gelatin capsules.
- the capsules are immediately rinsed to remove any processing lubricant(s) and briefly immersed in an aqueous solution of acetaldehyde in order to crosslink the gelatin shell.
- concentration of the acetaldehyde solution and the immersion time is selected to achieve crosslinking to the desired degree, as determined by near-infrared spectrophotometry.
- the finished capsules are washed, dried and packaged.
- TWEEN Polysorbate 20 is warmed to approximately 50 to 60° F. (10 to 16° C.), and 25-hydroxyvitamin D 3 , dissolved in a minimal volume of absolute ethanol, is added with continuous stirring. The resulting uniform solution of 25-hydroxyvitamin D 3 , absolute ethanol and TWEEN Polysorbate 20 is transferred to a suitable volume of water for injection, which has been thoroughly sparged with nitrogen to remove all dissolved oxygen.
- Sodium chloride, sodium ascorbate, sodium phosphate (dibasic and monobasic), and disodium edetate are added, followed by sufficient stirring under a protective nitrogen atmosphere, to produce an isotonic homogeneous mixture containing, per 2 mL unit volume: 20 mcg of 25-hydroxyvitamin D 3 ; ⁇ 0.01% absolute ethanol; 0.40% (w/v) TWEEN Polysorbate 20; 0.15% (w/v) sodium chloride; 1.00% (w/v) sodium ascorbate; 0.75% (w/v) sodium phosphate dibasic anhydrous; 0.18% (w/v) sodium phosphate monobasic monohydrate; and, 0.11% (w/v) disodium edetate.
- This mixture is sterilized by filtration and filled, with suitable protection from oxygen contamination, into amber glass ampules having an oxygen headspace of less than 1%.
- each dog in Group #1 receives a single soft gelatin capsule containing 25 mcg of 25-hydroxyvitamin D 2 prepared in a controlled release formulation similar to the one disclosed in Example 1.
- Each dog in the other group receives a single immediate-release soft gelatin capsule containing 25 mcg of 25-hydroxyvitamin D 2 dissolved in medium chain triglyceride oil. All dogs have received no food for at least 8 hours prior to dosing. Blood is drawn from each dog at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 15, 24, 36, and 72 hours after dose administration.
- the collected blood is analyzed for the contained levels of 25-hydroxyvitamin D, and the data are analyzed by treatment group.
- Dogs in Group #1 show a slower rise and a lower maximum (C max) in mean blood levels of 25-hydroxyvitamin D than dogs in Group #2.
- dogs in Group #1 show a more prolonged elevation of mean blood levels of 25-hydroxyvitamin D 2 relative to dogs in Group #2, despite the fact that the C max recorded in Group #1 is lower.
- Formulation #1 Sixteen healthy non-obese adults, aged 18 to 24 years, participate in an 11-week pharmacokinetic study in which they receive successively, and in a double-blinded fashion, two formulations of 25-hydroxyvitamin D 2 .
- One of the formulations (Formulation #1) is a soft gelatin capsule containing 100 mcg of 25-hydroxyvitamin D 2 prepared in a controlled release formulation similar to the one disclosed in Example 1.
- the other formulation (Formulation #2) is an immediate-release soft gelatin capsule of identical appearance containing 100 mcg of 25-hydroxyvitamin D 2 dissolved in medium chain triglyceride oil. For 60 days prior to study start and continuing through study termination, the subjects abstain from taking other Vitamin D supplements.
- Blood is again drawn from each subject at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 15, 24, 36, 48, 72 and 108 hours after dose administration. All collected blood is analyzed for the contained levels of 25-hydroxyvitamin D, and the data are analyzed by treatment formulation after correction for baseline content.
- Formulation #1 is found to produce a slower rise and a lower C max in mean blood levels of 25-hydroxyvitamin D than Formulation #2. However, Formulation #1 also produces a more prolonged elevation of mean blood levels of 25-hydroxyvitamin D 2 relative to Formulation #2, despite the fact that the recorded C max is lower.
- the mean AUC is substantially greater after administration of Formulation #1 for 25-hydroxyvitamin D.
- Vitamin D in restoring serum 25-hydroxyvitamin D to optimal levels (>30 ng/mL) is examined in a 23-day study of healthy non-obese men diagnosed with Vitamin D insufficiency.
- One of the formulations is a soft gelatin capsule containing 30 mcg of 25-hydroxyvitamin D 3 prepared as illustrated in this invention.
- the second formulation is an immediate-release soft gelatin capsule of identical appearance containing 50,000 IU of ergocalciferol dissolved in medium chain triglyceride oil.
- the third formulation (Formulation #3) is an immediate-release soft gelatin capsule, also of identical appearance, containing 50,000 IU of cholecalciferol dissolved in medium chain triglyceride oil.
- Subjects in Group #4 receive a matching placebo capsule.
- Subjects in Group #1 each receive an additional capsule of Formulation #1 on the mornings of Days 4 through 22 before breakfast, but subjects in Groups #2, #3 and #4 receive no additional capsules.
- a fasting morning blood sample is drawn from each subject, irrespective of treatment group, on Days 4, 5, 6, 10, 17 and 23 (or 1, 2, 3, 7, 14 and 20 days after the start of dosing).
- Subjects in all four treatment groups exhibit mean baseline serum 25-hydroxyvitamin D levels of approximately 16 to 18 ng/mL, based on analysis of fasting blood samples drawn on Days 1 through 3.
- Subjects in Group #4 show no significant changes in mean serum 25-hydroxyvitamin D over the course of the study.
- Subjects in Group #1 show a steadily increasing mean serum 25-hydroxyvitamin D reaching at least 30 ng/mL by Day 23.
- subjects in Group #2 exhibit marked increases in mean serum 25-hydroxyvitamin D for the first few days post-dosing, reaching a maximum of just above 25 ng/mL, and then rapidly declining thereafter.
- serum 25-hydroxyvitamin D is significantly lower than baseline in Group #2.
- Subjects in Group #3 exhibit continuing increases in mean serum 25-hydroxyvitamin D through the first 2 weeks after dosing with gradual, but progressive, decreases occurring thereafter.
- mean serum 25-hydroxyvitamin D is below 30 ng/mL, being only approximately 11 ng/mL higher than pre-treatment baseline.
- the efficacy and safety of intravenous 25-hydroxyvitamin D 3 in restoring serum 25-hydroxyvitamin D to optimal levels are examined in a 3-month study of patients with end-stage renal disease (ESRD) requiring regular hemodialysis and diagnosed with Vitamin D insufficiency.
- the formulation examined in this study is an aqueous isotonic and sterile solution containing 20 mcg of 25-hydroxyvitamin D 3 similar to the one disclosed in Example 2.
- all subjects Prior to enrolling, all subjects provide two fasting morning blood samples, separated by at least one week, to establish pre-treatment baseline values of serum calcium, plasma intact PTH, and serum 25-hydroxyvitamin D.
- the subjects are randomly assigned to one of two treatment groups, and they begin thrice weekly dosing with the test preparation, or with a matching placebo. All dosing occurs during regularly scheduled hemodialysis sessions and is accomplished by gradual injection (over a period of 1 to 5 minutes) into the blood exiting from the hemodialysis machine. Additional fasting blood samples and 24-hour urine collections are obtained from each subject at quarterly intervals for determination of serum calcium, plasma intact PTH and serum 25-hydroxyvitamin D.
- Subjects in the treatment group receiving 25-hydroxyvitamin D 3 exhibit progressively increasing serum 25-hydroxyvitamin D levels during the first 3 months of dosing, reaching steady state levels thereafter.
- Mean serum calcium increases significantly from baseline in the treatment group receiving 25-hydroxyvitamin D 3 , and is significantly higher than those observed in the placebo group.
- Episodes of hypercalcemia, defined as serum calcium above 9.5 mg/dL, are infrequently observed in both treatment groups.
- Data from this study demonstrate that the intravenous formulation of 25-hydroxyvitamin D 3 is effective at increasing serum 25-hydroxyvitamin D without causing unacceptable side effects related to calcium and PTH metabolism.
- Embodiments contemplated in view of the foregoing description include the following numbered paragraphs.
- sustained release oral dosage formulation comprising the 25-hydroxyvitamin D 2 , 25-hydroxyvitamin D 3 , or combination of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 dispersed within a wax matrix.
- sustained release oral dosage formulation of any one of the preceding paragraphs, wherein the formulation is semi-solid at body temperature.
- sustained release oral dosage formulation comprising 1 to 50 mcg per unit dose of the 25-hydroxyvitamin D 2 , 25-hydroxyvitamin D 3 , or combination of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 .
- sustained release oral dosage formulation of any one of the preceding paragraphs, wherein the sustained release is effected over a period of at least four hours.
- sustained release oral dosage formulation of any one of the preceding paragraphs, comprising 25-hydroxyvitamin D 3 .
- a method of treating 25-hydroxyvitamin D insufficiency or deficiency in a patient comprising orally administering to the patient a delayed, sustained release formulation according to any one of the preceding paragraphs.
Abstract
Description
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/237,889 US11911398B2 (en) | 2006-02-03 | 2021-04-22 | Treating Vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US76466506P | 2006-02-03 | 2006-02-03 | |
PCT/US2007/061521 WO2007092755A2 (en) | 2006-02-03 | 2007-02-02 | Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3 |
US27805309A | 2009-02-23 | 2009-02-23 | |
US13/848,982 US8906410B2 (en) | 2006-02-03 | 2013-03-22 | Oral dosage form of 25-hydroxyvitamin D |
US14/548,275 US9943530B2 (en) | 2006-02-03 | 2014-11-19 | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
US15/722,757 US10213442B2 (en) | 2006-02-03 | 2017-10-02 | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
US16/171,100 US11007204B2 (en) | 2006-02-03 | 2018-10-25 | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
US17/237,889 US11911398B2 (en) | 2006-02-03 | 2021-04-22 | Treating Vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/171,100 Continuation US11007204B2 (en) | 2006-02-03 | 2018-10-25 | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
Publications (2)
Publication Number | Publication Date |
---|---|
US20210236517A1 US20210236517A1 (en) | 2021-08-05 |
US11911398B2 true US11911398B2 (en) | 2024-02-27 |
Family
ID=38134147
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/278,053 Active 2027-05-26 US8426391B2 (en) | 2006-02-03 | 2007-02-02 | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
US13/848,982 Active US8906410B2 (en) | 2006-02-03 | 2013-03-22 | Oral dosage form of 25-hydroxyvitamin D |
US14/548,275 Active US9943530B2 (en) | 2006-02-03 | 2014-11-19 | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
US15/722,757 Active US10213442B2 (en) | 2006-02-03 | 2017-10-02 | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
US16/171,100 Active US11007204B2 (en) | 2006-02-03 | 2018-10-25 | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
US17/237,889 Active 2028-01-18 US11911398B2 (en) | 2006-02-03 | 2021-04-22 | Treating Vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
Family Applications Before (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/278,053 Active 2027-05-26 US8426391B2 (en) | 2006-02-03 | 2007-02-02 | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
US13/848,982 Active US8906410B2 (en) | 2006-02-03 | 2013-03-22 | Oral dosage form of 25-hydroxyvitamin D |
US14/548,275 Active US9943530B2 (en) | 2006-02-03 | 2014-11-19 | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
US15/722,757 Active US10213442B2 (en) | 2006-02-03 | 2017-10-02 | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
US16/171,100 Active US11007204B2 (en) | 2006-02-03 | 2018-10-25 | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
Country Status (14)
Country | Link |
---|---|
US (6) | US8426391B2 (en) |
EP (3) | EP1993559B1 (en) |
JP (2) | JP5869745B2 (en) |
CA (2) | CA2640094C (en) |
CY (2) | CY1118017T1 (en) |
DK (2) | DK1993559T3 (en) |
ES (2) | ES2904546T3 (en) |
HK (2) | HK1231409A1 (en) |
HU (2) | HUE056937T2 (en) |
LT (2) | LT1993559T (en) |
PL (2) | PL1993559T3 (en) |
PT (2) | PT1993559T (en) |
SI (2) | SI1993559T1 (en) |
WO (1) | WO2007092755A2 (en) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1993559B1 (en) | 2006-02-03 | 2016-06-22 | OPKO Renal, LLC | Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3 |
EP2037936B1 (en) | 2006-06-21 | 2014-06-11 | Proventiv Therapeutics, LLC | Method of treating and preventing secondary hyperparathyroidism |
EP2148685A4 (en) * | 2007-04-25 | 2010-07-28 | Cytochroma Inc | Methods and compounds for vitamin d therapy |
WO2008134523A1 (en) | 2007-04-25 | 2008-11-06 | Proventiv Therapeutics, Llc | Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease |
ES2403107T3 (en) * | 2007-04-25 | 2013-05-14 | Cytochroma Inc. | Vitamin D insufficiency and deficiency treatment method |
PL2481400T3 (en) | 2007-04-25 | 2015-04-30 | Opko Ip Holdings Ii Inc | Oral controlled release compositions comprising vitamin D compound and waxy carrier |
EA018580B1 (en) * | 2008-02-13 | 2013-09-30 | ДСМ АйПи АССЕТС Б.В. | Combined use of 25-hydroxyvitamin d3 and vitamin d3 for improving bone mineral density and for treating osteoporosis |
EA019837B1 (en) * | 2008-02-13 | 2014-06-30 | ДСМ АйПи АССЕТС Б.В. | Use of 25-hydroxy-vitamin d3 to affect human muscle physiology |
KR20100126375A (en) * | 2008-02-13 | 2010-12-01 | 디에스엠 아이피 어셋츠 비.브이. | Combination of vitamin d and 25-hydroxyvitamin d3 |
EA201001288A1 (en) * | 2008-02-13 | 2011-02-28 | ДСМ АйПи АССЕТС Б. В. | TREATMENT OF HYPERTENSION WITH 25-HYDROXIVITAMIN D3 |
EP2240182B1 (en) * | 2008-02-13 | 2016-06-01 | DSM IP Assets B.V. | Treating hyperglycemia with 25-hydroxyvitamin d3 and vitamin d |
EP3112476B1 (en) | 2008-04-02 | 2023-08-02 | EirGen Pharma Ltd. | Methods, compositions, uses, and kits useful for vitamin d deficiency and related disorders |
PL2321273T3 (en) * | 2008-07-24 | 2015-05-29 | Wisconsin Alumni Res Found | Once-a-week administration of 25-hydroxy vitamin d3 to sustain elevated steady-state pharmacokinetic blood concentration |
EP2289555A1 (en) * | 2009-08-24 | 2011-03-02 | OrgaNext Research B.V. | Method of treating frailty |
WO2011048144A1 (en) * | 2009-10-20 | 2011-04-28 | Herbonis Ag | Composition comprising solanum glaucophyllum for preventing and/or treating hypocalcaemia and for stabilizing blood calcium levels |
SI2552484T1 (en) | 2010-03-29 | 2020-07-31 | Opko Ireland Global Holdings, Ltd. | Methods and compositions for reducing parathyroid levels |
US20140273021A1 (en) | 2013-03-14 | 2014-09-18 | Enzo Biochem, Inc. | Vitamin d assays |
KR101847947B1 (en) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | Stabilized modified release vitamin d formulation |
BR112017002526A2 (en) | 2014-08-07 | 2017-12-05 | Opko Ireland Global Holdings Ltd | adjuvant therapy with 25-hydroxyvitamin d |
EP3053598A1 (en) | 2015-02-06 | 2016-08-10 | Faes Farma, S.A. | Calcifediol soft capsules |
SG11201808227YA (en) | 2016-03-28 | 2018-10-30 | Opko Ireland Global Holdings Limited | Methods of vitamin d treatment |
JP6829101B2 (en) * | 2017-02-17 | 2021-02-10 | 株式会社ファンケル | Oral composition for prevention of upper respiratory tract infection or relief of upper respiratory tract infection symptoms |
CN112074275A (en) | 2018-04-03 | 2020-12-11 | 欧普科爱尔兰环球控股有限公司 | Use of calcifediol in the treatment of obesity in surgical patients |
KR20210054539A (en) * | 2018-08-31 | 2021-05-13 | 옵코 아일랜드 글로벌 홀딩스 리미티드 | Vitamin D dosage forms for children, their preparation and use |
CN113573714A (en) | 2019-02-06 | 2021-10-29 | 艾尔金制药有限公司 | Method for controlling hyperparathyroidism progression with calcifediol and compositions for use therein |
US20230084354A1 (en) * | 2020-01-27 | 2023-03-16 | Biomics, Llc | Nutraceutical extracts of hippophae rhamnoides and terminalia chebula and uses thereof |
CA3176559A1 (en) | 2020-04-06 | 2021-10-14 | Eirgen Pharma Ltd. | 25-hydroxyvitamin d for the treatment of sars-cov-2 infection |
CA3181945A1 (en) | 2020-05-31 | 2021-12-09 | Eirgen Pharma Ltd. | Hard capsule dosage form and uses thereof |
Citations (248)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3565924A (en) | 1968-07-01 | 1971-02-23 | Wisconsin Alumni Res Found | 25-hydroxycholfcalciferol |
US3833622A (en) | 1969-03-17 | 1974-09-03 | Upjohn Co | Crystalline 25-hydroxycholecalciferol hydrate and structurally related compounds |
US3880894A (en) | 1974-05-24 | 1975-04-29 | Wisconsin Alumni Res Found | 1,25-Dihydroxyergocalciferol |
US3974272A (en) | 1972-09-01 | 1976-08-10 | Merck & Co., Inc. | Palatable cholestyramine coacervate compositions |
US4004003A (en) | 1974-08-28 | 1977-01-18 | The Upjohn Company | 25-Hydroxycalciferol compounds for treatment of steroid-induced osteoporosis |
US4230701A (en) | 1979-03-21 | 1980-10-28 | Hoffmann-La Roche Inc. | Administration of biologically active vitamin D3 and vitamin D2 materials |
JPS55139320A (en) | 1979-04-16 | 1980-10-31 | Teijin Ltd | Bone metabolism regulator |
US4335120A (en) | 1979-03-21 | 1982-06-15 | Hoffmann-La Roche Inc. | Administration of biologically active vitamin D3 and vitamin D2 materials |
JPS57188520A (en) | 1981-05-15 | 1982-11-19 | Kureha Chem Ind Co Ltd | Antihyperkalemia |
JPS5832823A (en) | 1981-08-20 | 1983-02-25 | Chugai Pharmaceut Co Ltd | Cancer eliminating agent |
JPS58206524A (en) | 1982-05-26 | 1983-12-01 | Kureha Chem Ind Co Ltd | Antitumor agent |
US4442093A (en) | 1981-05-15 | 1984-04-10 | Kureha Kagaku Kogyo Kabushiki Kaisha | Method for administering 24,25-dihydroxycholecalciferol to persons suffering from hypercalcemia |
US4448721A (en) | 1982-09-20 | 1984-05-15 | Wisconsin Alumni Research Foundation | Hydroxyvitamin D2 compounds and process for preparing same |
US4555364A (en) | 1984-11-01 | 1985-11-26 | Wisconsin Alumni Research Foundation | Method for preparing 1-hydroxyvitamin D compounds |
US4668517A (en) | 1985-04-04 | 1987-05-26 | Norwich Eaton Pharmaceuticals, Inc. | Furazolidone dosage form |
EP0227836A1 (en) | 1985-06-24 | 1987-07-08 | Teijin Limited | Sustained releasing patch |
US4684524A (en) | 1984-03-19 | 1987-08-04 | Alza Corporation | Rate controlled dispenser for administering beneficial agent |
US4695591A (en) | 1985-03-29 | 1987-09-22 | Schering Corporation | Controlled release dosage forms comprising hydroxypropylmethylcellulose |
US4721613A (en) | 1982-12-13 | 1988-01-26 | Alza Corporation | Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use |
US4729895A (en) | 1983-02-22 | 1988-03-08 | Teijin Limited | Composition for solid pharmaceutical preparations of active vitamins D.sub.3 |
US4755544A (en) | 1985-06-04 | 1988-07-05 | Teijin Limited | Sustained release preparation |
JPS6431722A (en) | 1987-07-22 | 1989-02-02 | Teva Pharma | Composition of cholecalciferol derivative for treating renal bone disease |
US4892821A (en) | 1987-07-08 | 1990-01-09 | Taisho Pharmaceutical Co., Ltd. | Method for preparing vitamin D compounds |
JPH02229115A (en) | 1989-03-01 | 1990-09-11 | Teijin Ltd | Solid pharmaceutical of active type vitamin d3s improved in stability |
US5026559A (en) | 1989-04-03 | 1991-06-25 | Kinaform Technology, Inc. | Sustained-release pharmaceutical preparation |
WO1991012807A1 (en) | 1990-03-01 | 1991-09-05 | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) | Use of vitamin-d analogues in the treatment of acne |
WO1991016899A1 (en) | 1990-04-28 | 1991-11-14 | Sumitomo Pharmaceuticals Co., Ltd. | Composition for solid pharmaceutical preparations containing vitamin d3 derivative and process for preparation thereof |
WO1992009271A1 (en) | 1990-11-28 | 1992-06-11 | Sumitomo Pharmaceuticals Co., Ltd. | Composition for solid pharmaceutical preparations containing active vitamins d3 and process for preparation thereof |
JPH04208225A (en) | 1990-11-30 | 1992-07-29 | Ss Pharmaceut Co Ltd | Stable vitamin d pharmaceutical |
JPH04288016A (en) | 1991-03-14 | 1992-10-13 | Tokai Capsule Kk | Production of soft capsule agent of active type vitamin d3s |
EP0508756A1 (en) | 1991-04-09 | 1992-10-14 | Takeda Chemical Industries, Ltd. | Stabilized vitamin D preparation |
US5160742A (en) | 1991-12-31 | 1992-11-03 | Abbott Laboratories | System for delivering an active substance for sustained release |
US5167965A (en) | 1987-02-09 | 1992-12-01 | The Dow Chemical Company | Palatable cholestyramine granules, tablets and methods for preparation thereof |
EP0387808B1 (en) | 1989-03-13 | 1993-05-12 | Ss Pharmaceutical Co., Ltd. | Compositions for the preparation of dosage-form active vitamins d3 and process for preparing stable dosage-form active vitamins d3 by using the same |
WO1994000128A1 (en) | 1992-06-22 | 1994-01-06 | Lunar Corporation | ORAL 1α-HYDROXYPREVITAMIN D |
US5342626A (en) | 1993-04-27 | 1994-08-30 | Merck & Co., Inc. | Composition and process for gelatin-free soft capsules |
US5354743A (en) | 1992-09-15 | 1994-10-11 | Thys Jacobs Susan | Method for the treatment of premenstrual syndrome with vitamin D |
EP0629405A1 (en) | 1993-06-21 | 1994-12-21 | Kureha Chemical Industry Co., Ltd. | Agent for inhibiting a decrease in bone mass in renal osteodystrophy |
US5403831A (en) | 1988-08-02 | 1995-04-04 | Bone Care International, Inc. | Method of treating and preventing loss of bone mass using 1α-hydroxy-vitamin D2 |
US5431917A (en) | 1992-10-08 | 1995-07-11 | Japan Elanco Company, Ltd. | Hard capsule for pharmaceutical drugs and method for producing the same |
JPH07242550A (en) | 1994-03-02 | 1995-09-19 | Teijin Ltd | Therapeutic agent for secondary hyperparathyroidism |
US5472712A (en) | 1991-12-24 | 1995-12-05 | Euroceltique, S.A. | Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
WO1996000074A1 (en) | 1994-06-24 | 1996-01-04 | Ben-Gurion University Of The Negev | Pharmaceutical compositions comprising vitamin-d analogs |
WO1996001621A1 (en) | 1994-07-08 | 1996-01-25 | Astra Aktiebolag | New beads for controlled release and a pharmaceutical preparation containing the same |
JPH0892098A (en) | 1994-09-27 | 1996-04-09 | Teijin Ltd | Therapeutic medicine for consumption |
WO1996031215A1 (en) | 1995-04-03 | 1996-10-10 | Bone Care International, Inc. | Use of vitamin d2 or vitamin d4-derivatives for the manufacture of a medicament for the treatment of secondary hyperparathyroidism |
US5593690A (en) | 1988-11-08 | 1997-01-14 | Takeda Chemical Industries, Ltd. | Sustained release preparations |
WO1997011053A1 (en) | 1995-09-21 | 1997-03-27 | Wisconsin Alumni Research Foundation | Calcitriol derivatives and their uses |
CA2241205A1 (en) | 1995-12-21 | 1997-07-03 | Schering Aktiengesellschaft | Pharmaceutical compositions with vitamin d analogues |
US5693615A (en) | 1991-06-05 | 1997-12-02 | The Procter & Gamble Company | Therapeutic compositions for osteoinduction |
WO1998018610A1 (en) | 1996-10-28 | 1998-05-07 | Lengerich Bernhard H Van | Embedding and encapsulation of controlled release particles |
US5756123A (en) | 1994-12-01 | 1998-05-26 | Japan Elanco Co., Ltd. | Capsule shell |
JPH10158171A (en) | 1996-12-02 | 1998-06-16 | Kita:Kk | Intraocular administrating agent formulating vitamin d compound therein |
WO1998029105A2 (en) | 1996-12-30 | 1998-07-09 | Bone Care International, Inc. | Method of treating prostatic diseases using delayed and/or sustained release vitamin d formulations |
US5869473A (en) | 1988-08-02 | 1999-02-09 | Bone Care International, Inc. | Method for treating and preventing hyperparathyroidism |
US5872113A (en) | 1997-05-16 | 1999-02-16 | Syntex (U.S.A.) Inc. | Fluorinated vitamin D3 analogs |
WO1999011272A1 (en) | 1997-09-02 | 1999-03-11 | Johns Hopkins University School Of Medicine | Vitamin d3 analog loaded polymer formulations for cancer and neurodegenerative disorders |
US5888994A (en) | 1996-05-23 | 1999-03-30 | Hoffmann-La Roche Inc. | Fluorinated Vitamin D3 analogs |
JPH11158074A (en) | 1997-12-03 | 1999-06-15 | Hayashi Tomie | Amino acid-rich active vitamin d potentiation composition |
US5919986A (en) | 1997-10-17 | 1999-07-06 | Hoffmann-La Roche Inc. | D-homo vitamin D3 derivatives |
US5939408A (en) | 1996-05-23 | 1999-08-17 | Hoffman-La Roche Inc. | Vitamin D3 analogs |
US5958451A (en) | 1996-09-03 | 1999-09-28 | Yung Shin Pharm Ind. Co., Ltd. | Process for producing porous, controlled-release capsules and encapsulated composition |
WO1999049027A1 (en) | 1998-03-25 | 1999-09-30 | Cutanogen, Inc. | Methods for prevention and treatment of cancer |
US5976784A (en) | 1996-09-20 | 1999-11-02 | Wisconsin Alumni Research Foundation | Calcitriol derivatives and their uses |
WO1999061398A2 (en) | 1998-05-29 | 1999-12-02 | Bone Care International | 24-hydroxyvitamin d, analogs and uses thereof |
US6001884A (en) | 1991-08-23 | 1999-12-14 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US6011068A (en) | 1991-08-23 | 2000-01-04 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US6031003A (en) | 1991-08-23 | 2000-02-29 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US6034075A (en) | 1997-03-20 | 2000-03-07 | The Trustees Of Columbia University In The City Of New York | Method of treating polycystic ovarian syndrome |
US6051567A (en) | 1999-08-02 | 2000-04-18 | Abbott Laboratories | Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol |
WO2000021504A1 (en) | 1998-10-09 | 2000-04-20 | General Mills, Inc. | Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles |
WO2000035419A2 (en) | 1998-12-17 | 2000-06-22 | Alza Corporation | Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings |
US6096876A (en) | 1997-08-06 | 2000-08-01 | Shriners Hospitals For Children | 1-α-hydroxylase materials and methods |
US6121469A (en) | 1993-12-23 | 2000-09-19 | The Regents Of The University Of California | Therapeutically effective 1α,25-dihydroxyvitamin D3 analogs |
WO2000060109A1 (en) | 1999-04-02 | 2000-10-12 | The Regents Of The University Of California | Amplification of cyp24 and uses thereof |
WO2000061123A2 (en) | 1999-04-08 | 2000-10-19 | Schering Aktiengesellschaft | Compound preparation made of vitamin d metabolites or vitamin d analogues and an oestrogenic component for treating osteoporosis |
US6139875A (en) | 1998-09-29 | 2000-10-31 | Eastman Chemical Company | Aqueous enteric coating composition and low gastric permeability enteric coating |
US6190695B1 (en) | 1919-04-09 | 2001-02-20 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition containing osteogenesis-promoting substance |
US6211244B1 (en) | 1994-10-21 | 2001-04-03 | Nps Pharmaceuticals, Inc. | Calcium receptor-active compounds |
US6214376B1 (en) | 1998-08-25 | 2001-04-10 | Banner Pharmacaps, Inc. | Non-gelatin substitutes for oral delivery capsules, their composition and process of manufacture |
WO2001037808A1 (en) | 1999-11-23 | 2001-05-31 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6274169B1 (en) | 1999-08-02 | 2001-08-14 | Abbott Laboratories | Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol |
US6288849B1 (en) | 1998-11-12 | 2001-09-11 | Olympus Optical Co., Ltd. | Optical element |
WO2001072286A1 (en) | 2000-03-27 | 2001-10-04 | Glaxosmithkline Consumer Healthcare Gmbh & Co Kg | Sustained release vitamin composition |
US20010028896A1 (en) | 1998-05-28 | 2001-10-11 | Byrd Edward A. | Controlled release lipoic acid |
US6313146B1 (en) | 1991-08-23 | 2001-11-06 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US6340473B1 (en) | 1999-07-07 | 2002-01-22 | R.P. Scherer Technologies, Inc. | Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same |
US6342249B1 (en) | 1998-12-23 | 2002-01-29 | Alza Corporation | Controlled release liquid active agent formulation dosage forms |
US20020018810A1 (en) | 1991-11-27 | 2002-02-14 | Benjamin Oshlack | Controlled release oxycodone compositions |
WO2002012182A1 (en) * | 2000-08-08 | 2002-02-14 | Chugai Seiyaku Kabushiki Kaisha | 3-methyl-20-epi-vitamin d derivatives |
US20020031798A1 (en) | 1997-07-10 | 2002-03-14 | Hideharu Anazawa | Antibody recognizing human 25-hydroxyvitamin D3-1a-hydroxylase |
US20020044968A1 (en) | 1996-10-28 | 2002-04-18 | General Mills, Inc. | Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles |
US6375981B1 (en) | 2000-06-01 | 2002-04-23 | A. E. Staley Manufacturing Co. | Modified starch as a replacement for gelatin in soft gel films and capsules |
US6376479B1 (en) | 1995-04-03 | 2002-04-23 | Bone Care International, Inc. | Method for treating and preventing hyperparathyroidism |
US6380408B1 (en) | 1999-04-01 | 2002-04-30 | The Johns Hopkins University | Non-calcemic, antiproliferative, transcriptionally active sulfur-containing analogs of 1α, 25-dihydroxy vitamin D3 |
EP1208843A1 (en) | 1999-08-31 | 2002-05-29 | Chugai Seiyaku Kabushiki Kaisha | Soft capsules |
US6413463B1 (en) | 1998-10-29 | 2002-07-02 | Shionogi Qualicaps Co., Ltd. | Process for producing hard capsule |
US6432936B1 (en) | 1999-01-20 | 2002-08-13 | Wisconsin Alumni Research Foundation | Crystalline 1α-hydroxyvitamin D2 and method of purification thereof |
US20020128240A1 (en) | 1996-12-30 | 2002-09-12 | Bone Care International, Inc. | Treatment of hyperproliferative diseases using active vitamin D analogues |
JP2002302447A (en) | 2001-04-03 | 2002-10-18 | Shimizu Pharmaceutical Co Ltd | Cancer therapeutic agent for topical administration |
WO2002092056A1 (en) | 2001-05-15 | 2002-11-21 | Warner-Lambert Company Llc | Compaction process for manufacture of sodium phenytoin dosage form |
US20020183288A1 (en) | 1995-04-03 | 2002-12-05 | Bone Care International, Inc. | Method for treating and preventing hyperparathyroidism |
US6491950B1 (en) | 2000-08-07 | 2002-12-10 | Kos Pharmaceuticals, Inc. | Controlled release pharmaceutical composition |
US6503893B2 (en) | 1996-12-30 | 2003-01-07 | Bone Care International, Inc. | Method of treating hyperproliferative diseases using active vitamin D analogues |
WO2003009572A1 (en) | 2001-07-20 | 2003-01-30 | Net2Phone, Inc. | Active voice messaging method and system |
US6521608B1 (en) | 1998-03-27 | 2003-02-18 | Oregon Health & Science University | Vitamin D and its analogs in the treatment of tumors and other hyperproliferative disorders |
US6524788B1 (en) | 2001-11-02 | 2003-02-25 | Thomas L. Cantor | Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism |
US20030059471A1 (en) | 1997-12-15 | 2003-03-27 | Compton Bruce Jon | Oral delivery formulation |
WO2003030869A1 (en) | 2001-10-09 | 2003-04-17 | Apogepha Arzneimittel Gmbh | Oral dosage form for propiverine or its pharmaceutically acceptable salts with an extended release of the active ingredient |
WO2003039572A1 (en) | 2001-11-02 | 2003-05-15 | Scantibodies Laboratory, Inc. | Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism |
WO2003039521A1 (en) | 2001-11-09 | 2003-05-15 | Farmatron Ltd. | Solid, stabilized, prompt- and/or modified-release therapeutical systems for the oral administration of liquid active principles, excipients or foodstuffs |
WO2003045381A1 (en) | 2001-11-27 | 2003-06-05 | Molecular Skincare Limited | Aminoalkylimidazole derivatives and their use in medicine |
WO2003047595A1 (en) | 2001-12-03 | 2003-06-12 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin d compounds |
US20030129194A1 (en) | 1997-02-13 | 2003-07-10 | Bone Care International, Inc. | Targeted therapeutic delivery of vitamin D compounds |
US20030138482A1 (en) | 2002-01-18 | 2003-07-24 | Fonkwe Linus G. | Non-gelatin capsule shell formulation |
US20030152629A1 (en) | 2000-10-25 | 2003-08-14 | Adi Shefer | Multi component controlled release system for oral care, food products, nutracetical, and beverages |
US6627622B2 (en) | 2002-02-18 | 2003-09-30 | Wisconsin Alumni Research Foundation | (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses |
US20030195171A1 (en) | 2002-04-05 | 2003-10-16 | Daifotis Anastasia G. | Method for inhibiting bone resorption with an alendronate and vitamin D formulation |
WO2003086267A2 (en) | 2002-04-10 | 2003-10-23 | Miller Fred H | Multi-phase, multi-compartment capsular system |
US6645527B2 (en) | 1997-07-02 | 2003-11-11 | Euro-Celtique S.A. | Stabilized sustained release tramadol formulations |
WO2003093459A1 (en) | 2002-05-02 | 2003-11-13 | Cytochroma Inc. | Stable cytochrome p450 24 (cyp24) expressing cell line and methods and uses thereof |
WO2003106411A1 (en) | 2002-06-13 | 2003-12-24 | Johns Hopkins University | 24-sulfoximine vitamin d3 compounds |
WO2004010981A1 (en) | 2002-07-29 | 2004-02-05 | Alza Corporation | Methods and dosage forms for controlled delivery of paliperidone |
US20040043971A1 (en) | 1995-04-03 | 2004-03-04 | Bone Care International, Inc. | Method of treating and preventing hyperparathyroidism with active vitamin D analogs |
WO2004028515A1 (en) | 2002-09-26 | 2004-04-08 | Young-Kweon Choi | Matrix type patch for transdermal administration of vitamin d analog and the use thereof |
US20040101554A1 (en) | 1999-05-27 | 2004-05-27 | Drugtech Corporation | Nutritional formulations |
JP2004175750A (en) | 2002-11-28 | 2004-06-24 | Kose Corp | Dermopathy inhibitor and dermopathy improving agent, and skin care preparation for external use containing them |
WO2004054968A2 (en) | 2002-12-18 | 2004-07-01 | Johns Hopkins University | 25-so2-substituted analogs of 1alpha, 25-dihydroxyvitamin d3 (calcitriol) |
US20040132695A1 (en) | 2001-08-22 | 2004-07-08 | Posner Gary H. | 24-Sulfur-substituted analogs of 1 alpha, 25-dihydroxy vitamin D3 |
WO2004058235A2 (en) | 2002-12-16 | 2004-07-15 | Teva Pharmaceutical Industries Ltd. | Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin d derivative |
US6770295B1 (en) | 1998-08-27 | 2004-08-03 | Pharmacia Ab | Therapeutic formulation for administering tolterodine with controlled release |
WO2004071497A1 (en) | 2003-02-11 | 2004-08-26 | Alza Corporation | Methods and dosage forms with modified layer geometry |
WO2004098617A2 (en) | 2003-05-07 | 2004-11-18 | Osteologix A/S | Controlled release composition containing a strontium salt |
WO2004101554A1 (en) | 2003-05-19 | 2004-11-25 | Sanofi-Aventis Deutschland Gmbh | New indole derivatives as factor xa inhibitors |
WO2004110381A2 (en) | 2003-06-11 | 2004-12-23 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin d compounds |
WO2004110391A2 (en) | 2003-06-16 | 2004-12-23 | Solx, Inc. | Shunt for the treatment of glaucoma |
WO2005000268A2 (en) | 2003-06-26 | 2005-01-06 | Control Delivery Systems, Inc. | Bioerodible sustained release drug delivery systems |
WO2005003358A1 (en) | 2003-07-03 | 2005-01-13 | Medvet Science Pty Ltd | Inhibition of calcitriol mediated cyp24 induction screening for compounds therefore and uses thereof |
US20050014211A1 (en) | 1998-06-25 | 2005-01-20 | Armbruster Franz Paul | Functional vitamin D derivatives and method of determining 25-hydroxy- and 1alpha, 25-dihydroxy vitamin D |
US20050019374A1 (en) | 2003-04-14 | 2005-01-27 | Fmc Corporation | Homogeneous, thermoreversible gel film containing kappa-2 carragenan and soft capsules made therefrom |
WO2005011652A2 (en) | 2003-07-29 | 2005-02-10 | Abbott Laboratories | Use of a vitamin d receptor activator or a vitamin d analog to treat kidney disease |
US20050037064A1 (en) | 2001-12-27 | 2005-02-17 | Ulice And Pierre Fabre Medicament | Heteroxylan film-forming composition for making capsules and resulting capsules |
US20050069579A1 (en) | 2001-11-22 | 2005-03-31 | Ryosei Kamaguchi | Non-gelatinous capsule film compositions and capsules using the same |
US20050101576A1 (en) | 2003-11-06 | 2005-05-12 | Novacea, Inc. | Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes |
US20050106233A1 (en) | 2002-04-04 | 2005-05-19 | Fmc Biopolymers As | Polysaccharide capsules and methods of preparation |
US6903083B2 (en) | 2000-07-18 | 2005-06-07 | Bone Care International, Inc. | Stabilized hydroxyvitamin D |
US20050124591A1 (en) | 2003-07-29 | 2005-06-09 | Jin Tian | Use of vitamin Ds to treat kidney disease |
US6911217B1 (en) | 1998-11-11 | 2005-06-28 | Pharmacia Ab | Controlled release bead, a method of producing the same and multiple unit formulation comprising it |
US20050143358A1 (en) | 2003-11-25 | 2005-06-30 | Deltanoid Pharmaceuticals, Inc. | Methods for reducing body fat using vitamin D compounds |
US20050147669A1 (en) | 2003-09-12 | 2005-07-07 | Lawrence Glen G. | Rapid dissolution formulation of a calcium receptor-active compound |
US20050186268A1 (en) | 2000-08-29 | 2005-08-25 | Noboru Hoshi | Hard capsule |
US20050208055A1 (en) | 2003-12-19 | 2005-09-22 | Chuang Samuel S | Cytochrome P450 24 (CYP24) monoclonal antibody and methods and uses thereof |
JP2005538189A (en) | 2002-07-25 | 2005-12-15 | グラクソ グループ リミテッド | Multi-component pharmaceutical dosage form |
US20050287213A1 (en) | 2004-06-28 | 2005-12-29 | Wong Patrick S | Dosage forms for low solubility and or low dissolution rate free acid pharmaceutical agents |
WO2005123120A1 (en) | 2004-06-16 | 2005-12-29 | Smart Drug Systems Inc. | Sustained release vaccine composition |
US6982258B2 (en) | 2001-10-12 | 2006-01-03 | Cytochroma Inc. | Low-calcemic oxime analogs of 1α,25-dihydroxy vitamin D3 |
US20060009425A1 (en) | 2004-05-28 | 2006-01-12 | Leticia Delgado-Herrera | Oral formulations of paricalcitol |
US20060019933A1 (en) | 2004-07-22 | 2006-01-26 | David Boardman | Process for preparing stabilized vitamin D |
US20060034937A1 (en) | 1999-11-23 | 2006-02-16 | Mahesh Patel | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US7033996B2 (en) | 2001-08-31 | 2006-04-25 | University Of Medicine & Dentistry Of New Jersey | Method for the treatment of vitamin D related disease |
WO2006052452A1 (en) | 2004-11-08 | 2006-05-18 | R.P. Scherer Technologies, Inc. | Non-gelatin soft capsule system |
WO2006059180A2 (en) | 2004-12-03 | 2006-06-08 | Council Of Scientific And Industrial Research | Process of preparation of biodegradable films from semi refined kappa carrageenan |
US20060193877A1 (en) | 2005-02-28 | 2006-08-31 | Pfab, Lp | Compositions and methods of making sustained release liquid formulations |
US20060210610A1 (en) | 2002-11-14 | 2006-09-21 | Davidson Robert S | Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use |
US20060228808A1 (en) | 2005-04-06 | 2006-10-12 | Nigel Clarke | Methods for detecting vitamin D metabolites |
WO2006113505A2 (en) | 2005-04-15 | 2006-10-26 | Clarus Therapeutics, Inc. | Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same |
US20060257481A1 (en) | 2005-04-21 | 2006-11-16 | Decode Genetics Ehf. | Sustained release formulation and dosing schedule of leukotriene synthesis inhibitor for human therapy |
US20070026067A1 (en) | 2005-07-28 | 2007-02-01 | Yam Noymi V | Liquid formulations for controlled delivery of benzisoxazole derivatives |
US20070032461A1 (en) | 2003-04-30 | 2007-02-08 | Bioxell S.P.A. | 1,3 Aclyated 24-keto-vitamin d3 compounds and methods of use thereof |
US7189843B2 (en) | 2000-12-13 | 2007-03-13 | Fmc Corporation | Production of carrageenan and carrageenan products |
WO2007039569A2 (en) | 2005-09-30 | 2007-04-12 | Valpharma S.A. | Controlled release pharmaceutical composition of venlafaxine hydrochloride, and process for preparation thereof |
WO2007039193A1 (en) | 2005-09-29 | 2007-04-12 | Roche Diagnostics Gmbh | Antibodies against 25-hydroxyvitamin d |
WO2007047327A2 (en) | 2005-10-12 | 2007-04-26 | Proventiv Therapeutics, Llc | Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency |
WO2007050975A2 (en) | 2005-10-26 | 2007-05-03 | Banner Pharmacaps, Inc. | Hydrophilic vehicle-based dual controlled release matrix system as capsule fill |
WO2007050724A2 (en) | 2005-10-26 | 2007-05-03 | Banner Pharmacaps, Inc. | Lipophilic vehicle-based dual controlled release matrix system as capsule fill |
WO2007053608A2 (en) | 2005-11-01 | 2007-05-10 | Andries Hanzen | Films and capsules made from modified carboxymethycellulose materials and methods of making same |
US7226932B2 (en) | 1994-07-22 | 2007-06-05 | G.D. Searle Llc | Self-emulsifying drug delivery system |
WO2007068287A1 (en) | 2005-12-15 | 2007-06-21 | Laboratoria Qualiphar | Sustained release vitamin preparation |
US20070155664A1 (en) | 2003-07-04 | 2007-07-05 | Nycomed Danmark A/S | Parathyroid hormone (pth) containing pharmaceutical compositions for oral use |
WO2007092221A2 (en) | 2006-01-31 | 2007-08-16 | Health Research Inc. | Method for identifying altered vitamin d metabolism |
WO2007092755A2 (en) | 2006-02-03 | 2007-08-16 | Proventiv Therapeutics, Llc | Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3 |
US20070190146A1 (en) | 2004-07-29 | 2007-08-16 | Sanofi-Aventis | Pharmaceutical Multilayer Tablet for Controlled Release of Active Ingredients With Highly pH-Dependent Solubility |
WO2007146004A1 (en) | 2006-06-06 | 2007-12-21 | Fmc Corporation | Kappa-2 carrageenan composition and products made therefrom |
WO2008008608A2 (en) | 2006-06-21 | 2008-01-17 | Proventiv Therapeutics, Llc | Method of treating and preventing secondary hyperparathyroidism |
WO2008043449A1 (en) | 2006-10-10 | 2008-04-17 | Panasonic Corporation | Method and apparatus for mobile ip route optimization |
US20080109983A1 (en) | 2006-11-10 | 2008-05-15 | Kegel, Llc | Zero Turning Radius Lane Maintenance Machine |
US20080134937A1 (en) | 2005-05-25 | 2008-06-12 | Joo Hwan Yang | Cellulose hard capsule enhancing mechanical film strength |
WO2008097646A1 (en) | 2007-02-09 | 2008-08-14 | Schering Corporation | Methods to treat and/or prevent mucositis |
US20080199534A1 (en) | 2007-02-15 | 2008-08-21 | Wyeth | Stability in vitamin and mineral supplements |
WO2008116133A1 (en) | 2007-03-21 | 2008-09-25 | Duke University | Medication kits and formulations for preventing, treating or reducing secondary fractures after previous fracture |
WO2008116113A1 (en) | 2007-03-20 | 2008-09-25 | Electrolock, Inc. | Roebel winding with conductive felt |
EP1980255A1 (en) | 2005-12-20 | 2008-10-15 | ESPINOZA ABDALA, Leopoldo de Jesús | Pharmaceutical compositions containing synthetic steroid derivatives such as tibolone, minerals such as calcium and the active metabolite of vitamin d (calcitrol) for the prevention and treatment of osteoporosis and menopause |
WO2008134512A1 (en) | 2007-04-25 | 2008-11-06 | Cytochroma Inc. | Oral controlled release compositions comprising vitamin d compound and waxy carrier |
WO2008134523A1 (en) | 2007-04-25 | 2008-11-06 | Proventiv Therapeutics, Llc | Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease |
WO2008134518A2 (en) | 2007-04-25 | 2008-11-06 | Cytochroma Inc. | Methods and compounds for vitamin d therapy |
DE20321698U1 (en) | 2002-12-16 | 2008-12-24 | Teva Pharmaceutical Industries Ltd. | A medicament for increasing the bioavailability of alendronate or another bisphosphonate by administering a pre-dose of a vitamin D derivative |
US20090004284A1 (en) | 2007-06-26 | 2009-01-01 | Watson Pharmaceuticals, Inc. | Controlled release tamsulosin hydrochloride formulation |
US20090069389A1 (en) | 2007-09-07 | 2009-03-12 | Seoul Pharma. Co., Ltd. | Novel controlled release-niacin formulation |
WO2009047644A2 (en) | 2007-04-25 | 2009-04-16 | Cytochroma Inc. | Method of treating vitamin d insufficiency and deficiency |
US7528122B2 (en) | 2006-02-02 | 2009-05-05 | Wisconsin Alumni Research Foundation | Vitamin D analog—NEL, methods and uses thereof |
US20090155355A1 (en) | 2007-12-12 | 2009-06-18 | Multi Formulations Ltd. | Particles in a capsule |
WO2009101137A1 (en) | 2008-02-13 | 2009-08-20 | Dsm Ip Assets B.V. | Use of 25-hydroxy-vitamin d3 to affect human muscle physiology |
WO2009101135A1 (en) | 2008-02-13 | 2009-08-20 | Dsm Ip Assets B.V. | Combined use of 25-hydroxy-vitamin d3 and vitamin d3 for improving bone mineral density and for treating osteoporosis |
WO2009101132A1 (en) | 2008-02-13 | 2009-08-20 | Dsm Ip Assets B.V. | Combination of vitamin d and 25-hydroxyvitamin d 3 |
WO2009124210A1 (en) | 2008-04-02 | 2009-10-08 | Cytochroma Inc. | Methods, compositions, uses, and kits useful for vitamin d deficiency and related disorders |
US7632518B2 (en) | 2002-01-15 | 2009-12-15 | Dsm Ip Assets B.V. | 25-hydroxy vitamin D3 compositions |
WO2010011906A1 (en) | 2008-07-24 | 2010-01-28 | Wisconsin Alumni Research Foundation | Once-a-week administration of 25-hydroxy vitamin d3 to sustain elevated steady-state pharmacokinetic blood concentration |
WO2010034342A1 (en) | 2008-09-24 | 2010-04-01 | Evonik Röhm Gmbh | Ph-dependent controlled release pharmaceutical opioid composition with resistance against the influence of ethanol |
US20100227889A1 (en) | 2006-03-30 | 2010-09-09 | Marc Gerspacher | Benzimidazole Derivatives |
US7816341B2 (en) | 2003-04-14 | 2010-10-19 | Fmc Corporation | Homogeneous, thermoreversible gel containing reduced viscosity carrageenan and products made therefrom |
US20100291197A1 (en) | 2007-09-28 | 2010-11-18 | Swiss Caps Rechte Und Lizenzen Ag | hot melt-filled soft capsules |
US20100291191A1 (en) | 2005-04-25 | 2010-11-18 | Shoichet Molly S | Tunable sustained release of a sparingly soluble hydrophobic therapeutic agent from a hydrogel matrix |
US7846475B2 (en) | 2001-07-05 | 2010-12-07 | Wakunaga Pharmaceutical Co., Ltd. | Soft capsules |
US20110039811A1 (en) | 2008-02-12 | 2011-02-17 | Neil Robert Buck | Treating hyperglycemia with 25-hydroxyvitamin d3 |
WO2011031621A2 (en) | 2009-09-10 | 2011-03-17 | Fmc Corporation | High strength seamless alginate capsules |
US20110118218A1 (en) | 2008-02-13 | 2011-05-19 | Neil Robert Buck | Treating hypertension with 25-hydroxyvitamin d3 |
US20110130370A1 (en) | 2009-11-27 | 2011-06-02 | Les Laboratories Servier | Pharmaceutical composition comprising a strontium salt, vitamin D and A cyclodextrin |
WO2011063952A1 (en) | 2009-11-26 | 2011-06-03 | Tiberio Bruzzese | Formulations of bisphosphonates and vitamin d suitable for intermittent intramuscular and subcutaneous administration |
US20110171298A1 (en) | 2010-01-14 | 2011-07-14 | Karl Wei Cao | Hard capsule composition and method of use |
US20110182986A1 (en) | 2002-07-05 | 2011-07-28 | Temrel, Inc. | Controlled release composition |
WO2011095388A1 (en) | 2010-02-04 | 2011-08-11 | Synthon Bv | Tolterodine bead |
WO2011123476A1 (en) | 2010-03-29 | 2011-10-06 | Cytochroma Inc. | Methods and compositions for reducing parathyroid levels |
US20110256230A1 (en) | 2008-10-27 | 2011-10-20 | Roquette Freres | Water insoluble polymer: indigestible water-soluble polysaccharide film coatings for colon targeting |
US20110300210A1 (en) | 1998-10-01 | 2011-12-08 | Elan Pharma International Limited | Controlled release nanoparticulate clozapine compositions |
US20110319503A1 (en) | 2009-03-03 | 2011-12-29 | Rolf Muller | Soft capsule based on starch and a method and device for the production thereof |
US20110318321A1 (en) | 2009-01-23 | 2011-12-29 | AZIENDE CHIM.RIUN.ANG.FRANC.A.C.R.A.F. S.p.A. | Controlled release pharmaceutical or food formulation and process for its preparation |
WO2012006475A1 (en) | 2010-07-07 | 2012-01-12 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
KR20120005228A (en) | 2010-07-08 | 2012-01-16 | 주식회사 네비팜 | An enteric pharmaceutical composition for the treatment of osteoporosis comprising bisphosphonate and the process thereof |
US8101204B2 (en) | 2010-01-14 | 2012-01-24 | Karl Wei Cao | Hard capsule composition and method of use |
WO2012018329A1 (en) | 2010-08-04 | 2012-02-09 | R.P. Scherer Technologies, Llc | Film-forming composition for soft capsules |
US8142811B2 (en) | 2000-10-30 | 2012-03-27 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
US20120135103A1 (en) | 2010-11-30 | 2012-05-31 | Mead Johnson Nutrition Company | Staged Infant Feeding Regimen To Promote Healthy Development And Growth |
WO2012076429A1 (en) | 2010-12-06 | 2012-06-14 | Dsm Ip Assets B.V. | Treating conditions associated with increased eotaxin with 25-hydroxyvitamin d3 |
WO2012091569A1 (en) | 2010-12-28 | 2012-07-05 | Future Diagnostics B.V. | Release reagent for vitamin d |
WO2012117236A1 (en) | 2011-03-02 | 2012-09-07 | D3 Pharma Limited | Vitamin d composition |
US8268352B2 (en) | 2002-08-05 | 2012-09-18 | Torrent Pharmaceuticals Limited | Modified release composition for highly soluble drugs |
WO2012145491A2 (en) | 2011-04-20 | 2012-10-26 | Jason Fisher | Composition and method for enhancing an immune response |
US20130085121A1 (en) | 2011-09-30 | 2013-04-04 | Jianguo Wang | Pharmaceutical compositions comprising phosphate binder, calcium receptor-active compound and/or active vitamin d |
US20130302309A1 (en) | 2011-04-20 | 2013-11-14 | Suheung Capsule Co., Ltd. | Non-animal soft capsule shell composition having improved disintegration and shell hardness |
WO2014029953A1 (en) | 2012-08-21 | 2014-02-27 | Cipla Limited | Hot melt extruded (hme) pharmaceutical composition of cinacalcet |
US20140088202A1 (en) | 2006-10-27 | 2014-03-27 | Capsugel Belgium Nv | Hydroxypropyl Methyl Cellulose Hard Capsules and Process of Manufacture |
US20140248400A1 (en) | 2011-05-13 | 2014-09-04 | Fmc Corporation | Edible Liquid Filled Polysaccharide Capsules |
WO2014143941A1 (en) | 2013-03-15 | 2014-09-18 | Opko IP Holdings II, Inc. | Stabilized modified release vitamin d formulation and method of administring same |
WO2014193255A1 (en) | 2013-05-31 | 2014-12-04 | Tecnimede Sociedade Tecnico-Medicinal S.A. | Solid composition for oral administration containing ibandronic acid or a pharmaceutically acceptable salt thereof and vitamin d |
WO2014202754A1 (en) | 2013-06-21 | 2014-12-24 | Swiss Caps Rechte Und Lizenzen Ag | Soft shell capsule and process for its manufacture |
US20150119473A1 (en) | 2013-10-26 | 2015-04-30 | Zhongshan Capsule Starch Material Technology Co., Ltd. | Coating And Extruding Method For Producing Starch Softgel Capsules |
US20150119472A1 (en) | 2013-10-26 | 2015-04-30 | Zhongshan Capsule Starch Material Technology Co., Ltd. | Mixing and extruding method for preparing starch softgel capsules |
WO2016020508A2 (en) | 2014-08-07 | 2016-02-11 | Opko Ireland Global Holdings Ltd. | Adjunctive therapy with 25-hydroxyvitamin d |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE59552T1 (en) | 1986-04-05 | 1991-01-15 | Scherer Gmbh R P | CONTROLLED-RELEASE GELATIN CAPSULES AND METHOD OF MANUFACTURE THE SAME. |
US7655717B2 (en) * | 2002-07-17 | 2010-02-02 | Mary J. Goulbourne | Ointment composition for treating decubitus ulcers and methods for its making and its use |
-
2007
- 2007-02-02 EP EP07763210.7A patent/EP1993559B1/en active Active
- 2007-02-02 ES ES16164563T patent/ES2904546T3/en active Active
- 2007-02-02 PL PL07763210T patent/PL1993559T3/en unknown
- 2007-02-02 HU HUE16164563A patent/HUE056937T2/en unknown
- 2007-02-02 PT PT77632107T patent/PT1993559T/en unknown
- 2007-02-02 PL PL16164563T patent/PL3095447T3/en unknown
- 2007-02-02 ES ES07763210.7T patent/ES2593047T3/en active Active
- 2007-02-02 US US12/278,053 patent/US8426391B2/en active Active
- 2007-02-02 DK DK07763210.7T patent/DK1993559T3/en active
- 2007-02-02 JP JP2008553520A patent/JP5869745B2/en active Active
- 2007-02-02 EP EP18154648.2A patent/EP3332788A1/en active Pending
- 2007-02-02 CA CA2640094A patent/CA2640094C/en active Active
- 2007-02-02 LT LTEP07763210.7T patent/LT1993559T/en unknown
- 2007-02-02 SI SI200731831A patent/SI1993559T1/en unknown
- 2007-02-02 LT LTEP16164563.5T patent/LT3095447T/en unknown
- 2007-02-02 WO PCT/US2007/061521 patent/WO2007092755A2/en active Application Filing
- 2007-02-02 HU HUE07763210A patent/HUE029572T2/en unknown
- 2007-02-02 CA CA2882048A patent/CA2882048C/en active Active
- 2007-02-02 PT PT161645635T patent/PT3095447T/en unknown
- 2007-02-02 SI SI200732182T patent/SI3095447T1/en unknown
- 2007-02-02 DK DK16164563.5T patent/DK3095447T3/en active
- 2007-02-02 EP EP16164563.5A patent/EP3095447B1/en active Active
-
2013
- 2013-03-22 US US13/848,982 patent/US8906410B2/en active Active
-
2014
- 2014-01-24 JP JP2014011219A patent/JP6023731B2/en active Active
- 2014-11-19 US US14/548,275 patent/US9943530B2/en active Active
-
2016
- 2016-09-15 CY CY20161100919T patent/CY1118017T1/en unknown
-
2017
- 2017-05-22 HK HK17105233.7A patent/HK1231409A1/en unknown
- 2017-10-02 US US15/722,757 patent/US10213442B2/en active Active
-
2018
- 2018-10-25 US US16/171,100 patent/US11007204B2/en active Active
- 2018-12-13 HK HK18116035.3A patent/HK1256920A1/en unknown
-
2021
- 2021-04-22 US US17/237,889 patent/US11911398B2/en active Active
-
2022
- 2022-01-19 CY CY20221100046T patent/CY1125077T1/en unknown
Patent Citations (382)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6190695B1 (en) | 1919-04-09 | 2001-02-20 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition containing osteogenesis-promoting substance |
US3565924A (en) | 1968-07-01 | 1971-02-23 | Wisconsin Alumni Res Found | 25-hydroxycholfcalciferol |
US3833622A (en) | 1969-03-17 | 1974-09-03 | Upjohn Co | Crystalline 25-hydroxycholecalciferol hydrate and structurally related compounds |
US3974272A (en) | 1972-09-01 | 1976-08-10 | Merck & Co., Inc. | Palatable cholestyramine coacervate compositions |
US3880894A (en) | 1974-05-24 | 1975-04-29 | Wisconsin Alumni Res Found | 1,25-Dihydroxyergocalciferol |
US4004003A (en) | 1974-08-28 | 1977-01-18 | The Upjohn Company | 25-Hydroxycalciferol compounds for treatment of steroid-induced osteoporosis |
US4230701A (en) | 1979-03-21 | 1980-10-28 | Hoffmann-La Roche Inc. | Administration of biologically active vitamin D3 and vitamin D2 materials |
US4335120A (en) | 1979-03-21 | 1982-06-15 | Hoffmann-La Roche Inc. | Administration of biologically active vitamin D3 and vitamin D2 materials |
JPS55139320A (en) | 1979-04-16 | 1980-10-31 | Teijin Ltd | Bone metabolism regulator |
JPS57188520A (en) | 1981-05-15 | 1982-11-19 | Kureha Chem Ind Co Ltd | Antihyperkalemia |
US4442093A (en) | 1981-05-15 | 1984-04-10 | Kureha Kagaku Kogyo Kabushiki Kaisha | Method for administering 24,25-dihydroxycholecalciferol to persons suffering from hypercalcemia |
JPS5832823A (en) | 1981-08-20 | 1983-02-25 | Chugai Pharmaceut Co Ltd | Cancer eliminating agent |
JPS58206524A (en) | 1982-05-26 | 1983-12-01 | Kureha Chem Ind Co Ltd | Antitumor agent |
US4448721A (en) | 1982-09-20 | 1984-05-15 | Wisconsin Alumni Research Foundation | Hydroxyvitamin D2 compounds and process for preparing same |
US4721613A (en) | 1982-12-13 | 1988-01-26 | Alza Corporation | Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use |
US4729895A (en) | 1983-02-22 | 1988-03-08 | Teijin Limited | Composition for solid pharmaceutical preparations of active vitamins D.sub.3 |
US4684524A (en) | 1984-03-19 | 1987-08-04 | Alza Corporation | Rate controlled dispenser for administering beneficial agent |
US4555364A (en) | 1984-11-01 | 1985-11-26 | Wisconsin Alumni Research Foundation | Method for preparing 1-hydroxyvitamin D compounds |
US4695591A (en) | 1985-03-29 | 1987-09-22 | Schering Corporation | Controlled release dosage forms comprising hydroxypropylmethylcellulose |
US4668517A (en) | 1985-04-04 | 1987-05-26 | Norwich Eaton Pharmaceuticals, Inc. | Furazolidone dosage form |
US4755544A (en) | 1985-06-04 | 1988-07-05 | Teijin Limited | Sustained release preparation |
EP0227836A1 (en) | 1985-06-24 | 1987-07-08 | Teijin Limited | Sustained releasing patch |
US5167965A (en) | 1987-02-09 | 1992-12-01 | The Dow Chemical Company | Palatable cholestyramine granules, tablets and methods for preparation thereof |
US4892821A (en) | 1987-07-08 | 1990-01-09 | Taisho Pharmaceutical Co., Ltd. | Method for preparing vitamin D compounds |
JPS6431722A (en) | 1987-07-22 | 1989-02-02 | Teva Pharma | Composition of cholecalciferol derivative for treating renal bone disease |
US4997824A (en) | 1987-07-22 | 1991-03-05 | Teva Pharmaceutical Industries Ltd. | Combination of cholecalciferol derivatives for the treatment of renal bone disease |
US5869473A (en) | 1988-08-02 | 1999-02-09 | Bone Care International, Inc. | Method for treating and preventing hyperparathyroidism |
US5861386A (en) | 1988-08-02 | 1999-01-19 | Bone Care International, Inc. | Method for treating and preventing secondary hyperparathyroidism |
US5707980A (en) | 1988-08-02 | 1998-01-13 | Bone Care International, Inc. | Method for treating and preventing secondary hyperparathyroidism |
US5602116A (en) | 1988-08-02 | 1997-02-11 | Bone Care International, Inc. | Method for treating and preventing secondary hyperparathyroidism |
US5403831A (en) | 1988-08-02 | 1995-04-04 | Bone Care International, Inc. | Method of treating and preventing loss of bone mass using 1α-hydroxy-vitamin D2 |
US5593690A (en) | 1988-11-08 | 1997-01-14 | Takeda Chemical Industries, Ltd. | Sustained release preparations |
JPH02229115A (en) | 1989-03-01 | 1990-09-11 | Teijin Ltd | Solid pharmaceutical of active type vitamin d3s improved in stability |
EP0413828A1 (en) | 1989-03-01 | 1991-02-27 | Teijin Limited | Solid preparation of active vitamin d3 having improved stability |
EP0387808B1 (en) | 1989-03-13 | 1993-05-12 | Ss Pharmaceutical Co., Ltd. | Compositions for the preparation of dosage-form active vitamins d3 and process for preparing stable dosage-form active vitamins d3 by using the same |
US5026559A (en) | 1989-04-03 | 1991-06-25 | Kinaform Technology, Inc. | Sustained-release pharmaceutical preparation |
WO1991012807A1 (en) | 1990-03-01 | 1991-09-05 | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) | Use of vitamin-d analogues in the treatment of acne |
WO1991016899A1 (en) | 1990-04-28 | 1991-11-14 | Sumitomo Pharmaceuticals Co., Ltd. | Composition for solid pharmaceutical preparations containing vitamin d3 derivative and process for preparation thereof |
US5328903A (en) | 1990-04-28 | 1994-07-12 | Taisho Pharmaceutical Co. Ltd. | Composition for solid pharmaceutical preparations containing vitamin D3 derivative |
JPH04198129A (en) | 1990-11-28 | 1992-07-17 | Sumitomo Pharmaceut Co Ltd | Active type vitamin d>=3*s-containing composition |
WO1992009271A1 (en) | 1990-11-28 | 1992-06-11 | Sumitomo Pharmaceuticals Co., Ltd. | Composition for solid pharmaceutical preparations containing active vitamins d3 and process for preparation thereof |
JPH04208225A (en) | 1990-11-30 | 1992-07-29 | Ss Pharmaceut Co Ltd | Stable vitamin d pharmaceutical |
JPH04288016A (en) | 1991-03-14 | 1992-10-13 | Tokai Capsule Kk | Production of soft capsule agent of active type vitamin d3s |
EP0508756A1 (en) | 1991-04-09 | 1992-10-14 | Takeda Chemical Industries, Ltd. | Stabilized vitamin D preparation |
US5487900A (en) | 1991-04-09 | 1996-01-30 | Takeda Chemical Industries, Limited | Stabilized vitamin D preparation |
US5693615A (en) | 1991-06-05 | 1997-12-02 | The Procter & Gamble Company | Therapeutic compositions for osteoinduction |
US6011068A (en) | 1991-08-23 | 2000-01-04 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US6313146B1 (en) | 1991-08-23 | 2001-11-06 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US6031003A (en) | 1991-08-23 | 2000-02-29 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US6001884A (en) | 1991-08-23 | 1999-12-14 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US20020018810A1 (en) | 1991-11-27 | 2002-02-14 | Benjamin Oshlack | Controlled release oxycodone compositions |
US5472712A (en) | 1991-12-24 | 1995-12-05 | Euroceltique, S.A. | Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
US5160742A (en) | 1991-12-31 | 1992-11-03 | Abbott Laboratories | System for delivering an active substance for sustained release |
US5529991A (en) | 1992-06-22 | 1996-06-25 | Lunar Corporation | Oral 1α-hydroxyprevitamin D |
US5622941A (en) | 1992-06-22 | 1997-04-22 | Lunar Corporation | Oral 1 α-hydroxyprevitamin D |
WO1994000128A1 (en) | 1992-06-22 | 1994-01-06 | Lunar Corporation | ORAL 1α-HYDROXYPREVITAMIN D |
US6150346A (en) | 1992-06-22 | 2000-11-21 | Bone Care International, Inc. | Method and composition for treating or preventing osteoporosis |
US6147064A (en) | 1992-06-22 | 2000-11-14 | Bone Care International, Inc. | Oral 1α-hydroxyprevitamin D in composition and method for treating psoriasis |
US6133250A (en) | 1992-06-22 | 2000-10-17 | Bone Care International, Inc. | Oral 1α-hydroxyprevitamin D in methods for increasing blood level of activated vitamin D |
US5614513A (en) | 1992-06-22 | 1997-03-25 | Bone Care International, Inc. | Oral 1α-hydroxyprevitamin D |
US5795882A (en) | 1992-06-22 | 1998-08-18 | Bone Care International, Inc. | Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations |
US5354743A (en) | 1992-09-15 | 1994-10-11 | Thys Jacobs Susan | Method for the treatment of premenstrual syndrome with vitamin D |
US6228849B1 (en) | 1992-09-15 | 2001-05-08 | Susan Thys-Jacobs | Method for treating symptoms associated with premenstrual syndrome by administering a combination of calcium and vitamin D |
US5431917A (en) | 1992-10-08 | 1995-07-11 | Japan Elanco Company, Ltd. | Hard capsule for pharmaceutical drugs and method for producing the same |
US5342626A (en) | 1993-04-27 | 1994-08-30 | Merck & Co., Inc. | Composition and process for gelatin-free soft capsules |
EP0629405A1 (en) | 1993-06-21 | 1994-12-21 | Kureha Chemical Industry Co., Ltd. | Agent for inhibiting a decrease in bone mass in renal osteodystrophy |
US6121469A (en) | 1993-12-23 | 2000-09-19 | The Regents Of The University Of California | Therapeutically effective 1α,25-dihydroxyvitamin D3 analogs |
JPH07242550A (en) | 1994-03-02 | 1995-09-19 | Teijin Ltd | Therapeutic agent for secondary hyperparathyroidism |
WO1996000074A1 (en) | 1994-06-24 | 1996-01-04 | Ben-Gurion University Of The Negev | Pharmaceutical compositions comprising vitamin-d analogs |
US5783215A (en) | 1994-07-08 | 1998-07-21 | Astra Aktiebolag | Pharmaceutical preparation |
WO1996001621A1 (en) | 1994-07-08 | 1996-01-25 | Astra Aktiebolag | New beads for controlled release and a pharmaceutical preparation containing the same |
US7226932B2 (en) | 1994-07-22 | 2007-06-05 | G.D. Searle Llc | Self-emulsifying drug delivery system |
JPH0892098A (en) | 1994-09-27 | 1996-04-09 | Teijin Ltd | Therapeutic medicine for consumption |
US6211244B1 (en) | 1994-10-21 | 2001-04-03 | Nps Pharmaceuticals, Inc. | Calcium receptor-active compounds |
US5756123A (en) | 1994-12-01 | 1998-05-26 | Japan Elanco Co., Ltd. | Capsule shell |
US20020183288A1 (en) | 1995-04-03 | 2002-12-05 | Bone Care International, Inc. | Method for treating and preventing hyperparathyroidism |
US6376479B1 (en) | 1995-04-03 | 2002-04-23 | Bone Care International, Inc. | Method for treating and preventing hyperparathyroidism |
US20040043971A1 (en) | 1995-04-03 | 2004-03-04 | Bone Care International, Inc. | Method of treating and preventing hyperparathyroidism with active vitamin D analogs |
WO1996031215A1 (en) | 1995-04-03 | 1996-10-10 | Bone Care International, Inc. | Use of vitamin d2 or vitamin d4-derivatives for the manufacture of a medicament for the treatment of secondary hyperparathyroidism |
US20090137536A1 (en) | 1995-04-03 | 2009-05-28 | Mazess Richard B | Method for treating and preventing hyperparathyroidism |
WO1997011053A1 (en) | 1995-09-21 | 1997-03-27 | Wisconsin Alumni Research Foundation | Calcitriol derivatives and their uses |
CA2241205A1 (en) | 1995-12-21 | 1997-07-03 | Schering Aktiengesellschaft | Pharmaceutical compositions with vitamin d analogues |
US5939408A (en) | 1996-05-23 | 1999-08-17 | Hoffman-La Roche Inc. | Vitamin D3 analogs |
US5888994A (en) | 1996-05-23 | 1999-03-30 | Hoffmann-La Roche Inc. | Fluorinated Vitamin D3 analogs |
US5958451A (en) | 1996-09-03 | 1999-09-28 | Yung Shin Pharm Ind. Co., Ltd. | Process for producing porous, controlled-release capsules and encapsulated composition |
US5976784A (en) | 1996-09-20 | 1999-11-02 | Wisconsin Alumni Research Foundation | Calcitriol derivatives and their uses |
US20020044968A1 (en) | 1996-10-28 | 2002-04-18 | General Mills, Inc. | Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles |
US6190591B1 (en) | 1996-10-28 | 2001-02-20 | General Mills, Inc. | Embedding and encapsulation of controlled release particles |
WO1998018610A1 (en) | 1996-10-28 | 1998-05-07 | Lengerich Bernhard H Van | Embedding and encapsulation of controlled release particles |
JPH10158171A (en) | 1996-12-02 | 1998-06-16 | Kita:Kk | Intraocular administrating agent formulating vitamin d compound therein |
WO1998029105A2 (en) | 1996-12-30 | 1998-07-09 | Bone Care International, Inc. | Method of treating prostatic diseases using delayed and/or sustained release vitamin d formulations |
JP2001512418A (en) | 1996-12-30 | 2001-08-21 | ボーン ケア インターナショナル インコーポレイテッド | Method for treating prostate disease using slow-acting and / or sustained-release vitamin D preparation |
US6503893B2 (en) | 1996-12-30 | 2003-01-07 | Bone Care International, Inc. | Method of treating hyperproliferative diseases using active vitamin D analogues |
US20020128240A1 (en) | 1996-12-30 | 2002-09-12 | Bone Care International, Inc. | Treatment of hyperproliferative diseases using active vitamin D analogues |
US20030129194A1 (en) | 1997-02-13 | 2003-07-10 | Bone Care International, Inc. | Targeted therapeutic delivery of vitamin D compounds |
US6034075A (en) | 1997-03-20 | 2000-03-07 | The Trustees Of Columbia University In The City Of New York | Method of treating polycystic ovarian syndrome |
US5872113A (en) | 1997-05-16 | 1999-02-16 | Syntex (U.S.A.) Inc. | Fluorinated vitamin D3 analogs |
US6645527B2 (en) | 1997-07-02 | 2003-11-11 | Euro-Celtique S.A. | Stabilized sustained release tramadol formulations |
US20020031798A1 (en) | 1997-07-10 | 2002-03-14 | Hideharu Anazawa | Antibody recognizing human 25-hydroxyvitamin D3-1a-hydroxylase |
US6096876A (en) | 1997-08-06 | 2000-08-01 | Shriners Hospitals For Children | 1-α-hydroxylase materials and methods |
US6242434B1 (en) | 1997-08-08 | 2001-06-05 | Bone Care International, Inc. | 24-hydroxyvitamin D, analogs and uses thereof |
WO1999011272A1 (en) | 1997-09-02 | 1999-03-11 | Johns Hopkins University School Of Medicine | Vitamin d3 analog loaded polymer formulations for cancer and neurodegenerative disorders |
US5919986A (en) | 1997-10-17 | 1999-07-06 | Hoffmann-La Roche Inc. | D-homo vitamin D3 derivatives |
JPH11158074A (en) | 1997-12-03 | 1999-06-15 | Hayashi Tomie | Amino acid-rich active vitamin d potentiation composition |
US20030059471A1 (en) | 1997-12-15 | 2003-03-27 | Compton Bruce Jon | Oral delivery formulation |
WO1999049027A1 (en) | 1998-03-25 | 1999-09-30 | Cutanogen, Inc. | Methods for prevention and treatment of cancer |
US6521608B1 (en) | 1998-03-27 | 2003-02-18 | Oregon Health & Science University | Vitamin D and its analogs in the treatment of tumors and other hyperproliferative disorders |
US6572888B2 (en) | 1998-05-28 | 2003-06-03 | Medical Research Institute | Controlled release lipoic acid |
US20010028896A1 (en) | 1998-05-28 | 2001-10-11 | Byrd Edward A. | Controlled release lipoic acid |
EP1080055A2 (en) | 1998-05-29 | 2001-03-07 | Bone Care International, Inc. | 24-hydroxyvitamin d, analogs and uses thereof |
US7122530B2 (en) | 1998-05-29 | 2006-10-17 | Genzyme Corporation | 24-hydroxyvitamin D, analogs and uses thereof |
WO1999061398A2 (en) | 1998-05-29 | 1999-12-02 | Bone Care International | 24-hydroxyvitamin d, analogs and uses thereof |
US20050014211A1 (en) | 1998-06-25 | 2005-01-20 | Armbruster Franz Paul | Functional vitamin D derivatives and method of determining 25-hydroxy- and 1alpha, 25-dihydroxy vitamin D |
US6214376B1 (en) | 1998-08-25 | 2001-04-10 | Banner Pharmacaps, Inc. | Non-gelatin substitutes for oral delivery capsules, their composition and process of manufacture |
US6770295B1 (en) | 1998-08-27 | 2004-08-03 | Pharmacia Ab | Therapeutic formulation for administering tolterodine with controlled release |
US6139875A (en) | 1998-09-29 | 2000-10-31 | Eastman Chemical Company | Aqueous enteric coating composition and low gastric permeability enteric coating |
US20110300210A1 (en) | 1998-10-01 | 2011-12-08 | Elan Pharma International Limited | Controlled release nanoparticulate clozapine compositions |
WO2000021504A1 (en) | 1998-10-09 | 2000-04-20 | General Mills, Inc. | Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles |
US6413463B1 (en) | 1998-10-29 | 2002-07-02 | Shionogi Qualicaps Co., Ltd. | Process for producing hard capsule |
US6911217B1 (en) | 1998-11-11 | 2005-06-28 | Pharmacia Ab | Controlled release bead, a method of producing the same and multiple unit formulation comprising it |
US6288849B1 (en) | 1998-11-12 | 2001-09-11 | Olympus Optical Co., Ltd. | Optical element |
US20020155154A1 (en) | 1998-12-17 | 2002-10-24 | Wong Patrick S.L. | Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings |
US6929803B2 (en) | 1998-12-17 | 2005-08-16 | Alza Corporation | Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings |
WO2000035419A2 (en) | 1998-12-17 | 2000-06-22 | Alza Corporation | Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings |
US20010036472A1 (en) | 1998-12-17 | 2001-11-01 | Wong Patrick S.-L. | Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings |
US6342249B1 (en) | 1998-12-23 | 2002-01-29 | Alza Corporation | Controlled release liquid active agent formulation dosage forms |
US6596314B2 (en) | 1998-12-23 | 2003-07-22 | Alza Corporation | Controlled release liquid active agent formulation dosage forms |
US6432936B1 (en) | 1999-01-20 | 2002-08-13 | Wisconsin Alumni Research Foundation | Crystalline 1α-hydroxyvitamin D2 and method of purification thereof |
US6380408B1 (en) | 1999-04-01 | 2002-04-30 | The Johns Hopkins University | Non-calcemic, antiproliferative, transcriptionally active sulfur-containing analogs of 1α, 25-dihydroxy vitamin D3 |
US7648826B1 (en) | 1999-04-02 | 2010-01-19 | The Regents Of The University Of California | Detecting CYP24 expression level as a marker for predisposition to cancer |
WO2000060109A1 (en) | 1999-04-02 | 2000-10-12 | The Regents Of The University Of California | Amplification of cyp24 and uses thereof |
EP1165061B1 (en) | 1999-04-08 | 2005-10-19 | Schering Aktiengesellschaft | Use of compound preparation made of vitamin d metabolites or vitamin d analogues and partial estrogen agonists for treating osteoporosis |
WO2000061123A2 (en) | 1999-04-08 | 2000-10-19 | Schering Aktiengesellschaft | Compound preparation made of vitamin d metabolites or vitamin d analogues and an oestrogenic component for treating osteoporosis |
US20040101554A1 (en) | 1999-05-27 | 2004-05-27 | Drugtech Corporation | Nutritional formulations |
US6340473B1 (en) | 1999-07-07 | 2002-01-22 | R.P. Scherer Technologies, Inc. | Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same |
USRE39079E1 (en) | 1999-07-07 | 2006-04-25 | R.P. Scherer Technologies, Inc. | Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same |
US6582727B2 (en) | 1999-07-07 | 2003-06-24 | R. P. Scherer Technologies, Inc. | Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same |
US20020081331A1 (en) | 1999-07-07 | 2002-06-27 | R.P. Scherer Technologies, Inc. | Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same |
US6265392B1 (en) | 1999-08-02 | 2001-07-24 | Abbott Laboratories | Low oxygen content compositions of 1α, 25-dihydroxycholeclciferol |
US6274169B1 (en) | 1999-08-02 | 2001-08-14 | Abbott Laboratories | Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol |
US6051567A (en) | 1999-08-02 | 2000-04-18 | Abbott Laboratories | Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol |
EP1208843A1 (en) | 1999-08-31 | 2002-05-29 | Chugai Seiyaku Kabushiki Kaisha | Soft capsules |
US6893658B1 (en) | 1999-08-31 | 2005-05-17 | Chugai Seiyaku Kabushiki Kaisha | Soft capsules |
US6923988B2 (en) | 1999-11-23 | 2005-08-02 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
WO2001037808A1 (en) | 1999-11-23 | 2001-05-31 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US20060034937A1 (en) | 1999-11-23 | 2006-02-16 | Mahesh Patel | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6569463B2 (en) | 1999-11-23 | 2003-05-27 | Lipocine, Inc. | Solid carriers for improved delivery of hydrophobic active ingredients in pharmaceutical compositions |
WO2001072286A1 (en) | 2000-03-27 | 2001-10-04 | Glaxosmithkline Consumer Healthcare Gmbh & Co Kg | Sustained release vitamin composition |
US7422758B2 (en) | 2000-03-27 | 2008-09-09 | Glaxosmithkline Consumer Healthcare Gmbh & Co. Kg | Sustained release vitamin composition |
US6375981B1 (en) | 2000-06-01 | 2002-04-23 | A. E. Staley Manufacturing Co. | Modified starch as a replacement for gelatin in soft gel films and capsules |
US20050148558A1 (en) | 2000-07-18 | 2005-07-07 | Bone Care International, Inc. | Stabilized hydroxyvitamin D |
US6903083B2 (en) | 2000-07-18 | 2005-06-07 | Bone Care International, Inc. | Stabilized hydroxyvitamin D |
US6491950B1 (en) | 2000-08-07 | 2002-12-10 | Kos Pharmaceuticals, Inc. | Controlled release pharmaceutical composition |
WO2002012182A1 (en) * | 2000-08-08 | 2002-02-14 | Chugai Seiyaku Kabushiki Kaisha | 3-methyl-20-epi-vitamin d derivatives |
US20050186268A1 (en) | 2000-08-29 | 2005-08-25 | Noboru Hoshi | Hard capsule |
US6887493B2 (en) | 2000-10-25 | 2005-05-03 | Adi Shefer | Multi component controlled release system for oral care, food products, nutraceutical, and beverages |
US20030152629A1 (en) | 2000-10-25 | 2003-08-14 | Adi Shefer | Multi component controlled release system for oral care, food products, nutracetical, and beverages |
US8142811B2 (en) | 2000-10-30 | 2012-03-27 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
US7189843B2 (en) | 2000-12-13 | 2007-03-13 | Fmc Corporation | Production of carrageenan and carrageenan products |
JP2002302447A (en) | 2001-04-03 | 2002-10-18 | Shimizu Pharmaceutical Co Ltd | Cancer therapeutic agent for topical administration |
JP2004531548A (en) | 2001-05-15 | 2004-10-14 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | Compression method for the production of sodium phenytoin dosage form |
US20030083360A1 (en) | 2001-05-15 | 2003-05-01 | George Crotts | Compaction process for manufacture of sodium phenytoin dosage form |
WO2002092056A1 (en) | 2001-05-15 | 2002-11-21 | Warner-Lambert Company Llc | Compaction process for manufacture of sodium phenytoin dosage form |
US7846475B2 (en) | 2001-07-05 | 2010-12-07 | Wakunaga Pharmaceutical Co., Ltd. | Soft capsules |
WO2003009572A1 (en) | 2001-07-20 | 2003-01-30 | Net2Phone, Inc. | Active voice messaging method and system |
US20040132695A1 (en) | 2001-08-22 | 2004-07-08 | Posner Gary H. | 24-Sulfur-substituted analogs of 1 alpha, 25-dihydroxy vitamin D3 |
US7166585B2 (en) | 2001-08-22 | 2007-01-23 | Cytochroma Inc. | 24-Sulfur-substituted analogs of 1α,25-dihydroxy vitamin D3 |
US7033996B2 (en) | 2001-08-31 | 2006-04-25 | University Of Medicine & Dentistry Of New Jersey | Method for the treatment of vitamin D related disease |
JP2005505589A (en) | 2001-10-09 | 2005-02-24 | アポゲフア・アルツナイミツテル・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング | Oral formulation of propiverine or a pharmaceutically acceptable salt thereof for long-term release of the active agent |
US20040258749A1 (en) | 2001-10-09 | 2004-12-23 | Peter Guldner | Oral dosage form for propiverine or its pharmaceutically acceptable salts with an extended release of the active ingredient |
WO2003030869A1 (en) | 2001-10-09 | 2003-04-17 | Apogepha Arzneimittel Gmbh | Oral dosage form for propiverine or its pharmaceutically acceptable salts with an extended release of the active ingredient |
US6982258B2 (en) | 2001-10-12 | 2006-01-03 | Cytochroma Inc. | Low-calcemic oxime analogs of 1α,25-dihydroxy vitamin D3 |
US6524788B1 (en) | 2001-11-02 | 2003-02-25 | Thomas L. Cantor | Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism |
US7056655B2 (en) | 2001-11-02 | 2006-06-06 | Scantibodies Laboratory, Inc. | Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism |
US20060223119A1 (en) | 2001-11-02 | 2006-10-05 | Cantor Thomas L | Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism |
JP2005513419A (en) | 2001-11-02 | 2005-05-12 | スキャンティボディーズ・ラボラトリー,インコーポレイテッド | Methods for monitoring and inducing therapeutic suppression of parathyroid hormone in renal patients with secondary hyperparathyroidism |
WO2003039572A1 (en) | 2001-11-02 | 2003-05-15 | Scantibodies Laboratory, Inc. | Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism |
US20030157560A1 (en) | 2001-11-02 | 2003-08-21 | Cantor Thomas L. | Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism |
WO2003039521A1 (en) | 2001-11-09 | 2003-05-15 | Farmatron Ltd. | Solid, stabilized, prompt- and/or modified-release therapeutical systems for the oral administration of liquid active principles, excipients or foodstuffs |
US20050069579A1 (en) | 2001-11-22 | 2005-03-31 | Ryosei Kamaguchi | Non-gelatinous capsule film compositions and capsules using the same |
US7255921B2 (en) | 2001-11-22 | 2007-08-14 | Morishita Jintan Co., Ltd. | Non-gelatinous capsule shell composition and a capsule formed from the same |
WO2003045381A1 (en) | 2001-11-27 | 2003-06-05 | Molecular Skincare Limited | Aminoalkylimidazole derivatives and their use in medicine |
WO2003047595A1 (en) | 2001-12-03 | 2003-06-12 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin d compounds |
US20050037064A1 (en) | 2001-12-27 | 2005-02-17 | Ulice And Pierre Fabre Medicament | Heteroxylan film-forming composition for making capsules and resulting capsules |
US8088410B2 (en) | 2002-01-15 | 2012-01-03 | Dsm Ip Assets B.V. | 25-hydroxy Vitamin D3 compositions |
US7632518B2 (en) | 2002-01-15 | 2009-12-15 | Dsm Ip Assets B.V. | 25-hydroxy vitamin D3 compositions |
US20030138482A1 (en) | 2002-01-18 | 2003-07-24 | Fonkwe Linus G. | Non-gelatin capsule shell formulation |
US20060029660A1 (en) | 2002-01-18 | 2006-02-09 | Fonkwe Linus G | Non-gelatin capsule shell formulation |
US6949256B2 (en) | 2002-01-18 | 2005-09-27 | Banner Pharmacaps, Inc. | Non-gelatin capsule shell formulation |
US6627622B2 (en) | 2002-02-18 | 2003-09-30 | Wisconsin Alumni Research Foundation | (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses |
US9017720B2 (en) | 2002-04-04 | 2015-04-28 | FMC Bioploymer AS | Polysaccharide capsules and method of preparation |
US20050106233A1 (en) | 2002-04-04 | 2005-05-19 | Fmc Biopolymers As | Polysaccharide capsules and methods of preparation |
WO2003086415A1 (en) | 2002-04-05 | 2003-10-23 | Merck & Co., Inc. | Method for inhibiting bone resorption with an alendronate and vitamin d formulation |
JP2005531532A (en) | 2002-04-05 | 2005-10-20 | メルク エンド カムパニー インコーポレーテッド | Bone resorption inhibition method using alendronate and vitamin D preparation |
US20030195171A1 (en) | 2002-04-05 | 2003-10-16 | Daifotis Anastasia G. | Method for inhibiting bone resorption with an alendronate and vitamin D formulation |
JP2005528383A (en) | 2002-04-10 | 2005-09-22 | ミラー,フレッド,エイチ. | Multiphase, multiple compartment capsule system |
WO2003086267A2 (en) | 2002-04-10 | 2003-10-23 | Miller Fred H | Multi-phase, multi-compartment capsular system |
WO2003088976A1 (en) | 2002-04-19 | 2003-10-30 | Bone Care International, Inc. | Method for treating and preventing hyperparathyroidism |
WO2003093459A1 (en) | 2002-05-02 | 2003-11-13 | Cytochroma Inc. | Stable cytochrome p450 24 (cyp24) expressing cell line and methods and uses thereof |
US7973024B2 (en) | 2002-06-13 | 2011-07-05 | Cyctochroma Inc. | 24-sulfoximine vitamin D3 compounds |
WO2003106411A1 (en) | 2002-06-13 | 2003-12-24 | Johns Hopkins University | 24-sulfoximine vitamin d3 compounds |
US7101865B2 (en) | 2002-06-13 | 2006-09-05 | Cytochroma Inc. | 24-sulfoximine vitamin D3 compounds |
US20110182986A1 (en) | 2002-07-05 | 2011-07-28 | Temrel, Inc. | Controlled release composition |
US20060057201A1 (en) | 2002-07-25 | 2006-03-16 | Bonney Stanley G | Multicomponent pharmaceutical dosage form |
JP2005538189A (en) | 2002-07-25 | 2005-12-15 | グラクソ グループ リミテッド | Multi-component pharmaceutical dosage form |
US20040092534A1 (en) | 2002-07-29 | 2004-05-13 | Yam Nyomi V. | Methods and dosage forms for controlled delivery of paliperidone |
WO2004010981A1 (en) | 2002-07-29 | 2004-02-05 | Alza Corporation | Methods and dosage forms for controlled delivery of paliperidone |
JP2005535682A (en) | 2002-07-29 | 2005-11-24 | アルザ・コーポレーシヨン | Methods and dosage forms for controlled delivery of paliperidone |
US8268352B2 (en) | 2002-08-05 | 2012-09-18 | Torrent Pharmaceuticals Limited | Modified release composition for highly soluble drugs |
WO2004028515A1 (en) | 2002-09-26 | 2004-04-08 | Young-Kweon Choi | Matrix type patch for transdermal administration of vitamin d analog and the use thereof |
US20070027120A1 (en) | 2002-11-06 | 2007-02-01 | Whitehouse Martha J | Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes |
US20060210610A1 (en) | 2002-11-14 | 2006-09-21 | Davidson Robert S | Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use |
JP2004175750A (en) | 2002-11-28 | 2004-06-24 | Kose Corp | Dermopathy inhibitor and dermopathy improving agent, and skin care preparation for external use containing them |
WO2004058235A2 (en) | 2002-12-16 | 2004-07-15 | Teva Pharmaceutical Industries Ltd. | Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin d derivative |
DE20321698U1 (en) | 2002-12-16 | 2008-12-24 | Teva Pharmaceutical Industries Ltd. | A medicament for increasing the bioavailability of alendronate or another bisphosphonate by administering a pre-dose of a vitamin D derivative |
WO2004054968A2 (en) | 2002-12-18 | 2004-07-01 | Johns Hopkins University | 25-so2-substituted analogs of 1alpha, 25-dihydroxyvitamin d3 (calcitriol) |
US20040224930A1 (en) | 2002-12-18 | 2004-11-11 | Posner Gary H. | 25-SO2-Substituted analogs of 1mu,25-dihydroxyvitamin D3 |
WO2004071497A1 (en) | 2003-02-11 | 2004-08-26 | Alza Corporation | Methods and dosage forms with modified layer geometry |
US20040197407A1 (en) | 2003-02-11 | 2004-10-07 | Ramkumar Subramanian | Methods and dosage forms with modified layer geometry |
JP2006517593A (en) | 2003-02-11 | 2006-07-27 | アルザ・コーポレーシヨン | Method for modifying the layer shape of a dosage form and dosage forms subjected to such modification |
WO2004080467A2 (en) | 2003-03-10 | 2004-09-23 | Bone Care International, Inc. | Method of treating and preventing hyperparathyroidism with vitamin d2 or d4 compounds |
JP2006523221A (en) | 2003-03-13 | 2006-10-12 | サルヴォナ エルエルシー | Controlled release systems for drugs, foods, and nutritional supplements |
US7807194B2 (en) | 2003-04-14 | 2010-10-05 | Fmc Corporation | Homogeneous, thermoreversible gel film containing kappa-2 carrageenan and soft capsules made therefrom |
US20050019374A1 (en) | 2003-04-14 | 2005-01-27 | Fmc Corporation | Homogeneous, thermoreversible gel film containing kappa-2 carragenan and soft capsules made therefrom |
US7816341B2 (en) | 2003-04-14 | 2010-10-19 | Fmc Corporation | Homogeneous, thermoreversible gel containing reduced viscosity carrageenan and products made therefrom |
US20070032461A1 (en) | 2003-04-30 | 2007-02-08 | Bioxell S.P.A. | 1,3 Aclyated 24-keto-vitamin d3 compounds and methods of use thereof |
WO2004098617A2 (en) | 2003-05-07 | 2004-11-18 | Osteologix A/S | Controlled release composition containing a strontium salt |
WO2004101554A1 (en) | 2003-05-19 | 2004-11-25 | Sanofi-Aventis Deutschland Gmbh | New indole derivatives as factor xa inhibitors |
WO2004110381A2 (en) | 2003-06-11 | 2004-12-23 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin d compounds |
WO2004110391A2 (en) | 2003-06-16 | 2004-12-23 | Solx, Inc. | Shunt for the treatment of glaucoma |
WO2005000268A2 (en) | 2003-06-26 | 2005-01-06 | Control Delivery Systems, Inc. | Bioerodible sustained release drug delivery systems |
WO2005003358A1 (en) | 2003-07-03 | 2005-01-13 | Medvet Science Pty Ltd | Inhibition of calcitriol mediated cyp24 induction screening for compounds therefore and uses thereof |
JP2007525472A (en) | 2003-07-04 | 2007-09-06 | ニコメド ダンマーク エイピーエス | Pharmaceutical composition containing parathyroid hormone (PTH) for oral use |
US20070155664A1 (en) | 2003-07-04 | 2007-07-05 | Nycomed Danmark A/S | Parathyroid hormone (pth) containing pharmaceutical compositions for oral use |
US20050124591A1 (en) | 2003-07-29 | 2005-06-09 | Jin Tian | Use of vitamin Ds to treat kidney disease |
US20050148557A1 (en) | 2003-07-29 | 2005-07-07 | Jin Tian | Use of Vitamin Ds to treat kidney disease |
WO2005011652A2 (en) | 2003-07-29 | 2005-02-10 | Abbott Laboratories | Use of a vitamin d receptor activator or a vitamin d analog to treat kidney disease |
US20050147669A1 (en) | 2003-09-12 | 2005-07-07 | Lawrence Glen G. | Rapid dissolution formulation of a calcium receptor-active compound |
US7829595B2 (en) | 2003-09-12 | 2010-11-09 | Amgen Inc. | Rapid dissolution formulation of a calcium receptor-active compound |
US20050101576A1 (en) | 2003-11-06 | 2005-05-12 | Novacea, Inc. | Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes |
US20050143358A1 (en) | 2003-11-25 | 2005-06-30 | Deltanoid Pharmaceuticals, Inc. | Methods for reducing body fat using vitamin D compounds |
US20050208055A1 (en) | 2003-12-19 | 2005-09-22 | Chuang Samuel S | Cytochrome P450 24 (CYP24) monoclonal antibody and methods and uses thereof |
US20060009425A1 (en) | 2004-05-28 | 2006-01-12 | Leticia Delgado-Herrera | Oral formulations of paricalcitol |
WO2005123120A1 (en) | 2004-06-16 | 2005-12-29 | Smart Drug Systems Inc. | Sustained release vaccine composition |
US20050287213A1 (en) | 2004-06-28 | 2005-12-29 | Wong Patrick S | Dosage forms for low solubility and or low dissolution rate free acid pharmaceutical agents |
US20060019933A1 (en) | 2004-07-22 | 2006-01-26 | David Boardman | Process for preparing stabilized vitamin D |
US20070190146A1 (en) | 2004-07-29 | 2007-08-16 | Sanofi-Aventis | Pharmaceutical Multilayer Tablet for Controlled Release of Active Ingredients With Highly pH-Dependent Solubility |
US8231896B2 (en) | 2004-11-08 | 2012-07-31 | R.P. Scherer Technologies, Llc | Non-gelatin soft capsule system |
WO2006052452A1 (en) | 2004-11-08 | 2006-05-18 | R.P. Scherer Technologies, Inc. | Non-gelatin soft capsule system |
US8377470B2 (en) | 2004-11-08 | 2013-02-19 | R.P. Scherer Technologies, Llc | Non-gelatin soft capsule system |
WO2006059180A2 (en) | 2004-12-03 | 2006-06-08 | Council Of Scientific And Industrial Research | Process of preparation of biodegradable films from semi refined kappa carrageenan |
US20060193877A1 (en) | 2005-02-28 | 2006-08-31 | Pfab, Lp | Compositions and methods of making sustained release liquid formulations |
US20060228808A1 (en) | 2005-04-06 | 2006-10-12 | Nigel Clarke | Methods for detecting vitamin D metabolites |
WO2006113505A2 (en) | 2005-04-15 | 2006-10-26 | Clarus Therapeutics, Inc. | Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same |
US20060257481A1 (en) | 2005-04-21 | 2006-11-16 | Decode Genetics Ehf. | Sustained release formulation and dosing schedule of leukotriene synthesis inhibitor for human therapy |
US20100291191A1 (en) | 2005-04-25 | 2010-11-18 | Shoichet Molly S | Tunable sustained release of a sparingly soluble hydrophobic therapeutic agent from a hydrogel matrix |
US20080134937A1 (en) | 2005-05-25 | 2008-06-12 | Joo Hwan Yang | Cellulose hard capsule enhancing mechanical film strength |
US20070026067A1 (en) | 2005-07-28 | 2007-02-01 | Yam Noymi V | Liquid formulations for controlled delivery of benzisoxazole derivatives |
US20080317764A1 (en) | 2005-09-29 | 2008-12-25 | Eramus Huber | Antibodies against 25-hydroxyvitamin d |
WO2007039193A1 (en) | 2005-09-29 | 2007-04-12 | Roche Diagnostics Gmbh | Antibodies against 25-hydroxyvitamin d |
WO2007039569A2 (en) | 2005-09-30 | 2007-04-12 | Valpharma S.A. | Controlled release pharmaceutical composition of venlafaxine hydrochloride, and process for preparation thereof |
WO2007047327A2 (en) | 2005-10-12 | 2007-04-26 | Proventiv Therapeutics, Llc | Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency |
US20070122477A1 (en) | 2005-10-12 | 2007-05-31 | Cytochroma, Inc. | Methods and articles for treating 25-hydroxyvitamin D insufficiency and deficiency |
WO2007050975A2 (en) | 2005-10-26 | 2007-05-03 | Banner Pharmacaps, Inc. | Hydrophilic vehicle-based dual controlled release matrix system as capsule fill |
WO2007050724A2 (en) | 2005-10-26 | 2007-05-03 | Banner Pharmacaps, Inc. | Lipophilic vehicle-based dual controlled release matrix system as capsule fill |
US8293270B2 (en) | 2005-10-26 | 2012-10-23 | Banner Pharmacaps, Inc. | Lipophilic vehicle-based dual controlled release matrix system |
WO2007053608A2 (en) | 2005-11-01 | 2007-05-10 | Andries Hanzen | Films and capsules made from modified carboxymethycellulose materials and methods of making same |
WO2007068287A1 (en) | 2005-12-15 | 2007-06-21 | Laboratoria Qualiphar | Sustained release vitamin preparation |
EP1980255A1 (en) | 2005-12-20 | 2008-10-15 | ESPINOZA ABDALA, Leopoldo de Jesús | Pharmaceutical compositions containing synthetic steroid derivatives such as tibolone, minerals such as calcium and the active metabolite of vitamin d (calcitrol) for the prevention and treatment of osteoporosis and menopause |
WO2007092221A2 (en) | 2006-01-31 | 2007-08-16 | Health Research Inc. | Method for identifying altered vitamin d metabolism |
US20070207488A1 (en) | 2006-01-31 | 2007-09-06 | Trump Donald L | Method for identifying altered vitamin D metabolism |
US7528122B2 (en) | 2006-02-02 | 2009-05-05 | Wisconsin Alumni Research Foundation | Vitamin D analog—NEL, methods and uses thereof |
US8426391B2 (en) | 2006-02-03 | 2013-04-23 | Proventiv Therapeutics, Llc | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
US20090311316A1 (en) | 2006-02-03 | 2009-12-17 | Proventiv Thereapeutics, Llc | Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3 |
US20150079165A1 (en) | 2006-02-03 | 2015-03-19 | Opko Renal, Llc | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
WO2007092755A2 (en) | 2006-02-03 | 2007-08-16 | Proventiv Therapeutics, Llc | Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3 |
US9943530B2 (en) | 2006-02-03 | 2018-04-17 | Opko Renal, Llc | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
US8906410B2 (en) | 2006-02-03 | 2014-12-09 | Opko Health, Inc. | Oral dosage form of 25-hydroxyvitamin D |
US20100227889A1 (en) | 2006-03-30 | 2010-09-09 | Marc Gerspacher | Benzimidazole Derivatives |
WO2007146004A1 (en) | 2006-06-06 | 2007-12-21 | Fmc Corporation | Kappa-2 carrageenan composition and products made therefrom |
EP2037936B1 (en) | 2006-06-21 | 2014-06-11 | Proventiv Therapeutics, LLC | Method of treating and preventing secondary hyperparathyroidism |
US20090209501A1 (en) | 2006-06-21 | 2009-08-20 | Proventiv Therapeutics, Llc. | Method of treating and preventing secondary hyperparathyroidism |
US20130178451A1 (en) | 2006-06-21 | 2013-07-11 | Proventiv Therapeutics, Llc | Method of treating and preventing secondary hyperparathyroidism |
US9402855B2 (en) | 2006-06-21 | 2016-08-02 | Opko Renal, Llc | Method of treating and preventing secondary hyperparathyroidism |
US8329677B2 (en) | 2006-06-21 | 2012-12-11 | Cytochroma, Inc. | Method of treating and preventing secondary hyperparathyroidism |
WO2008008608A2 (en) | 2006-06-21 | 2008-01-17 | Proventiv Therapeutics, Llc | Method of treating and preventing secondary hyperparathyroidism |
US9913852B2 (en) | 2006-06-21 | 2018-03-13 | Opko Ireland Global Hodlings, Ltd. | Method of treating and preventing secondary hyperparathyroidism |
US20090262685A1 (en) | 2006-10-10 | 2009-10-22 | Panasonic Corporation | Method and apparatus for mobile ip route optimization |
JP2010506520A (en) | 2006-10-10 | 2010-02-25 | パナソニック株式会社 | Method and apparatus for MobileIP route optimization |
WO2008043449A1 (en) | 2006-10-10 | 2008-04-17 | Panasonic Corporation | Method and apparatus for mobile ip route optimization |
US20140088202A1 (en) | 2006-10-27 | 2014-03-27 | Capsugel Belgium Nv | Hydroxypropyl Methyl Cellulose Hard Capsules and Process of Manufacture |
US20080109983A1 (en) | 2006-11-10 | 2008-05-15 | Kegel, Llc | Zero Turning Radius Lane Maintenance Machine |
WO2008097646A1 (en) | 2007-02-09 | 2008-08-14 | Schering Corporation | Methods to treat and/or prevent mucositis |
US20080199534A1 (en) | 2007-02-15 | 2008-08-21 | Wyeth | Stability in vitamin and mineral supplements |
WO2008116113A1 (en) | 2007-03-20 | 2008-09-25 | Electrolock, Inc. | Roebel winding with conductive felt |
WO2008116133A1 (en) | 2007-03-21 | 2008-09-25 | Duke University | Medication kits and formulations for preventing, treating or reducing secondary fractures after previous fracture |
US20100144679A1 (en) | 2007-03-21 | 2010-06-10 | Duke University | Medication kits and formulations for preventing, treating or reducing secondary fractures after previous fracture |
US8592401B2 (en) | 2007-04-25 | 2013-11-26 | Proventiv Therapeutics, Llc | Methods and compounds for vitamin D therapy |
US20140357603A1 (en) | 2007-04-25 | 2014-12-04 | Opko Renal, Llc | Methods for Controlled Release Oral Dosage of a Vitamin D Compound |
WO2008134518A2 (en) | 2007-04-25 | 2008-11-06 | Cytochroma Inc. | Methods and compounds for vitamin d therapy |
US20090176748A1 (en) | 2007-04-25 | 2009-07-09 | Cytochroma Inc. | Methods and compositions for controlled release oral dosage of a vitamin d compound |
WO2008134523A1 (en) | 2007-04-25 | 2008-11-06 | Proventiv Therapeutics, Llc | Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease |
US20140274977A1 (en) | 2007-04-25 | 2014-09-18 | Opko Renal, Llc | Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease |
US8778373B2 (en) | 2007-04-25 | 2014-07-15 | Opko IP Holdings II, Inc. | Methods for controlled release oral dosage of a vitamin D compound |
WO2008134512A1 (en) | 2007-04-25 | 2008-11-06 | Cytochroma Inc. | Oral controlled release compositions comprising vitamin d compound and waxy carrier |
US9408858B2 (en) | 2007-04-25 | 2016-08-09 | Opko Renal, Llc | Method for treating secondary hyperparathyroidism in CKD |
US8207149B2 (en) | 2007-04-25 | 2012-06-26 | Cytochroma, Inc. | Method for treating secondary hyperparathyroidism in CKD |
CN101668517A (en) | 2007-04-25 | 2010-03-10 | 赛特克罗公司 | Oral controlled release compositions comprising vitamin d compound and waxy carrier |
US20100204189A1 (en) | 2007-04-25 | 2010-08-12 | Petkovich P Martin | Methods and Compounds for Vitamin D Therapy |
US9918940B2 (en) | 2007-04-25 | 2018-03-20 | Opko Renal, Llc | Methods for controlled release oral dosage of a vitamin D compound |
US20170119677A1 (en) | 2007-04-25 | 2017-05-04 | Opko Renal, Llc | Method for treating secondary hyperparathyroidism in ckd |
WO2009047644A2 (en) | 2007-04-25 | 2009-04-16 | Cytochroma Inc. | Method of treating vitamin d insufficiency and deficiency |
JP2010525079A (en) | 2007-04-25 | 2010-07-22 | シトクロマ インコーポレイテッド | Methods and compounds for vitamin D therapy |
US8361488B2 (en) | 2007-04-25 | 2013-01-29 | Cytochroma Inc. | Methods and compositions for controlled release oral dosage of a vitamin D compound |
EP2148661B1 (en) | 2007-04-25 | 2012-12-12 | Cytochroma Inc. | Oral controlled release compositions comprising vitamin d compound and waxy carrier |
US9498486B1 (en) | 2007-04-25 | 2016-11-22 | Opko Renal, Llc | Method for controlled release oral dosage of a vitamin D compound |
US20100120728A1 (en) | 2007-04-25 | 2010-05-13 | Cytochroma Inc. | Method of Treating Vitamin D Insufficiency and Deficiency |
US20100144684A1 (en) | 2007-04-25 | 2010-06-10 | Proventiv Therapeutics, Inc. | Method of Safely and Effectively Treating and Preventing Secondary Hyperparathyroidism in Chronic Kidney Disease |
US20120015916A1 (en) | 2007-04-25 | 2012-01-19 | Cytochroma | Method for Treating Secondary Hyperparathyroidism in CKD |
US20090004284A1 (en) | 2007-06-26 | 2009-01-01 | Watson Pharmaceuticals, Inc. | Controlled release tamsulosin hydrochloride formulation |
US20090069389A1 (en) | 2007-09-07 | 2009-03-12 | Seoul Pharma. Co., Ltd. | Novel controlled release-niacin formulation |
US20100291197A1 (en) | 2007-09-28 | 2010-11-18 | Swiss Caps Rechte Und Lizenzen Ag | hot melt-filled soft capsules |
US20090155355A1 (en) | 2007-12-12 | 2009-06-18 | Multi Formulations Ltd. | Particles in a capsule |
US20110039811A1 (en) | 2008-02-12 | 2011-02-17 | Neil Robert Buck | Treating hyperglycemia with 25-hydroxyvitamin d3 |
WO2009101137A1 (en) | 2008-02-13 | 2009-08-20 | Dsm Ip Assets B.V. | Use of 25-hydroxy-vitamin d3 to affect human muscle physiology |
US20110039810A1 (en) | 2008-02-13 | 2011-02-17 | Neil Robert Buck | Use of 25-hydroxy-vitamin d3 to affect human muscle physiology |
WO2009101135A1 (en) | 2008-02-13 | 2009-08-20 | Dsm Ip Assets B.V. | Combined use of 25-hydroxy-vitamin d3 and vitamin d3 for improving bone mineral density and for treating osteoporosis |
US20110039809A1 (en) | 2008-02-13 | 2011-02-17 | Neil Robert Buck | Combined use of 25-hydroxy-vitamin d3 and vitamin d3 for improving bone mineral density and for treating osteoporisis |
US20110118218A1 (en) | 2008-02-13 | 2011-05-19 | Neil Robert Buck | Treating hypertension with 25-hydroxyvitamin d3 |
JP2011512343A (en) | 2008-02-13 | 2011-04-21 | ディーエスエム アイピー アセッツ ビー.ブイ. | Combination of 25-hydroxy-vitamin D3 and vitamin D3 to improve bone mineral density and treat osteoporosis |
WO2009101132A1 (en) | 2008-02-13 | 2009-08-20 | Dsm Ip Assets B.V. | Combination of vitamin d and 25-hydroxyvitamin d 3 |
US8962239B2 (en) | 2008-04-02 | 2015-02-24 | Opko Renal, Llc | Methods useful for vitamin D deficiency and related disorders |
US9500661B2 (en) | 2008-04-02 | 2016-11-22 | Opko Renal, Llc | Methods useful for vitamin D deficiency and related disorders |
WO2009124210A1 (en) | 2008-04-02 | 2009-10-08 | Cytochroma Inc. | Methods, compositions, uses, and kits useful for vitamin d deficiency and related disorders |
US20110105444A1 (en) | 2008-07-24 | 2011-05-05 | Deluca Hector F | Once-a-week administration of 25-hydroxy vitamin d3 to sustain elevated steady-state pharmacokinetic blood concentration |
WO2010011906A1 (en) | 2008-07-24 | 2010-01-28 | Wisconsin Alumni Research Foundation | Once-a-week administration of 25-hydroxy vitamin d3 to sustain elevated steady-state pharmacokinetic blood concentration |
US8759328B2 (en) | 2008-07-24 | 2014-06-24 | Wisconsin Alumni Research Foundation | Once-a-week administration of 25-hydroxy vitamin D3 to sustain elevated steady-state pharmacokinetic blood concentration |
WO2010034342A1 (en) | 2008-09-24 | 2010-04-01 | Evonik Röhm Gmbh | Ph-dependent controlled release pharmaceutical opioid composition with resistance against the influence of ethanol |
US20110256230A1 (en) | 2008-10-27 | 2011-10-20 | Roquette Freres | Water insoluble polymer: indigestible water-soluble polysaccharide film coatings for colon targeting |
US9125823B2 (en) | 2009-01-23 | 2015-09-08 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Controlled release pharmaceutical or food formulation and process for its preparation |
US20110318321A1 (en) | 2009-01-23 | 2011-12-29 | AZIENDE CHIM.RIUN.ANG.FRANC.A.C.R.A.F. S.p.A. | Controlled release pharmaceutical or food formulation and process for its preparation |
JP2012515738A (en) | 2009-01-23 | 2012-07-12 | アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ | Controlled release formulation or food formulation and method for producing the same |
US20130216618A1 (en) | 2009-03-03 | 2013-08-22 | Innogel Ag | Soft capsule based on starch and a method and device for the production thereof |
US20110319503A1 (en) | 2009-03-03 | 2011-12-29 | Rolf Muller | Soft capsule based on starch and a method and device for the production thereof |
WO2011031621A2 (en) | 2009-09-10 | 2011-03-17 | Fmc Corporation | High strength seamless alginate capsules |
WO2011063952A1 (en) | 2009-11-26 | 2011-06-03 | Tiberio Bruzzese | Formulations of bisphosphonates and vitamin d suitable for intermittent intramuscular and subcutaneous administration |
US20110130370A1 (en) | 2009-11-27 | 2011-06-02 | Les Laboratories Servier | Pharmaceutical composition comprising a strontium salt, vitamin D and A cyclodextrin |
US20110171298A1 (en) | 2010-01-14 | 2011-07-14 | Karl Wei Cao | Hard capsule composition and method of use |
US8101203B2 (en) | 2010-01-14 | 2012-01-24 | Karl Wei Cao | Hard capsule composition and method of use |
US8101204B2 (en) | 2010-01-14 | 2012-01-24 | Karl Wei Cao | Hard capsule composition and method of use |
WO2011095388A1 (en) | 2010-02-04 | 2011-08-11 | Synthon Bv | Tolterodine bead |
US20130137663A1 (en) | 2010-03-29 | 2013-05-30 | Eric J. Messner | Methods and compositions for reducing parathyroid levels |
WO2011123476A1 (en) | 2010-03-29 | 2011-10-06 | Cytochroma Inc. | Methods and compositions for reducing parathyroid levels |
EP2591354A1 (en) | 2010-07-07 | 2013-05-15 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
WO2012006475A1 (en) | 2010-07-07 | 2012-01-12 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
KR20120005228A (en) | 2010-07-08 | 2012-01-16 | 주식회사 네비팜 | An enteric pharmaceutical composition for the treatment of osteoporosis comprising bisphosphonate and the process thereof |
WO2012018329A1 (en) | 2010-08-04 | 2012-02-09 | R.P. Scherer Technologies, Llc | Film-forming composition for soft capsules |
US20130189522A1 (en) | 2010-08-04 | 2013-07-25 | R.P. Scherer Technologies, Llc | Film-forming composition for soft capsules |
US20120135103A1 (en) | 2010-11-30 | 2012-05-31 | Mead Johnson Nutrition Company | Staged Infant Feeding Regimen To Promote Healthy Development And Growth |
WO2012076429A1 (en) | 2010-12-06 | 2012-06-14 | Dsm Ip Assets B.V. | Treating conditions associated with increased eotaxin with 25-hydroxyvitamin d3 |
WO2012091569A1 (en) | 2010-12-28 | 2012-07-05 | Future Diagnostics B.V. | Release reagent for vitamin d |
WO2012117236A1 (en) | 2011-03-02 | 2012-09-07 | D3 Pharma Limited | Vitamin d composition |
US8992971B2 (en) | 2011-04-20 | 2015-03-31 | Suheung Capsule Co., Ltd. | Non-animal soft capsule shell composition having improved disintegration and shell hardness |
US20130302309A1 (en) | 2011-04-20 | 2013-11-14 | Suheung Capsule Co., Ltd. | Non-animal soft capsule shell composition having improved disintegration and shell hardness |
WO2012145491A2 (en) | 2011-04-20 | 2012-10-26 | Jason Fisher | Composition and method for enhancing an immune response |
US20140248400A1 (en) | 2011-05-13 | 2014-09-04 | Fmc Corporation | Edible Liquid Filled Polysaccharide Capsules |
US20130085121A1 (en) | 2011-09-30 | 2013-04-04 | Jianguo Wang | Pharmaceutical compositions comprising phosphate binder, calcium receptor-active compound and/or active vitamin d |
WO2014029953A1 (en) | 2012-08-21 | 2014-02-27 | Cipla Limited | Hot melt extruded (hme) pharmaceutical composition of cinacalcet |
US10300078B2 (en) | 2013-03-15 | 2019-05-28 | Opko Ireland Global Holdings, Ltd. | Stabilized modified release vitamin D formulation and method of administering same |
US10350224B2 (en) | 2013-03-15 | 2019-07-16 | Opko Ireland Global Holdings, Ltd. | Stabilized modified release vitamin D formulation and method of administering same |
US20140349979A1 (en) | 2013-03-15 | 2014-11-27 | Opko IP Holdings II, Inc. | Stabilized modified release vitamin d formulation and method of administering same |
US9861644B2 (en) | 2013-03-15 | 2018-01-09 | Opko Ireland Global Holdings, Ltd. | Stabilized modified release vitamin D formulation and method of administering same |
US10357502B2 (en) | 2013-03-15 | 2019-07-23 | Opko Ireland Global Holdings, Ltd. | Stabilized modified release vitamin D formulation and method of administering same |
WO2014143941A1 (en) | 2013-03-15 | 2014-09-18 | Opko IP Holdings II, Inc. | Stabilized modified release vitamin d formulation and method of administring same |
WO2014193255A1 (en) | 2013-05-31 | 2014-12-04 | Tecnimede Sociedade Tecnico-Medicinal S.A. | Solid composition for oral administration containing ibandronic acid or a pharmaceutically acceptable salt thereof and vitamin d |
WO2014202754A1 (en) | 2013-06-21 | 2014-12-24 | Swiss Caps Rechte Und Lizenzen Ag | Soft shell capsule and process for its manufacture |
US20150119473A1 (en) | 2013-10-26 | 2015-04-30 | Zhongshan Capsule Starch Material Technology Co., Ltd. | Coating And Extruding Method For Producing Starch Softgel Capsules |
US20150119472A1 (en) | 2013-10-26 | 2015-04-30 | Zhongshan Capsule Starch Material Technology Co., Ltd. | Mixing and extruding method for preparing starch softgel capsules |
US10220047B2 (en) | 2014-08-07 | 2019-03-05 | Opko Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
WO2016020508A2 (en) | 2014-08-07 | 2016-02-11 | Opko Ireland Global Holdings Ltd. | Adjunctive therapy with 25-hydroxyvitamin d |
US20180021354A1 (en) | 2014-08-07 | 2018-01-25 | Opko Ireland Global Holdings, Ltd. | Adjunctive Therapy With 25-Hydroxyvitamin D and Articles Therefor |
US10493084B2 (en) | 2014-08-07 | 2019-12-03 | Opko Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
Non-Patent Citations (360)
Title |
---|
9 Things That Can Undermine Your Vitamin D Level: Don't Let Your Vitamin D Absorption Slip Away, Harvard Health Publishing, downloaded from the Internet at: <https://www.health.harvard.edu/healthbeat/9-things-that-can-undermine-your-vitamin-d-level> (Feb. 11, 2019)., Feb. 11, 2019. |
ACP Formulary and Pocket Guide To Psychopharmacology, Virginia DMHMRSAS, vol. 1, Iss. 1, (2004-2005). |
Al-Aly, Z., Changes in Serum 25-Hydroxyvitamin D and Plasma Intact PTH Levels Following Treatment with Ergocalciferol in Patients With CKD, Am. J. Kid. Dis., 50(1):59-68 (2007). |
Albertson et al., Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene, Nat. Genet., 25(2):144-6 (2000). |
AlfaD3® 0.25, 0.5 or 1 microgram Capsules (Alfacalcidol, Package Leaflet, Apr. 2010). |
Alfarol® Capsules 3 μg (Package Leaflet, Mar. 2011). |
Alvarez et al., Vitamin D Supplementation in Pre-Dialysis Chronic Kidney Disease, Dermato-Endocrinology, 4(2):118-127 (2012). |
Amin, The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure, Nephrol Dial Transplant, 17:340-345 (2002). |
Anderson et al., Expression of VDR and CYP24A1 mRNA in human tumors, Cancer Chemother. Pharmacol., 57(2):234-40 (2006). |
Anderson et al., Quantification of mRNA for the vitamin D metabolizing enzymes CYP27B1 and CYP24 and vitamin D receptor in kidney using real-time reverse transcriptase-polymerase chain reaction, 2003. J. Mol. Endoc 31:123-132. |
Andress, Vitamin D in chronic kidney disease: A systematic role for selective vitamin D receptor activation, Kidney Int., 69:33-43 (2006). |
Arekat et al., Dramatic Improvement of BMD Following Vitamin D Therapy in a Bone Marrow Transplant Recipient, J. Clin. Densitometry, 5:267-271 (2002). |
Armas et al., Vitamin D2 is Much Less Effective than Vitamin D3 in Humans, J. Clin. Endocrinol. Metab., 89:5387-5391 (2004). |
Ashford, Chapter 20: Bioavailability—physicochemical and dosage form factors, pp. 314-333 IN: Aulton et al. (eds.), Aulton's Pharmaceutics. The Design and Manufacture of Medicines, Fourth Edition, Elsevier Publishing (2013). |
Baez et al., Hipocalcemia severa posdenosumab, Nefrologfa (Madrid), 33(4): 614-615 (2013). |
Baggiolini et al., Stereocontrolled Total Synthesis of 1 alpha, 25-Dihydroxycholecalciferol 1 and 1 alpha, 25-Dihydroxyergocalciferol, J. Org. Chem. 21:3098-3108 (1986). |
Bagnis et al., Biochemical and Hormonal Short-Term Effects of 25-hydroxyvitamin D3 in Patients on Continuous Peritoneal Dialysis, Ital. J. Mineral Electrolyte Metab., 12:73-76 (1998). |
Bailie et al. Comparative Review of the Pharmacokinetics of Vitamin D Analogues, Seminars in Dialysis, 15(5):352-357 (2000). |
Baird et al., Steroid Dynamics Under Steady-State Conditions, Recent Prog. Horm. Res., 25:611-664 (1969). |
Baker et al., Plasma 25-hydroxy vitamin D concentrations in patients with fractures of the femoral neck, Br. Med. J., 1(6163):589 (1979). |
Barger-Lux M.J. et al., Vitamin D And Its Major Metabolites: Serum Levels After Graded Oral Dosing In Healthy Men Osteoporosis International, United Kingdom, 8(3):222-230 (1998). |
Barreto et al., 25-Hydroxyvitamin D3, the Prohormone of 1,25-Dihydroxyvitamin D3, Inhibits the Proliferation of Primary Prostatic Epithelial Cells, Cancer Epidemiol, Biomarkers & Prevention, 9:265-270 (2000). |
Beckman, et al., Up-Regulation of the Intestinal 1, 25-Dihydroxyvitamin D Receptor During Hypervitaminosis D: A Comparison Between Vitamin D2 and Vitamin D31, Biochemical and Biophysical Research Communications, vol. 169, No. 3, pp. 910-915 (Jun. 29, 1990). |
Beer et al., Pharmacokinetics and Tolerability of a Single Dose of DN-101, a New Formulation of Calcitriol, in Patients with Cancer, Clin. Cancer Res., 11:7794-7799 (2005). |
Bell et al., Evidence that 1,25-Dihydroxyvitamin D3 Inhibits the Hepatic Production of 25-Hydroxyvitamin D in Man, J. Clin. Invest., 74:1540-1544 (1984). |
Belostotsky et al., A single high dose of ergocalciferol can be used to boost 25-hydroxyvitamin D levels in children with kidney disease, Pediatr Nephrol, 24:625-626 (2009). |
Berg et al., 24,25-Dihydroxyvitamin d3 and vitamin D status of community-dwelling black and white Americans, Clin. Chem., 61(6):877-84 (Jun. 2015). |
Berruti et al., Prognostic role of serum parathyroid hormone levels in advanced prostate cancer patients undergoing zoledronic acid administration, Oncologist, 17(5):645-52 (2012). |
Bertoldo et al., Serum 25-hydroxyvitamin D levels modulate the acute-phase response associated with the first nitrogen-containing bisphosphonate infusion, J. Bone Miner. Res., 25(3):447-54 (Mar. 2010). |
Bhatia et al., EB1089 inhibits the parathyroid hormone-related protein-enhanced bone metastasis and xenograft growth of human prostate cancer cells, Mol. Cancer Ther., 8(7):1787-98 (2009). |
Bianchi et al., No Difference in Intestinal Strontium Absorption After an Oral or an Intravenous 1,25(OH)2D3 Bolus in Normal Subjects, J. Bone Miner. Res., 14:1789-1795 (1999). |
Binkley et al., Laboratory Reporting of 25-Hydroxyvitamin D Results: Potential for Clinical Misinterpretation, Clinical Chemistry, 52(11);2124-2125 (2006). |
BioTrends Research Group, TreatmentTrends (Registered): Nephrology (US) Q4 2014 (Dec. 2014). |
Blair et al., Prevalence of vitamin D [25(OH)D] deficiency and effects of supplementation with ergocalciferol (vitamin D2) in stage 5 chronic kidney disease patients. J. Ren Nutr., 18:375-382 (2008). |
Blunt et al., Biological activity of 25-hydroxycholecalciferol, a metabolite of vitamin D3, Proc. Natl. Acad. Sci. USA, 61(4):1503-6 (1968). |
Bordier et al., Evolution of renal osteodystrophy: Correlation of bone histomorphometry and serum mineral and immunoreactive parathyroid hormone values before and after treatment with calcium carbonate or 25-hydroxycholecalciferol, Kidney Int Suppl, 2:S102-S112 (1975). |
Boudville et al., Renal Function and 25-Hydroxyvitamin D Concentrations Predict Parathyroid Hormone Levels in Renal Transplant Patients, Nephrol Dial Transplant, 21:2621-2624 (2006). |
Bouillon et al., Influence of dialysate calcium concentration and vitamin D on serum parathyroid hormone during repetitive dialysis, Kidney Int., 7:422-432 (1975). |
Boxtel et al., Drug Benefits and Risks, International Textbook of Clinical Pharmacology, p. 75-76 (2001). |
Briese et al., Arterial and cardiac disease in young adults with childhood-onset end-stage renal disease-impact of calcium and vitamin D therapy, Nephrology Dialysis Transplantation., 21:1906-1914 (2006). |
Brodowicz et al., Early identification and intervention matters: A comprehensive review of current evidence and recommendations for the monitoring of bone health in patients with cancer, Cancer Treat Rev., 61:23-34 (2017). |
Brossard et al. Influence of Glomerular Filtration Rate on Non-(1-84) Parathyroid Hormone (PTH) Detected by Intact PTH Assays, Clinical Chemistry, 46(5):697-703 (2000). |
Brown et al., The Vitamin D Prodrugs 1α(OH)D2, 1α(OH)D3 and BCI-210 Suppress PTH Secretion by Bovine Parathyroid Cells, Nephrol Dial Transplant, 21:644-650 (2006). |
Brown et al., Vitamin D Analogues for Secondary Hyperparathyroidism, Nephrol Dial Transplant, 17[Suppl. 10]:10-19 (2002). |
Buccianti et al., Effects of Calcifediol Treatment on the Progression of Renal Osteodystrophy during Continuous Ambulatory Peritoneal Dialysis, Nephron, 56:353-356 (1990). |
Budavari (ed.), Merck Index: an Encyclopedia of Chemicals, Drugs, and Biologicals, 11th Edition, Merck & Co., 9927-9930 (1989). |
Bulla et al., Renal bone disorders in children: therapy with vitamin D3 or 1,25-dihydroxycholecalciferol, Proc.Eur.Dial.Transplant.Assoc., 16: 644-648 (1979). |
Cavalli et al., Biological effects of various regimes of 25-hydroxyvitamin D3 (calcidiol) administration on bone mineral metabolism in postmenopausal women, Clinical Cases in Mineral and Bone Metabolism, 6(2): 169-173 (2009). |
Centorrino et al., Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits, Am J. Psychiatry, 161(4): 700-06 (2004). |
Chandra et al., Cholecalciferol (vitamin D3) therapy and vitamin D insufficiency in patients with chronic kidney disease: a randomized controlled pilot study, Endocr.Pract., 14: 10-17 (2008). |
Chapuy et al., Biochemical effects of calcium and vitamin D supplementation in elderly, institutionalized, vitamin D-deficient patients, Rev. Rhum. [Engl. Ed. 63 (2), 135-140), Feb. 1996. |
Charnow, Novel Formulation Corrects Vitamin D, Lowers iPTH, Renal & Urology News (2012). |
Chen et al., Safety of Denosumab Versus Zoledronic Acid in Patients with Bone Metastases: A Meta-Analysis of Randomized Controlled Trials, Oncol. Res. Treat., 39(7-9):453-9 (2016). |
Chonchol et al., 25-Hydroxyvitamin D, insulin resistance, and kidney function in the Third National Health and Nutrition Examination Survey, Kidney Int., 71(2):134-9 (2007). |
Claris-Appiani et al., Phosphate-Induced PTH Stimulation and Calcitriol Treatment in Children with Early Chronic Renal Insufficiency, J. Bone Miner. Met., 12:S91-S97 (1994). |
Coburn et al., Doxercalciferol Safely Suppresses PTH Levels in Patients with Secondary Hyperparathyroidism Associated with Chronic Kidney Disease Stages 3 and 4, Am. J. Kidney Dis., 43(5):877-890 (2004). |
Coburn, An Update on Vitamin D as Related to Nephrology Practice: 2003, Kidney International, vol. 64, Supplement 87, pp. S125-S130 (2003). |
Coburn, et al., Use of Active Vitamin D Sterols in Patients with Chronic Kidney Disease, Stages 3 and 5, Kidney International, vol. 63, Supplement 85, pp. S49-S53 (2003). |
Coen et al., 1,25(OH)2D3 and 25-OHD3 in the Treatment of Renal Osteodystrophy: Comparison of Combined Versus 1,25(OH)2D3 Administration Alone, Miner. Electrolyte Metab., 9:19-27 (1983). |
Coen et al., 25-hydroxycholecalciferol in the treatment of renal osteodystrophy in haemodialysed patients, Int J Artificial Organs, 2(6): 278-281 (1979). |
Cohen-Solal et al., Non-Aluminic Adynamic Bone Disease in Non-Dialyzed Uremic Patients: A New Type of Osteopathy Due to Overtreatment? Bone, 13:1-5 (1992). |
Collet et al. Modified-Release Peroral Dosage Forms, Aulton (ed.), Pharmaceutics: The Science of Dosage Forms, Churchill Livingston, London, pp. 289-305 (2002). |
Colodro et al., Effect of 25-Hydroxy-Vitamin D3 on Intestinal Absorption of Calcium in Normal Man and Patients With Renal Failure, Metabolism, 27(6):745-753 (1978). |
Cooke et al., Vitamin D-Binding Protein (Gc-Globulin): Update 1995, Endocrine Rev., 4:125-128 (1995). |
Coyne et al., Paricalcitol Capsule for the Treatment of Secondary Hyperparathyroidism in Stages 3 and 4 CKD, American Journal of Kidney Diseases, 47(2):263-276 (2006). |
Daisley-Kydd et al., Calcitriol in the Management of Secondary Hyperparathyroidism of Renal Failure, Pharmacotherapy., 16:619-630 (1996). |
Database WPI Week 199546 Thomson Scientific, London, GB; AN 1995-355178 XP002464406. |
Database WPI Week 199546 Thomson Scientific, London, GB; An 1995-355178 XP002680886. |
Davies, M. et al. The Absorption and Metabolism of Vitamin D3 from Parenteral Injection Sites, Proceedings of the Workshop on Vitamin D, 4th, Vitam. D: Basic Res. Its Clin. Appl. (1979), abstract. |
DB-Pharma, Dedrogyl 15 Mg/10ML Calcifediol Oral Drops, Solution, Marketing Authorization No. 317 863.2 (2000). |
DeLuca, Treatment of renal osteodystrophy with 25-hydroxycholecalciferol, Arch Intern Med, 126(5):896-899 (1970). |
Deroisy et al., Comparison of the Short-Term Effects of Three Oral Calcium-Vitamin D Formulations and Placebo on Calcium Metabolism, Curr. Ther. Res., 59:370-378 (1998). |
DeVille et al., Effect of Ergocalciferol Supplementation on Serum Parathyroid Hormone and Serum 25-Hydroxyvitamin D in Chronic Kidney Disease, Nephrology, 11:555-559 (2006). |
Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride, Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine, National Academy Press, Washington DC, pp. 250-287 (1997). |
Dietary Supplement Fact Sheet: Vitamin D, National Institutes of Health, Office of Dietary Supplements (last update: Aug. 5, 2005), retrieved from <URL: http:ods.od.nih.gov/factsheets/vitamind.asp> on Aug. 31, 2007. |
Disease and Vitamin D, University of California Riverside, retrieved from Internet, <URL: <http://vitamind.ucr.edu/disease.html>> (last update: May 19, 1999). |
Disintegration, chapter 701; Dissolution, chapter 711; Distilling Range, chapter 721; Drug Release, chapter 724; Electrophoresis, chapter 726; pp. 276-292, in: U.S. Pharmacopeia vol. 30. |
Dogan et al., Effect of depot oral cholecalciferol treatment on secondary hyperparathyroidism in stage 3 and stage 4 chronic kidney diseases patients, Ren Fail., 30: 407-410 (2008). |
Drueke et al., Recurrence of hyperparathyroidism from autografted parathyroid fragments in uremic patients in spite of administration of 25(OH)D3 and 1a(OH)D3. In: Vitamin D. Basic Research and its Clinical Application, (Eds. Norman AW, Schaefer K, Herrath Dv, Grigoleit HG, Coburn JW, DeLuca HF, Mawer EB, and Suda T), pp. 791-794. Willem de Gruyter, New York (1979). |
Dusso et al, Metabolic Clearance Rate and Production Rate of Calcitriol in Uremia, Kidney Int., 35 860-864 (1989). |
Dusso et al., Extra-renal production of calcitriol in chronic renal failure, Kidney Int., 34:368-375 (1988). |
Dusso et al., Extrarenal Production of Calcitrol in Normal and Uremic Humans*, Journal of Clinical Endocrinology and Metabolism, 72(1):157-164 (1991). |
E.W. Martin, Drug Interactions, in Hazards of Medication, J.B. Lippincott Co. (1978). |
Eastwood et al., Biochemical and histological effects of 1,25 dihydroxycholecalciferol (1,25-DHCC) in the osteomalacia of chronic renal failure, J Urol Nephrol (Paris,) 80(12): 984-985 (1974). |
Eastwood et al., The contrasting effects on bone histology of vitamin D and of calcium carbonate in the osteomalacia of chronic renal failure, Clin Sci Molec Med, 47:23-42 (1974). |
Eastwood et al., The Effect of 25-Hydroxy Vitamin D3 in the Osteomalacia of Chronic Renal Failure, Clin. Sci. Molec. Med., 52:499-508 (1977). |
El Abdaimi et al., Reversal of hypercalcemia with the vitamin D analogue EB1089 in a human model of squamous cancer, Cancer Res., 59(14):3325-8 (1999). |
English translation of WO0212182 (Year: 2002). * |
Ennis et al., Current recommended 25-hydroxyvitamin D targets for chronic kidney disease management may be too low, J. Nephrol., 29(1):63-70 (Feb. 2016). |
Epps et al., Vitamin D Metabolism: Implications for Treatment in Oncology, Oncology News, 4:42-44 (2009). |
Fernandez et al., Guidelines for Dosing of Intravenous Calcitriol in Dialysis Patients with Hyperparathyroidism, Nephrol. Dial. Transplant., 11:96-101 (1996). |
Final Office Action, U.S. Appl. No. 16/089,235, dated Dec. 10, 2019, 35 pages. |
Fliser et al., Fibroblast gowth factor 23 (FGF23) predicts progression of chronic kidney disease: the mild to moderate kidney disease (MMKD) study, J. Am. Soc. Nephrol., 18:2601-8 (2007). |
Fournier et al., 1-alpha-Hydroxycholecalciferol and 25-Hydroxycholecalciferol in Renal Bone Disease, Calcified Tissues 1975: Proceedings of the 11th European Symposium on Calcified Tissues, 226-235 (1975). |
Fournier et al., 1α Hydroxycholecalciferol and 25 Hydroxycholecalciferol in Renal Bone Disease Proc Eur Dial Transplant Assoc 12:227-236 (1976). |
Fournier et al., 1α-hydroxycholecalciferol and 25-hydroxycholecalciferol in Renal Bone Disease Calcif Tissue Res. 21:226-235 (1976). |
Fournier et al., Advances in Nephrology from the Necker Hospital Adv. Nephrol Necker Hosp. 21:237-306 (1992). |
Fournier et al., Comparison of 1α-hydroxycholecalciferol and 25-hydroxycholecalciferol in the treatment of renal osteodystrophy: Greater effect of 25-hydroxycholecalciferol on bone mineralization Kidney International 15:196-204 (1979). |
Fournier et al., Current Status of the Management of Renal Osteodystrophy Proceedings of the European Dialysis and Transplant Association 15:547-568 (1978). |
Fournier et al., Impact of calcium and vitamin D therapy on arterial and cardiac disease in young adults with childhood-onset and stage renal disease, Nephrol Dial Transplant , 22:956-957 (2006). |
Fournier et al., Importance of Vitamin D Repletion in Uraemia, Nephrol Dial Transplant, 14(4):819-823 (1999). |
Fournier et al., Low doses of calcitriol or calcium carbonate for the prevention of hyperparathyroidism in predialysis patients? Nephrol Dial Transplant 11(7):1493-1495 (1996). |
Fournier et al., Present-Day Concepts in the Treatment of Chronic Renal Failure Contrib Nephrol. 71:64-80 (1989). |
Fournier et al., Preventing Renal Bone Disease in Moderate Renal Failure with CaCO3 and 25(OH) Vitamin D3, Kidney Int., 33:S178-S279 (1988). |
Fournier et al., Renal Osteodystrophy in Dialysis Patients: Diagnosis and Treatment, Artificial Organs, 22:530-557 (1998). |
Fournier et al., Renal Osteodystrophy: Pathophysiology and Treatment Hormone Res. 20:44-58 (1984). |
Fournier et al., The Approach to the Treatment of Secondary Hyperparathyroidism in Early Renal Failure Am. J. Nephrol 8:170-172 (1988). |
Fournier et al., Traitement vitaminique D et ostéodystrophies rénales: indications et modalitiés Nephrologie 16(2):165-190 (1995) [journal in French]. |
Fournier, Vitamin D: Biochemical, Chemical, and Clinical Aspects Related to Calcium Metabolism, Vitamin D: Proceedings of the Third Workshop on Vitamin D, Asilomar, Pacific Grove, CA, USA 667-669 (1977). |
Friedman et al. The Role of Vitamin D in Mild to Moderate Chronic Kidney Disease, Trends in Endocrinology & Metab,. 13(5):189-194 (2002). |
Friedrich et al., Analysis of the vitamin D system in cervical carcinomas, breast cancer and ovarian cancer, Recent Results Cancer Res., 164:239-46 (2003). |
Fritsche et al., Regulation of 25-Hydroxyvitamin D3-1α-Hydroxylase and Production of 1α,25-Dihydroxyvitamin D3 by Human Dendritic Cells, Blood, 102(9):3314-3316 (2003). |
Frohling et al., Serum 25-hydroxyvitamin D in patients with chronic renal failure on long-term treatment with high doses of vitamin D2. Nephron 26: 116-120 (1980). |
Frost et al., Histomorphometric Changes in Trabecular Bone of Renal Failure Patients Treated with Calcifediol, Metab. Bone Dis. & Rel. Res., 2:285-295 (1981). |
Fukagawa et al., FGF23: its role in renal bone disease, Pediatr. Nephrol., 21:1802-6 (2006). |
Fukagawa et al., With or without the kidney: the role of FGF23 in CKD, Nephrol. Dial. Transplant., 20:1295-8 (2005). |
Gallagher et al., Comparison of the Histological Effect and Metabolism of 25-(OH)D and 1,25-(OH)2D in Rat Bone, p. 399-401, IN: Norman, Vitamin D: Basic Research and its Clinical Application: Proceedings of the Fourth Workshop on Vitamin D, Berlin, West Germany, Feb. 1979. |
Gal-Moscovici et al., Role of vitamin D deficiency in chronic kidney disease, Journal of Bone and Mineral Res. 22:V91-V94 (2007). |
Garland et al., Vitamin D for cancer prevention: global perspective, Ann. Epidemiol., 19(7):468-83 (2009). |
Ghazali et al., Is low plasma 25-(OH) vitamin D a major risk factor for hyperparathyroidism and Looser's zones independent of calcitriol? Kidney International 55:2169-2177 (1999). |
Gibson, ed., Product optimisation. Pharmaceutical Preformulation and Formulation: A Practical Guide from Candidate Drug Selection to Commercial Dosage Form, 295-8 (2004). |
Goldzieher et al., Single-monthly-dose vitamin D supplementation in elderly patients, Endocr. Pract., 5(5):229-32 (1999). |
Gómez-Alonso et al., Vitamin D Status and Secondary Hyperparathyroidism: The Importance of 25-Hydroxyvitamin D Cut-Off Levels, Kidney International, 63(Supp. 85):S44-S48 (2003). |
Goodman, Calcimimetic agents and secondary hyperparathyroidism: treatment and prevention, Nephrol Dial Transplant, 2002;17:204-207. |
Gopinath et al., Disintegrants—A Brief Review, J. Chem. Pharm. Sci., 5(3):105-12 (Jul.-Sep. 2012). |
Gradishar et al., Minimizing cancer's impact on bone with denosumab: current and future perspectives, Community oncology, 10(8):235-243 (2013). |
Granja et al., Studies on the Opening of Dioxanone and Acetal Templates and Application to the Synthesis of 1α,25-Dihydroxyvitamin D21, J. Org. Chem., 58:124-131 (1993). |
Guidance for Industry, Nonclinical Safety Evaluation of Drug or Biologic Combinations, U.S. Department of Health and Human Services, Food and Drug Administration (Mar. 2006). |
Haddad et al., Acute Administration of 25-Hydroxycholecalciferol in Man, J. Clin. Endocrinol. Metab., 42:284-289 (1976). |
Haddad et al., Human Serum Binding Capacity and Affinity for 25-Hydroxyergocalciferol and 25-Hydroxycholecalciferol, J. Clin. Endocrinol. Metab., 43:86-91 (1976). |
Haddad et al., Natural and Synthetic Sources of Circulating 25-Hydroxyvitamin D in Man, Nature, 244:515-517 (1973). |
Haddad et al., Vitamin D plasma binding protein. Turnover and fate in the rabbit, J. Clin. Invest., 67(5):1550-60 (1981). |
Haddad, Plasma Vitamin D-binding Protein (Gc-Globulin): Multiple Tasks, J. Steroid Biochem. Molec. Biol., 53:579-582 (1995). |
Haddad, Seasonal Diminution of Vitamin D Stores in the United States: Can Darker Winters Lead to Lighter Bones? Trends Endocrinol. Metab., 7:209-212 (1996). |
Haddad, Traffic, Binding and Cellular Access of Vitamin D Sterols, Bone and Mineral Res., Elsevier, 5:281-308 (1987). |
Haddad, Vitamin D—Solar Rays, The Milky Way, or Both? NEJM, 326:1213-1215 (1992). |
Haldimann et al., Effect of an Oral Dose of 25-Hydroxyvitamin D3 on Its Blood Levels in Patients with the Nephrotic Syndrome, J Clin Endocrinology and Metabolism, 50(3): 470-474 (1980). |
Halloran et al., Plasma Vitamin D Metabolite Concentrations in Chronic Renal Failure: Effect of Oral Administration of 25-Hydroxyvitamin D3, J. Clin. Endocrin. & Metab., 59:1063-1069 (1984). |
Hamida et al., Hyperparathyroïdie secondaire álinsuffisance rénale Annales d'Endocrin-ologie 55:147-158 (1994) [reference in French]. |
Hannula et al., Constant, But Not Pulsed Calcitriol Suppresses Hemodialysis Patients' Antigen-Induced Lymphocyte Proliferation, Nephron, 86:139-144 (2000). |
Hari et al., Vitamin D insufficiency and effect of cholecalciferol in children with chronic kidney disease, Pediatr.Nephrol,. 25: 2483-2488 (2010). |
Harris R Z et al: Pharmacokinetics of cinacalcet hydrochloride when administered with ketoconazole, Clinical Pharmacokinetics, Adis International Ltd., Auckland, NZ, vol. 46, No. 6, Jan. 1, 2007 (Jan. 1, 2007), pp. 495-501. |
Hay et al., Vitamin D2 in Vertebrate Evolution, Comp. Biochem. Physiol. B, 56:375-380 (1977). |
Hectorol® (doxercalciferol) Capsules (Label, FDA, 2010). |
Heike A. A. Bischoff-Ferrari (J. of Steroid & Molecular Biology 103 (2007) 614-619). |
Helvig et al., Dysregulation of renal vitamin D metabolism in the uremic rat, Kidney Int., 78(5):463-72 (2010). |
Hemodialysis (2015, 4 pages, Accessed from https://www.kidney.org/atoz/content/hemodialysis on Jun. 19, 2019) (Year: 2015). |
Henry et al., Response of chick parathyroid glands to the vitamin D metabolites, 1,25-dihydroxycholecalciferol and 24,25-dihydroxycholecalciferol, J. Nutr., 107(10):1918-26 (1977). |
Hidroferol® (calcifediol): Casos de Hipercalcemia e Hipervitaminosis D, Butlletí de Farmacovigilància de Catalunya, 9(5):17-20 (2011). |
Hodson et al., Treatment of childhood renal osteodystrophy with calcitriol or ergocalciferol, Clin Nephrology, 24(4): 192-200 (1985). |
Holick et al., Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline, J. Clin. Endocrinol. Metab., 96(7):1911-30 (Jul. 2011). |
Holick et al., Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-dydroxyvitamin D, J Clin Endocrinol Metab., 93(3):677-81 (2008). |
Holick, Vitamin D Deficiency in CKD: Why Should We Care? Am. J. Kidney Dis., 45:1119-1121 (2005). |
Holick, Vitamin D for health and in chronic kidney disease, Semin. Dial., 18(4):266-75 (2005). |
Holick, Vitamin D Status: Measurement, Interpretation and Clinical Application, Ann Epidemiol, 19(2):73-78 (2009). |
Holick, Vitamin D: A millenium perspective, J. Cell Biochem.. 88:296-307 (2003). |
Hollis, Circulating 25-Hydroxyvitamin D Levels Indicative of Vitamin D Sufficiency: Implications for Establishing a New Effective Dietary Intake Recommendation for Vitamin D, J. Nutr. 135: 317-322 (2005). |
Holmberg et al., Absorption of a pharmacological dose of vitamin D3 from two different lipid vehicles in man: comparison of peanut oil and a medium chain triglyceride, Biopharm. Drug Dispos., 11(9):807-15 (1990). |
Horst et al., A Sensitive Competitive Protein Binding Assay for Vitamin D in Plasma, Steroids, 37:581-592 (1981). |
Horst et al., Discrimination in the Metabolism of Orally Dosed Ergocalciferol and Cholecalciferol by the Pig, Rat and Chick, Biochem. J., 204:185-189 (1982). |
Horst et al., Rat cytochrome P450C24 (CYP24) does not metabolize 1,25-dihydroxyvitamin D2 to calcitroic acid, J. Cell Biochem., 88:282-285 (2003). |
Hottelart et al., Ostéodystrophie rénale (2): son traitement chez l'insuffisant rénal avant la dialyse Nephrologie 21(6):275-282 (2000) [reference in French]. |
Houghton et al., The Case Against Ergocalciferol (Vitamin D2) as a Vitamin Supplement, Am. J. Clin. Nutr., 84:694-697 (2006). |
Hunt, et al., A Comparison of the Toxicity of Ergocalciferol and Cholecalciferol in Rhesus Monkeys (Macaca mulatta), J. Nutrition, 102:975-986 (1972). |
Hussar, New Drugs of 1999, J. Am. Pharmacist. Assoc. 40(2):181-229 (2000). |
Ibrahim et al., Serum fibroblast growth factor-23 levels in chronic haemodialysis patients, Int. Urol. Nephrol., 41:163-9 (2009). |
Iladdad, Plasma Vitamin D-binding Protein (Gc-Globulin): Multiple Tasks, J. Steriod Biochem. Molec. Biol., 53:579-582 (1995). |
Inoue et al., Role of the vitamin D receptor in FGF23 action on phosphate metabolism, Biochem. J., 399:325-31 (2005). |
International Preliminary Report on Patentability for Corresponding International Application No. PCT/EP17/57282, dated Oct. 11, 2018, 7 pages. |
International Preliminary Report on Patentability for Corresponding International Application No. PCT/US09/39355, dated Oct. 14, 2010, 8 pages. |
International Search Report for Application No. PCT/US2007/061521, dated Jul. 17, 2007. |
International Search Report of counterpart PCT/US2008/061579 dated Aug. 21, 2008 (5 pages). |
International Search Report of PCT/US2008/061579 dated Aug. 21, 2008 (5 pages). |
Ishimura et al., Serum Levels of 1,25-Dihydroxyvitamin D, 24,25-Dihydroxyvitamin D, and 25-Hydroxyvitamin D in Nondialyzed Patients with Chronic Renal Failure, Kidney Int., 55:1019-1027 (1999). |
Japanese Office Action for Application No. 2008-553520, dated Jul. 24, 2013. |
Jara et al., Effect of Calcitriol Treatment and Withdrawal on Hyperparathyroidism in Haemodialysis Patients with Hypocalcaemia, Nephrol. Dial. Transplant., 16:1009-1016 (2001). |
Jean et al., Daily Oral 25-Hydroxycholecalciferol Supplementation for Vitamin D Deficiency in Haemodialysis Patients: Effects on Mineral Metabolism and Bone Markers, Nephrol. Dial. Transplant, 23:3670-3676 (2008). |
Jean et al., Evidence for Persistent Vitamin D 1-Alpha-Hydroxylation in Hemodialysis Patients: Evolution of Serum 1,25-Dihydroxycholecalciferol after 6 Months of 25-Hydroxycholecalciferol Treatment Nephron. Clin. Pract. 110:c58-c65 (2008). |
Jean et al., Monthly cholecalciferol administration in heamodialysis patients: a simple and efficient strategy for vitamin D supplementation Nephrol. Dial. Transplant 24(12):3799-3805 (2009). |
Jones et al., Cytochrome P450-mediated metabolism of vitamin D, J. Lipid Res., 55(1):13-31 (2014). |
Jones, Pharmacokinetics of vitamin D toxicity, Am. J. Clin. Nutr. 88(suppl): 582S-6S (2008). |
Jones, Why dialysis patients need combination therapy with both cholecalciferol and a calcitriol analogs, Seminars in Di alysis, pp. 1-5 (2010). |
Jones., Expanding the Role for Vitamin D in Chronic Kidney Disease: Importance of Blood 25-OH-D Levels and Extra-Renal 1α-Hydroxyase in the Classical and Nonclassical Actions of 1α, 25-Dihydroxyvitamin D3, Seminars in Dialysis, 20(4):316-324 (2007). |
Joy et al: Outcomes of Secondary Hyperparathyroidism in Chronic Kidney Disease and the Direct Costs of Treatment, Journal of Managed Care Pharmacy, Academy of, Managed Care Pharmacy, Alexandria, VA, vol. 13, No. 5, Jan. 1, 2007 (Jan. 1, 2007), pp. 397-411. |
K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease, National Kidney Foundation, Am. J. Kidney Dis., 42 (Supplement 3):1-202 (2003). |
Kajihara et al., Novel Method to Control Release of Lipophilic Drugs with High Potency from Silicone, Chem. Pharm. Bull., 51:11-14 (2003). |
Kalantar-Zadeh et al., Clinical Outcomes with Active versus Nutritional Vitamin D Compounds in Chronic Kidney Disease Clin J Am Soc Nephrol. 4(9):1529-1539 (2009). |
Kanis et al., Rate of Reversal of Hypercalcaemia and Hypercalciuria Induced by Vitamin D and Its 1-alpha-Hydroxylated Derivatives, BMJ, 1:78-81 (1977). |
Kaufmann et al. J. Clin. Endocrinol. Metab., 2014, vol. 99, pp. 2567-2574 (Year: 2014). |
Kaufmann et al., Clinical utility of simultaneous quantitation of 25-hydroxyvitamin D and 24,25-dihydroxyvitamin D by LC-MS/MS involving derivatization with DMEQ-TAD, J. Clin. Endocrinol. Metab., 99(7):2567-74 (Jul. 2014). |
Kazama et al., Role of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism, Ther. Apher. Dial., 9:328-30 (2005). |
KDOQI Clinical practice guidelines 2004. National Kidney Foundation). |
Khachane et al., Novel Suatained Release Drug Delivery System: Review, IJPRD, 3(12):1-14 (2012). |
Kidney Disease Improving Global Outcomes (KDIGO) 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2017;7(1):1-59. |
Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guidelines for Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD), Kidney International Supplement, 113:S1-130 (2009). |
Kim, Advanced Pharmaceutics: Physicochemical Principles, pp. 362-392, Boca Raton, Fla: CRC Press (2004). |
Kinoshita et al., 1,25-Dihydroxyvitamin D Suppresses Circulating Levels of Parathyroid Hormone in a Patient with Primary Hyperparathyroidism and Coexistent Sarcoidosis, J. Clin. Endo. & Metabol., 90(12):6727-6731 (2005). |
Kleinman et al., Effects of Calcifediol on Calcified Tissue in Uremia, Arch Intern Med, 138: 864-865 (1978). |
Kobayashi et al., 2β-(3-Hydroxyproxy)-α,25-Dihydroxyvitamin D3 (ED-71), Preventive and Therapeutic Effects on Bone Mineral Loss in Ovariectomized Rats, Bioorganic & Medicinal Chemistry Letters, 3(9):1815-1819 (1993). |
Kobayashi et al., Variation of 25-Hydroxyvitamin D3 and 25-Hydroxyvitamin D2 Levels in Human Plasma Obtained from 758 Japanese Healthy Subjects, J. Nutr. Sci. Vitaminol (Tokyo), 29(3):271-281 (1983). Abstract Only. |
Kooienga et al., The effect of combined calcium and vitamin D3 supplementation on serum intact parathyroid hormone in moderate CKD, Am.J.Kidney Dis,. 53: 408-416 (2009). |
Koshikawa, et al., Clinical Effect of Intravenous Calcitriol Administration on Secondary Hyperparathyroidism, Nephron; 90:413-423 (2002). |
Kovesdy et al., Association of activated vitamin D treatment and mortality in chronic kidney disease, Arch. Intern. Med., 168(4):397-403 (Feb. 2008). |
Krishnan et al., The role of vitamin Din cancer prevention and treatment, Rheum. Dis. Clin. North Am., 38(1):161-78 (2012). |
KURO-O, Klotho in chronic kidney disease—what's new?, Nephrol. Dial. Transplant., 4 pp. (2009). |
LaClair et al., Prevalence of Calcidiol Deficiency in Ckd: A Cross-Sectional Study Across Latitudes in the United States, Am. J. Kidney Dis., 45:1026-1033 (2005). |
Lafage et al., Ketodiet, Physiological Calcium Intake and Native Vitamin D Improve Renal Osteodystrophy, Kidney Int., 42:1217-1225 (1992). |
Lambert et al., Evidence for Extranrenal Production of 1-alpha,25-Dihydroxyvitamin D in Man, J. Clin. Invest., 69:722-725 (1982). |
Lambrey et al., 24, 25 Dihydroxycalciferol: Assay in Non-Anephric Patients on Chronic Haemodialysis and Assessment of it's Possible Pathophysiological Role in Renal Osteodystrophy Proc Eur Dial Transplant Assoc. 17:548-556 (1980). |
Lambrey, Possible Link Between Changes in Plasma 24,25-Dihydroxyvitamin D and Healing of Bone Resorption in Dialysis Osteodrstrophy Metab. Bone Dis. & Rel. Res. 4:25-30 (1982). |
Langman et al., 25-Hydroxyvitamin D3 (Calcifediol) Therapy of Juvenile Renal Osteodystrophy: Beneficial Effect on Linear Growth Velocity, J. Pediatrics, 100:815-820 (1982). |
Larrosa M. et al., Long-Term Treatment of Hypovitaminosis D. Calcidol Or Cholecalciferol? Annals Of The Rheumatic Diseases, vol. 64, No. Suppl. 3, Jul. 2005, p. 366. |
Lau et al., Vitamin D Therapy of Osteoporosis: Plain Vitamin D Therapy Versus Active Vitamin D Analog (D-Hormone) Therapy, Calcif. Tissue Int., 65:295-306 (1999). |
Lehmann et al., Coating of Tablets and Small Particles with Acrylic Resins by Fluid Bed Technology, Int. J. Pharm. Tech. & Prod. Mfr., 2:31-43 (1981). |
Letteri et al., Effects of 25-Hydroxycholecalciferol on Calcium Metabolism in Chronic Renal Failure Adv. Exp. Med. Biol. 81:591-601 (1977). |
Lips et al., A Global Study of Vitamin D Status and Parathyroid Function in Postmenopausal Women with Osteoporosis: Baseline Data from the Multiple Outcomes of Raloxifene Evaluation Clinical Trial, The Jour. of Clin. Endo. & Meta., 86(3):1212-1221 (2001). |
Lo et al., Vitamin D absorption in healthy subjects and in patients with intestinal malabsorption syndromes, Am. J. Clin. Nutr., 42(4):644-9 (1985). |
Lomonte et al., Are Low Plasma Levels of 25-(OH) Vitamin D a Major Risk Factor for Hyperparathyroidism Independent of Calcitriol in Renal Transplant Patients? J. Nephrol., 18:96-101 (2005). |
Lund et al., Serum 1,25-Dihydroxycholecalciferol in Anephric. Haemodialyzed and Kidney-transplanted Patients, Nephron, 25:30-33 (1980). |
Luo et al., 24-Hydroxylase in cancer: impact on vitamin D-based anticancer therapeutics, J. Steroid Biochem. Mal. Biol., 136:252-7 (2013). |
Maierhofer et al., Synthesis and Metabolic Clearance of 1,25-Dihydroxyvitamin D as Determinants of Serum Concentrations: a Comparison of Two Methods Journal of Clinical Endocrinology and Metabolism 53:472-475 (1981). |
Manni et al., Oral Calcitriol: Comparison Between the Same Weekly Dose Administered as a Single vs. Two Divided Pulsed Doses in Secondary Hyperparathyroidism of Chronic Renal Failure, Ital. J Mineral Electrolyte Metab., 11:61-64 (1997). |
Martin et al., 19-Nor-1-α-25-Dihydroxyvitamin D2 (Paricalcitol) Safely and Effectively Reduces the Levels of Intact Parathyroid Hormone in Patients on Hemodialysis, J. Am. Soc. Nephrol., 9:1427-1432 (1998). |
Martin-Baez et al., Severe hypocalcaemia post-denosumab, Nefrologia, 33(4):614-5 (2013). |
Matsushita et al., Clinical effects of 25-hydroxycholecalciferol in patients with chronic renal failure, J Nutr Sci Vitaminol, 23:257-261 (1977). |
Mazouz et al., Risk factors of renal failure progression two years prior to dialysisis Clinical Nephroloby 51(6):355-366 (1999). |
Mazur, Effects of 25-OHD3 on Renal Function in Pediatric Patients with Chronic Renal Failure, Mineral Electrolyte Metab. 10:351-358 (1984). |
Memmos et al., Response of uremic osteoid to vitamin D, Kidney Int, 21 (Suppl. 11): S50-S54 (1982). |
Menon et al., Vitamin D insufficiency and hyperparathyroidism in children with chronic kidney disease, Pedaitr Nephrol, 23:1831-1836 (2008). |
Messa et al., Direct In Vivo Assessment of Parathyroid Hormone-Calcium Relationship Curve in Renal Patients, Kidney Int., 46:1713-1720 (1994). |
Mimori et al., Clinical significance of the overexpression of the candidate oncogene CYP24 in esophageal cancer, Ann. Oncol., 15(2):236-41 (2004). |
Minutes of US FDA E&M Advisory Committee Meeting of Oct. 4, 1979 for Calderol® calcifediol capsules. |
Modern Pharmaceutics 4th ed., Marcel Dekker, Inc., New York, NY, p. 16-21 (2002). |
Moe et al., A randomized trial of cholecalciferol versus doxercalciferol for lowering parathyroid hormone in chronic kidney disease, Clin.J.Am.Soc.Nephrol. 5: 299-306 (2010). |
Moe et al., Safety and Efficacy of Pulse and Daily Calcitriol in Patients on CAPD: A Randomized Trial, Nephrol. Dial. Transplant., 13:1234-1241 (1998). |
Morris, Cats Discriminate Between Cholecalciferol and Ergocalciferol, J. Anim. Physiol. a. Anim. Nutr., 86:229-238 (2002). |
Morris, Vitamin D: A Hormone for All Seasons—How Much is Enough? Clin. Biochem. Rev., 26:21-32 (2005). |
Motellon et al., Parathyroid hormone-related protein, parathyroid hormone, and vitamin Din hypercalcemia of malignancy, Clin. Chim. Acta, 290(2):189-97 (2000). |
Muindi et al., Phamacokinetics of Liquid Calcitriol Formulation in Advanced Solid Tumor Patients: Comparison with Caplet Formulation, Cancer Chemother. Pharmacol., 56:492-496 (2005). |
Naik et al., Effects of Vitamin D Metabolites and Analogues on Renal Function, Nephron, 28:17-25 (1981). |
Nakanishi et al., The Roles of Vitamin D in Secondary Hyperparathyroidism, [journal in Japanese] 52:1107-1112 (2004). |
NASMHPD Medical Director's Technical Report on Psychiatric Polypharmacy (Sep. 2001). |
National Kidney Foundation Guidelines, NKF, Am. J. Kidney Dis., 42(4, Suppl 3):S1-5202 (2003). |
NewsWire (https://www.newswire.ca/news-releases/cytochroma-announces-data-presentations-at-american-society-of- hephrologys43rd-annual-meeting-and-scientific-exposition-546289852.html, published Nov. 18, 2010) (Year: 2010). |
NewsWire (https://www.newswire.ca/news-releases/cytochroma-announces-data-presentations-at-american-society-of-nephrologys43rd-annual-meeting-and-scientffic-exposition-546289852.html. published Nov. 18, 2010) (Year: 2010). |
Non-Final Office Action received for U.S. Appl. No. 12/597,230, dated Dec. 13, 2019, 15 pages. |
Norman et al. (eds.), Vitamin D—Gene Regulation, Structure-Function Analysis and Clinical Application: Proceedings of the Eighth Workshop on Vitamin d Paris, France, pp. 765-766, New York: Walter De Gruyter Inc. (1991). |
Notice of allowance dated Jul. 10, 2012, in counterpart EPO application 08746908.6. |
Notice of Allowance, U.S. Appl. No. 15/918,620, dated Nov. 29, 2019, 9 pages. |
Oksa et al., Effects of long-term cholecalciferol supplementation on mineral metabolism and calciotropic hormones in chronic kidney disease, Kidney Blood Press Res., 31: 322-329 (2008). |
Olmos et al., Effects of 25-hydroxyvitamin D3 therapy on bone turnover markers and PTH levels in postmenopausal osteoporotic women treated with alendronate, J. Clin. Endocrinol. Metab., 97(12):4491-7 (2012). |
OPKO Health Inc., Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT), <https://clinicaltrials.govict2/show/NCT01219855> Oct. 13, 2010. |
Package insert for Hectorol (doxercalciferol capsules), Genzyme (2011). |
Package insert for Zemplar (paricalcitol) Capsules, Abbott (2011). |
Pak et al., Treatment of Vitamin D-Resistant Rickets With 25-Hydroxycholecalciferol, Arch Intern Med, 129:894-899 (1972). |
Parfitt et al., Calcitriol But No Other Metabolite of Vitamin D is Essential for NormalBone Growth and Development in the Rat, J. Clin. Invest., 73:576-586 (1984). |
Parise et al., CYP24, the enzyme that catabolizes the antiproliferative agent vitamin D, is increased in lung cancer, Int. J. Cancer, 119(8):1819-28 (2006). |
Patel et al., Glomerular Filtration Rate is a Major Determinant of the Relationship Between 25-Hydroxyvitamin D and Parathyroid Hormone, Calcif. Tissue Int., 80:221-226 (2007). |
Peacock et al., Effect of Calcium or 25OH Vitamin D3 Dietary Supplementation on Bone Loss at the Hip in Men and Women over the Age of 60 The Journal of Clinical Endocrinology & Metabolism, 85(9):3011-3019 (2007). |
Perrie, Pharmaceutics: Drug Delivery and Targeting, Second Edition, Chapter 1 (2012). |
Petkovich et al., CYP24A1 and Kidney Disease, Current Opin. in Nephrology and Hypertension, 20:337-344 (2011). |
Phadnis et al., Direct, Rapid Effects of 25-Hydroxyvitamin D3 on Isolated Intestinal Cells, J. Cell. Biochem., 90:287-293 (2003). |
Posner et al., Vitamin D Analogues Targeting CYP24 in Chronic Kidney Disease, J. Steroid Biochem and Mol. Biol., 121:13-19 (2010). |
Pourgholami et al., 1, 25-Dihydroxyvitamin D3 Dissolved in Lipiodol Produces a Sustained Antiproliferative Effect in the Human Hepatoblastoma Cell Line HepG2, Anticancer Res., 20:723-728 (2000). |
Pourgholami et al., In Vitro Antiproliferative Activity of a Medium-Chain Triglyceride Solution of 1, 25-Dihydroxyvitamin D3 in HepG2 Cells, Anticancer Res., 20:4257-4260 (2000). |
Prescribing Information for Calderol® calcifediol capsules (1988). |
Prescribing Information for Hectorol® (doxercalciferol capsules), Genzyme (2011). |
Prescribing information for Zemplar® (paricalcitol) Capsules, Abbott (2011). |
Querfeld et al., Vitamin D deficiency and toxicity in chronic kidney disease: in search of the therapeutic window, Pediatr. Nephrol., 25(12):2413-30 (Dec. 2010). |
Rabbani, Molecular mechanism of action of parathyroid hormone related peptide in hypercalcemia of malignancy: therapeutic strategies (review), Int. J. Oncol., 16(1):197-206 (2000). |
Rambeck et al., Biological Activity of 1α,25-Dihydroxyergocalciferol in Rachitic Chicks and in Rats, IZVIAK, 54(2/3):135-139 (1984). |
Rapuri, P.B. et al., Effect of Vitamins D2 and D3 Supplement Use on Serum 25-OHD Concentration in Elderly Women in Summer and Winter, Calcified Tissue International, 74(2):150-156 (2004). |
Ravani et al., Vitamin D levels and patient outcome in chronic kidney disease, Kidney Int., 75(1):88-95 (Jan. 2009). |
Recker et al., The Efficacy of Calcifediol in Renal Osteodystrophy, Arch. Intern. Med., 138:857-863 (1978). |
Reddy et al., Abstracts Sixth Annual Scientific Meeting of the American Society for Bone and Mineral Research, 36:524 (1984). |
Reichel et al., Calcium Metabolism in Early Chronic Renal Failure: Implications for the Pathogenesis of Hyperparathyroidism, Nephrol. Dial. Transplant., 6:162-169 (1991). |
Reichel et al., Intermittent Versus Continuous Administration of 1,25-dihydroxyvitamin D3 in experimental renal hyperparathyroidism, Kidney Int., 44:1259-1265 (1993). |
Reichel, Current treatment options in secondary renal hyperparathyroidism, Nephrol Dial Transplant 21:23-28 (2006). |
Richard et al., PTHrP gene expression in cancer: do all paths lead to Ets?, Crit. Rev. Eukaryot. Gene Expr., 15(2):115-32 (2005). |
Ritter et al., 25-Hydroxyvitamin D3 suppresses PTH synthesis and secretion by bovine parathyroid cells, Kidney Int., 70:654-659 (2006). |
Rix et al., Effect of 18 Months of Treatment with Alfacalcidol on Bone in Patients with Mild to Moderate Chronic Renal Failure, Nephrol Dial Transplant, 19:870-876 (2004). |
Rocaltrol (Registered) Complete Product Information, Roche, Jul. 27, 2004. |
Rotuba marketing phthalate-free cellulosic, Plastic News, Nov. 26, 2007. |
Rucker et al., Vitamin D insufficiency and treatment with oral vitamin D3 in northern-dwelling patients with chronic kidney disease, J.Nephrol. 22: 75-82 (2009). |
Russell et al., Therapeutic Effects of 25-Hydroxyvitamin D3 on Renal Osteodystrophy, Mineral Electrolyte Metab., 1:129-138 (1978). |
Rutherford et al., Effect of 25-Hydroxycholecalciferol on Calcium Absorption in Chronic Renal Disease, Kidney International, 8:320-324 (1975). |
Saab et al., Prevalence of Vitamin D Deficiency and the Safety and Effectiveness of Monthly Ergocalciferol in Hemodialysis Patients, Nephron Clin. Pract., 105:c132-c138 (2007). |
Sanchez, Prevention and Treatment of Renal Osteodystrophy in Children With Chronic Renal Insufficiency and End-Stage Renal Disease, Seminars in Nephrology, 21:441-450 (2001). |
Saseen et al., Dual calcium-channel blocker therapy in the treatment of hypertension, Ann Pharmacother., 30(7-8): 802-10 (1996). |
Sato et al., Increased 1,25-(OH)2D2 concentration in a patient with malignancy-associated hypercalcemia receiving intravenous hyperalimentation inadvertently supplemented with vitamin D2, Intern. Med., 32(11):886-90 (1993). |
Schmidt, Measurement of 25-Hydroxyvitamin D Revisited, Clinical Chemistry, 52(12):2304-2305 (2006). |
Schwartz et al., Extended-release calcifediol (ERC) effectively increased serum 25-hydroxyvitamin D levels in breast and prostate cancer patients without significant impact on serum calcium or phosphorus, Opko Renal (2018). |
Sebert et al. Comparative effects of equal doses of vitamin D2 and vitamin D3 for the correction of vitamin D deficiency in the elderly in Norman et al. (eds.), Vitamin D—Gene Regulation, Structure-Function Analysis and Clinical Application: Proceedings of the Eighth Workshop on Vitamin d Paris, France, pp. 765-766, New York: Walter De Gruyter Inc. (1991). |
Sebert et al., Effets A Long Terme D'Une Association De 25-Hydroxycholécalciférol et de 1-Alpha-Hydroxycholécalciférol Sur L'Ostéodystrophie Des Hémodialysés Chroniques Rev. Rhum Mal Osteoartic 48(7-9):535-541 (1981). |
Sebert et al., Limit by Hyperphosphatemia of the Usefulness of Vitamin D Metabolites (1 alpha-Hydroxycholecalciferol and 25-Hydroxycholecalciferol) in the Treatment of Renal Osteodystrophy, Metab. Bone Dis. & Rel. Res., 2:217-222 (1980). |
Segersten et al.: Potentiating effects of nonactive/active vitamin D analogues and ketoconazole in parathyroid cells, Clinical Endocrinology., vol. 66, No. 3, Mar. 1, 2007 (Mar. 1, 2007), pp. 399-404. |
Sekkarie, The Impact of Over-the-counter Vitamin D Supplementals on Vitamin D and Parathyroid Hormone Levels in Chronic Kidney Disease, Clin. Nephrology, 65:91-96 (2006). |
Sensipar (cinacalcet) prescriptioninformation, revised Aug. 2011. |
Sensipar package insert (Year: 2004). |
Shah et al., Prevalence and correction of 25(OH) vitamin D deficiency in peritoneal dialysis patients, Peritoneal Dialysis Int., 25:362-366 ( 2005). |
Shi et al., Preparation of Chitosan/Ethylcellulose Complex Microcapsule and its Application in Controlled Release of Vitamin D2, Biomaterials, 23:4469-4473 (2002). |
Sicinski et al., Synthesis of 1 alpha, 25-Dihydroxyvitamin D2, Its 24 Epimer and Related Isomers, and Their Binding Affinity for the 1, 25-Dihydroxyvitamin D3 Receptor, Bioorganic Chemistry, 13:158-169 (1985). |
Singh et al., C-3 Epimers Can Account for a Significant Proportion of Total Circulating 25-Hydroxyvitamin D in Infants, Complicating Accurate Measurement and interpretation of Vitamin D Status, J. Clin. Endo. & Metabol., 91(8):3055-3061 (2006). |
Sirvent et al., Extreme hypocalcaemia and hyperparathyroidism following denosumab. Is this drug safe in chronic kidney disease?, Nefrologfa (Madrid), 34(4): 542-544 (2014). |
Sitrin et al., Comparison of vitamin D and 25-hydroxyvitamin D absorption in the rat, Am. J. Physiol., 242(4):G326-32 (1982). |
Sjoden, et al., 1α-Hydroxyvitamin D2 is Less Toxic than 1α-Hydroxyvitamin D3 in the Rat, Society for Experimental Biology and Medicine, 179: 432-436 (1985). |
Skelly et al., In vitro and in vivo testing an correlation for oral controlled/modified-release dosage forms. Pharm. Res., 7(9):975-82 (1990). |
Skugor M. et al.: Evolution and current state of assays for parathyriod hormone, Biochemia Medica, vol. 20, No. 2, 2010, pp. 221-228. |
Slatopolsky et al., Differential Effects of 19-nor-1,25-(OH)2D2 and 1α-Hydroxyvitamin D2 on Calcium and Phosphorus in Normal and Uremic Rats, Kidney International, 62:1277-1284 (2002). |
Somerville et al., Resistance to Parathyroid Hormone in Renal Failure: Role of Vitamin D Metabolites, Kidney Int., 14:245-254 (1978). |
Sömjen et al., Nonhypercalcemic Analogs of Vitamin D Stimulate Creatine Kinase B Activity in Osteoblast-Like ROS 17/2.8 Cells and Up-Regulate Their Responsiveness to Estrogens, Steroids, 63:340-343 (1998). |
Sommerfeldt et al., Metabolism of Orally Administered [3H]Ergocalciferol and [3H]Cholecalciferol by Dairy Calves, J. Nutr., 113:2595-2600 (1983). |
Sosa et al., The Effect of 25-dihydroxyvitamin D on the Bone Mineral Metabolism of Elderly Women with Hip Fracture, Rheumatology, 39:1263-1268 (2000). |
Soyfoo et al., Non-malignant causes of hypercalcemia in cancer patients: a frequent and neglected occurrence, Support Care Cancer, 21(5):1415-9 (2013). |
Sprague et al., Modified-release calcifediol effectively controls secondary hyperparathyroidism associated with vitamin D insufficiency in chronic kidney disease, Am. J. Nephrol., 40(6):535-45 (2015). |
Sprague et al., Use of Extended-Release Calcifediol to Treat Secondary Hyperparathyroidism in Stages 3 and 4 Chronic Kidney Disease, Am. J. Nephrol., 44(4):316-25 (2016). |
Stamp et al., Comparison of Oral 25-Hydroxycholecalciferol, Vitamin D, and Ultraviolet Light as Determinants of Circulating 25-Hydroxyvitamin D, The Lancet, 1341-1343 (Jun. 25, 1977). |
Stamp, Intestinal Absorption of 25-hydroxycholecalciferol, The Lancet, 121-123 (1974). |
Stavroulopoulos et al., Relationship between vitamin D status, parathyroid hormone levels and bone mineral density in patients with chronic kidney disease stages 3 and 4, Nephrology (Carlton), 13(1):63-7 (Feb. 2008). |
Stein et al., An Update on the Therapeutic Potential of Vitamin D Analogues, Expert Opin. Investig. Drugs, 12:825-840 (2003). |
Stubbs et al., Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD, J.Am.Soc.Nephrol., 21: 353-361 (2010). |
Stumpf, The Dose Makes the Medicine, Drug Discovery Today, 11:550-555 (2006). |
Szycher, Szycher's Dictionary of Biomaterials and Medical Devices, pp. 20, 48, 127, Lancaster, Penn: Technomic Publishing Co., Inc. (1992). |
Tamez et al., Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease, Am. Heart J., 164(6):902-9.e2 (Dec. 2012). |
Taylor et al., Interrelationship of Serum 25-Hydroxyvitamin D3 and 1,25-Dihydroxyvitamin D in Juvenile Renal Osteodystrophy after Therapy with 25-Hydroxyvitamin D3, Metab. Bone Dis. & Rel. Res., 4:255-261 (1982). |
Taylor et al., The absence of 24,25-dihydroxycholecalciferol in anephric patients, Clin.Sci.Mol.Med.Suppl., 55: 541-547 (1978). |
Taylor, CM, 24,25-Dihydroxyvitamin D in Human Serum. In: Vitamin D. Basic Research and Clinical Applications, pp. 197-203. Walter de Gruyter, New York (1979). |
Tebben et al., Elevated fibroblast growth factor 23 in women with malignant ovarian tumors, Mayo Clin. Proc., 80:745-51 (2005). |
Teitelbaum et al., Calcifediol in Chronic Renal Insufficiency JAMA 235(2):164-167 (1976). |
Teitelbaum et al., Tetracycline fluorescence in uremic and primary hyperparathyroid bone, Kidney Int., 12:366-372 (1977). |
Terrie, Monitoring Combination Drug Therapy, Pharmacy Times, published Jan. 18, 2010., Jan. 19, 2010,. |
Thomas et al., Hypovitaminosis D in Medical Inpatients, NEJM, 338:777-783 (1998). |
Thombre, Assessment of the feasibility of oral controlled release in an exploratory development setting, Drug Discovery Today, 10(17): 1159-1166 (2005). |
Tokmak et al., High-dose cholecalciferol to correct vitamin D deficiency in haemodialysis patients, Nephrol.Dial.Transplant., 23: 4016-4020 (2008). |
Tomida et al., Serum 25-hydroxyvitamin D as an independent determinant of 1-84 PTH and bone mineral density in non-diabetic predialysis CKD patients, Bone, 44(4):678-83 (Apr. 2009). |
Trakarnvanich et al., Effect of high dose ergocalciferol in chronic kidney disease patients with 25-hydroxyvitamin D deficiency, J.Med.Assoc.Thai. 93: 885-891 (2010). |
Tsuji, et al. A New and Convenient Synthesis of 1α,25-Dihydroxyvitamin D2 and It 24R-Epimer, Bull. Chem. Soc. Jpn., 62:10 pp. 3132-3137 (1989). |
Tuohimaa et al., Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries, Int. J. Cancer, 108(1):104-8 (2004). |
US FDA Clinical Review and Evaluation of NDA for Calderol® calcifediol capsules (believed to be available circa 1983). |
US FDA Summary of Basis of Approval for Calderol® calcifediol capsules (believed to be available circa 1980). |
Van Weelden et al., Apoptotic Regression of MCF-7 Xenografts in Nude Mice Treated with the Vitamin D3 Analog, EB1089, Endocrinology, 139:2102-2110 (1998). |
Verberckmoes et al., Osteodystrophy of Dialysed Patients Treated with Vitamin D, Proc Eur Dial Transplant Assoc., 10(0): 217-226 (1973). |
Vieth, Vitamin D Supplementation, 25-Hydroxyvitamin D Concentrations, and Safety, Am. J. Clin. Nutr., 69:842-856 (1999). |
Vieth, What is the optimal vitamin D status for health? Prog. Biophys. Mol. Biol., 92:26-32 (2006). |
Wagner et al., The ratio of serum 24,25-dihydroxyvitamin D(3) to 25-hydroxyvitamin D(3) is predictive of 25-hydroxyvitamin D(3) response to vitamin D(3) supplementation, J. Steriod Biochem. Mal. Biol., 126(3-5):72-7 (Sep. 2011). |
Wang-Gillam et al., Evaluation of vitamin D deficiency in breast cancer patients on bisphosphonates, Jul. 1, 2008, Oncologist, 821-7, 13(7). |
Wise (ed.), Handbook of Pharmaceutical Controlled Release Technology, An Overview of Controlled Release Systems, Chapter 22, pp. 431-445, 461-463; Research and Development Aspects of Oral Controlled-Release Dosage Forms, Chapter 23, pp. 465-473, New York: Marcel Dekker, Inc. 3 (2000). |
Witmer et al., Effects of 25-hydroxycholecalciferol on bone lesions of children with terminal renal failure Kidney International 10:395-408 (1976). |
Wootton, Improving the Measurement of 25-Hydroxyvitamin D, Clin Biochem Rev, 26:33-36 (2005). |
Written Opinion for Application No. PCT/US2007/061521, dated Jul. 17, 2007. |
Written Opinion for Application No. PCT/US2008/061579, dated Aug. 21, 2008. |
Yanoff et al., The Prevalence of Hypovitaminosis D and Secondary Hyperparathyroidism in Obese Black Americans, Clin. Endocrinol. (Oxf), 64(5):523-529 (2006). |
Yudianti et al., Effect of water soluble polymer on structure and mechanical properties of bacterial cellulose composites, J. Appl. Sci., 8(1):177-180 (2008). |
Yueh-Ting et al: Comparison between Calcitriol and Caltiriol Plus Low-Dose Cinacalcet for the Treatment of Moderate to Severe Secondary Hyperparathyroidism in Nutrients, vol. 5, No. 4, Apr. 19, 2013 (apr. 19, 2013), pp. 1336-1348. |
Zemplar® (paricalcitol) Capsules, Final Agreed Upon Label (FDA, May 5, 2009). |
Zerwekh et al., Extra-Renal Production of 24,25-Dihydroxyvitamin D in Chronic Renal Failure During 25 Hydroxyvitamin D3 Therapy, Kidney Int., 23:401-406 (1983). |
Zerwekh J. E .: Blood biomarkers of vitamin D status, The American Journal of Clinical Nutrition, vol. 87Suppl., 2008, pp. 1087S-1091S. |
Zisman et al., Impact of Ergocalciferol Treatment of Vitamin D Deficiency on Serum Parathyroid Hormone Concentrations in Chronic Kidney Disease, Am. J. Nephrol., 27:36-43 (2007). |
Zucchelli et al., Therapeutic effects of 25-hydroxycholecalciferol and sodium etidronate on renal osteodystrophy, Mineral.Electrolyte Metab. 7: 86-96 (1982). |
Zuradelli et al., High incidence of hypocalcemia and serum creatinine increase in patients with bone metastases treated with zoledronic acid, Oncologist, 14(5):548-56 (2009). |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11911398B2 (en) | Treating Vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 | |
EP1945185B1 (en) | Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency | |
ES2496915T3 (en) | Oral controlled release compositions comprising a vitamin D compound and a waxy support | |
CA2797537C (en) | Use of 25-hydroxyvitamin d compound for reducing parathyroid levels | |
US20220062304A1 (en) | Methods of vitamin D treatment | |
NZ786552A (en) | Methods of vitamin d treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: OPKO RENAL, LLC, FLORIDA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:OPKO HEALTH, INC.;REEL/FRAME:057869/0884 Effective date: 20131231 Owner name: OPKO HEALTH, INC., FLORIDA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PROVENTIV THERAPEUTICS, LLC;REEL/FRAME:057869/0874 Effective date: 20131231 Owner name: PROVENTIV THERAPEUTICS, LLC, ILLINOIS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BISHOP, CHARLES W.;CRAWFORD, KEITH H.;MESSNER, ERIC J.;REEL/FRAME:057869/0859 Effective date: 20080603 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |